Feed:All articles: Difference between revisions

{"articlesQuery":{"topic":"all","articles":[{"timestamp":"2016-04-02T05:14:37Z","briefDesignDescription":"Central line complications by insertion site","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1500964","pageid":2479,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1500964","trainingLevel":"Student","citation":"Parienti JJ, <i>et al</i>. \"Intravascular Complications of Central Venous Catheterization by Insertion Site\". <i>The New England Journal of Medicine</i>. 2015. 373(13):1220-1229.","subspecialties":"Critical Care;Infectious Disease","expansion":"","briefResultsDescription":"Subclavian lines yield fewer CRBSIs and DVTs compared to IJ/femoral lines","published":"2015-09-24","pageName":"3SITES","diseases":"Critical Illness;Catheter-Related Bloodstream Infection","abbreviation":"3SITES","title":"Intravascular Complications of Central Venous Catheterization by Insertion Site","pmid":"26398070"},{"timestamp":"2016-04-11T06:45:25Z","briefDesignDescription":"Simvastatin in stable CAD","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(94)90566-5/abstract","pageid":1587,"pdfurl":"","trainingLevel":"Student","citation":"Pedersen TR, <i>et al</i>. \"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)\". <i>The Lancet</i>. 1994. 344(8934):1383-1389.","subspecialties":"Cardiology","expansion":"Scandinavian Simvastatin Survival Study","briefResultsDescription":"Simvastatin reduces all mortality in stable CAD","published":"1994-11-19","pageName":"4S","diseases":"Hyperlipidemia;Coronary Artery Disease","abbreviation":"4S","title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","pmid":"7968073"},{"timestamp":"2016-01-05T16:15:17Z","briefDesignDescription":"ISDN/hydralazine for black patients with HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa042934","pageid":41,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa042934","trainingLevel":"Student","citation":"Taylor AL, <i>et al</i>. \"Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure\". <i>The New England Journal of Medicine</i>. 2004. 351(20):2049-2057.","subspecialties":"Cardiology","expansion":"African-American Heart Failure Trial","briefResultsDescription":"Improved survival among black patients with HF","published":"2004-11-11","pageName":"A-HeFT","diseases":"Heart Failure","abbreviation":"A-HeFT","title":"Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure","pmid":"15533851"},{"timestamp":"2016-12-04T22:11:25Z","briefDesignDescription":"AF ablation vs. amiodarone in HFrEF with LVEF ≤40%","fulltexturl":"http://circ.ahajournals.org/content/early/2016/03/30/CIRCULATIONAHA.115.019406","pageid":2829,"pdfurl":null,"trainingLevel":"Resident","citation":"Di Biase <i>et al</i>. \"Ablation vs. amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device\". <i>Circulation</i>. 2016. 133(17):1637-1634.","subspecialties":"Cardiology","expansion":"Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device","briefResultsDescription":"AF ablation superior to amiodarone in HFrEF with LVEF ≤40%","published":"2016-04-26","pageName":"AATAC","diseases":"Atrial Fibrillation;Heart Failure","abbreviation":"AATAC","title":"Ablation vs. amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device","pmid":"27029350"},{"timestamp":"2014-05-23T21:17:56Z","briefDesignDescription":"Benazepril/amlodipine vs. benazepril/HCTZ in HTN","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0806182","pageid":1448,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0806182","trainingLevel":"Resident","citation":"Jamerson K, <i>et al</i>. \"Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients\". <i>The New England Journal of Medicine</i>. 2008. 359(23):2417-2428.","subspecialties":"Cardiology","expansion":"Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension","briefResultsDescription":"Benazepril/amlodipine is associated with fewer CV events","published":"2008-12-04","pageName":"ACCOMPLISH","diseases":"Hypertension","abbreviation":"ACCOMPLISH","title":"Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients","pmid":"19052124"},{"timestamp":"2016-04-01T23:25:40Z","briefDesignDescription":"Intensive glycemic therapy in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0802743","pageid":105,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802743","trainingLevel":"Intern","citation":"Gerstein HC, <i>et al</i>. \"Effects of Intensive Glucose Lowering in Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2008. 358(24):2545-59.","subspecialties":"Endocrinology","expansion":"Action to Control Cardiovascular Risk in Diabetes","briefResultsDescription":"Increased mortality and no cardiovascular benefit with intensive glycemic control","published":"2008-06-12","pageName":"ACCORD","diseases":"Diabetes Mellitus","abbreviation":"ACCORD","title":"Effects of Intensive Glucose Lowering in Type 2 Diabetes","pmid":"18539917"},{"timestamp":"2015-11-15T16:57:13Z","briefDesignDescription":"Intensive BP control in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1001286","pageid":1760,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001286","trainingLevel":"Student","citation":"ACCORD Study Group. \"Effects of intensive blood-pressure control in type 2 diabetes mellitus\". <i>The New England Journal of Medicine</i>. 2010. 362(17):1575-1585.","subspecialties":"Endocrinology","expansion":"ACCORD Study Group","briefResultsDescription":"Intensive BP control doesn't reduce CV events in T2DM","published":"2010-03-14","pageName":"ACCORD BP","diseases":"Diabetes Mellitus","abbreviation":"ACCORD BP","title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","pmid":"20228401"},{"timestamp":"2015-09-27T04:43:00Z","briefDesignDescription":"Acetylcysteine with IV contrast","fulltexturl":"http://circ.ahajournals.org/cgi/pmidlookup?view","pageid":2425,"pdfurl":"http://circ.ahajournals.org/content/124/11/1250.full.pdf","trainingLevel":"Intern","citation":"ACT Investigators. \"Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Angiography\". <i>Circulation</i>. 2011. 124:1250-1259.","subspecialties":"Nephrology;Cardiology","expansion":"Acetylcysteine for Contrast-Induced Nephropathy Trial","briefResultsDescription":"Acetylcysteine doesn't prevent contrast-induced acute kidney injury","published":"2011-06-28","pageName":"ACT","diseases":"Acute Kidney Injury;Acute Coronary Syndrome","abbreviation":"ACT","title":"Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Angiography","pmid":"21859972"},{"timestamp":"2015-02-02T18:51:43Z","briefDesignDescription":"ASA/clopidogrel vs. ASA in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0901301","pageid":360,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0901301","trainingLevel":"Resident","citation":"Connolly SJ, <i>et al</i>. \"Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2009. 360(20):2066-78.","subspecialties":"Cardiology;Neurology","expansion":"Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events","briefResultsDescription":"ASA/clopidogrel  ↓ composite of stroke, non-CNS embolism, MI, or CV death and ↑ bleeding","published":"2009-05-14","pageName":"ACTIVE A","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"ACTIVE A","title":"Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation","pmid":"19336502"},{"timestamp":"2014-10-23T16:02:13Z","briefDesignDescription":"ASA/clopidogrel vs. warfarin in AF","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)68845-4","pageid":1438,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673606688454.pdf","trainingLevel":"Intern","citation":"Connolly SJ, <i>et al</i>. \"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.\". <i>The Lancet</i>. 2006. 367(9526):1903-12.","subspecialties":"Cardiology;Neurology","expansion":"Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events","briefResultsDescription":"Warfarin is superior to ASA/clopidogrel for stroke prevention in AF","published":"2006-06-10","pageName":"ACTIVE W","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"ACTIVE W","title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.","pmid":"16765759"},{"timestamp":"2017-01-19T20:24:11Z","briefDesignDescription":"Cisatracurium in ARDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1005372","pageid":1119,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005372","trainingLevel":"resident","citation":"Papazian L, <i>et al</i>. \"Neuromuscular blockers in early acute respiratory distress syndrome\". <i>The New England Journal of Medicine</i>. 2010. 363(12):1107-1116.","subspecialties":"Critical Care","expansion":"ARDS et Curarisation Systematique","briefResultsDescription":"Cisatracurium improves 90-day survival and increases ventilator-free days","published":"2010-09-16","pageName":"ACURASYS","diseases":"Acute Respiratory Distress Syndrome","abbreviation":"ACURASYS","title":"Neuromuscular blockers in early acute respiratory distress syndrome","pmid":"20843245"},{"timestamp":"2015-10-12T23:44:43Z","briefDesignDescription":"Age-adjusted D-dimer for PE","fulltexturl":"http://bit.ly/1QgJ5k1","pageid":2367,"pdfurl":"http://bit.ly/1HTY4kQ","trainingLevel":"Resident","citation":"Righini M, <i>et al</i>. \"Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study\". <i>JAMA</i>. 2014. 311(11):1117-1124.","subspecialties":"Hematology;Emergency Medicine","expansion":"Age aDJUSTed D-Dimer to rule out PE","briefResultsDescription":"Age-adjusted D-dimer (age × 10 in patients >50) rules out PE","published":"2014-03-19","pageName":"ADJUST-PE","diseases":"Pulmonary Embolism;Venous Thromboembolism","abbreviation":"ADJUST-PE","title":"Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study","pmid":"24643601"},{"timestamp":"2014-09-19T13:02:39Z","briefDesignDescription":"Intensive glycemic therapy in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0802987","pageid":248,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802987","trainingLevel":"Intern","citation":"Patel A, <i>et al</i>. \"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2008. 358(24):2560-2572.","subspecialties":"Endocrinology","expansion":"Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation","briefResultsDescription":"Intensive therapy reduces microvascular complications","published":"2008-06-06","pageName":"ADVANCE","diseases":"Diabetes Mellitus","abbreviation":"ADVANCE","title":"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes","pmid":"18539916"},{"timestamp":"2015-08-28T01:53:53Z","briefDesignDescription":"Rate vs. rhythm control in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa021328","pageid":87,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa021328","trainingLevel":"Student","citation":"Wyse DG, <i>et al</i>. \"A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2002. 347(23):1825-1833.","subspecialties":"Cardiology","expansion":"Atrial Fibrillation Follow-up Investigation of Rhythm Management","briefResultsDescription":"No mortality difference, trend towards harm with rhythm control","published":"2002-11-05","pageName":"AFFIRM","diseases":"Atrial Fibrillation","abbreviation":"AFFIRM","title":"A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation","pmid":"12466506"},{"timestamp":"2016-01-10T06:27:00Z","briefDesignDescription":"Mammograms for 40-49 year old women","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)69834-6","pageid":2307,"pdfurl":"","trainingLevel":"Student","citation":"Moss SM, <i>et al</i>. \"Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: A randomised controlled trial\". <i>The Lancet</i>. 2006. 368(9552):2053-2060.","subspecialties":"Oncology;Preventive Medicine","expansion":"","briefResultsDescription":"Mammograms don't reduce breast cancer mortality in age 40-49 year old women","published":"2006-12-09","pageName":"Age Trial","diseases":"Breast Cancer","abbreviation":"Age Trial","title":"Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: A randomised controlled trial","pmid":"17161727"},{"timestamp":"2017-01-28T19:50:05Z","briefDesignDescription":"Anakinra in colchicine-resistant pericarditis","fulltexturl":"http://jamanetwork.com/journals/jama/article-abstract/2579869","pageid":2865,"pdfurl":null,"trainingLevel":"Resident","citation":"Brucato A, <i>et al</i>. \"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence\". <i>Journal of the American Medical Association</i>. 2016. 316(18):1906-1912.","subspecialties":"Cardiology","expansion":"","briefResultsDescription":"Anakinra superior to placebo in colchicine resistant, steroid-dependent pericarditis","published":"2016-11-08","pageName":"AIRTRIP","diseases":"Pericarditis","abbreviation":"AIRTRIP","title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence","pmid":"27825009"},{"timestamp":"2017-03-06T14:47:01Z","briefDesignDescription":"Daily albumin in severe sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1305727","pageid":1781,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1305727","trainingLevel":"resident","citation":"Caironi P, <i>et al</i>. \"Albumin replacement in patients with severe sepsis or septic shock\". <i>The New England Journal of Medicine</i>. 2014. 370(15):1412-1421.","subspecialties":"Critical Care","expansion":"Albumin Italian Outcome Sepsis","briefResultsDescription":"Daily albumin with no mortality benefit at 28 days","published":"2014-03-18","pageName":"ALBIOS","diseases":"Sepsis","abbreviation":"ALBIOS","title":"Albumin replacement in patients with severe sepsis or septic shock","pmid":"24635772"},{"timestamp":"2015-08-24T04:58:54Z","briefDesignDescription":"Chlorthalidone in HTN","fulltexturl":"http://jama.ama-assn.org/content/288/23/2981.long","pageid":171,"pdfurl":"http://jama.ama-assn.org/content/288/23/2981.full.pdf","trainingLevel":"Student","citation":"Wright JT, <i>et al</i>. \"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic\". <i>Journal of the American Medical Association</i>. 2002. 288(23):2981-2997.","subspecialties":"Nephrology;Cardiology","expansion":"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","briefResultsDescription":"Chlorthalidone performs similarly to lisinopril and amlodipine","published":"2002-12-18","pageName":"ALLHAT","diseases":"Hypertension","abbreviation":"ALLHAT","title":"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic","pmid":"12479763"},{"timestamp":"2016-02-15T17:19:53Z","briefDesignDescription":"Apixaban vs. warfarin in VTE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1302507","pageid":1609,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1302507","trainingLevel":"Intern","citation":"Agnelli G, <i>et al</i>. \"Oral apixaban for the treatment of acute venous thromboembolism\". <i>The New England Journal of Medicine</i>. 2013. 369(9):799-808.","subspecialties":"Hematology;Pulmonology","expansion":"Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy","briefResultsDescription":"Apixaban noninferior to warfarin for VTE recurrence; less bleeding","published":"2013-07-01","pageName":"AMPLIFY","diseases":"Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis","abbreviation":"AMPLIFY","title":"Oral apixaban for the treatment of acute venous thromboembolism","pmid":"23808982"},{"timestamp":"2016-02-16T16:42:50Z","briefDesignDescription":"Apixaban after VTE treatment","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1207541","pageid":1245,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1207541","trainingLevel":"Resident","citation":"Agnelli G, <i>et al</i>. \"Apixaban for extended treatment of venous thromboembolism\". <i>The New England Journal of Medicine</i>. 2013. 368(8):699-708.","subspecialties":"Hematology","expansion":"Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment","briefResultsDescription":"Apixaban reduces recurrent VTE","published":"2013-02-21","pageName":"AMPLIFY-EXT","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","abbreviation":"AMPLIFY-EXT","title":"Apixaban for extended treatment of venous thromboembolism","pmid":"23216615"},{"timestamp":"2017-01-19T19:41:08Z","briefDesignDescription":"Corticosteroids in septic shock","fulltexturl":"http://jama.jamanetwork.com/article.aspx?articleid","pageid":939,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/4844/JCE10061.pdf","trainingLevel":"Resident","citation":"Annane D, <i>et al</i>. \"Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock\". <i>Journal of the American Medical Association</i>. 2002. 288(7):862-871.","subspecialties":"Critical Care","expansion":"","briefResultsDescription":"Corticosteroids reduce mortality in septic shock with adrenal insufficiency","published":"2002-08-21","pageName":"Annane Trial","diseases":"Sepsis;Shock","abbreviation":"","title":"Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock","pmid":"12186604"},{"timestamp":"2017-04-02T00:25:44Z","briefDesignDescription":"Andexanet for reversing Xa inhibitors","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1510991","pageid":2502,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1510991","trainingLevel":"Resident","citation":"Siegal DM, <i>et al</i>. \"Andexanet alfa for the reversal of factor Xa inhibitor activity\". <i>The New England Journal of Medicine</i>. 2015. 373(25):2413-2424.","subspecialties":"Hematology","expansion":"Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors","briefResultsDescription":"Andexanet reverses Xa inhibitors","published":"2015-12-17","pageName":"ANNEXA","diseases":"Hemorrhage","abbreviation":"ANNEXA","title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","pmid":"26559317"},{"timestamp":"2015-12-11T17:43:58Z","briefDesignDescription":"Pre-exposure prophylaxis in high-risk men","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1506273","pageid":2649,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506273","trainingLevel":"Student","citation":"Molina JM, <i>et al</i>. \"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection\". <i>The New England Journal of Medicine</i>. 2015. 373(23):2237-2246.","subspecialties":"Infectious Disease","expansion":"","briefResultsDescription":"Pre-exposure prophylaxis reduces HIV transmission in high-risk men","published":"2015-12-03","pageName":"ANRS IPERGAY","diseases":"HIV","abbreviation":"ANRS IPERGAY","title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","pmid":"26624850"},{"timestamp":"2016-04-01T23:26:41Z","briefDesignDescription":"Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed","fulltexturl":"http://www.gastrojournal.org/article/S0016-5085(06)01535-6/fulltext","pageid":82,"pdfurl":"http://www.gastrojournal.org/article/S0016-5085(06)01535-6/pdf","trainingLevel":"Intern","citation":"Fernández J, <i>et al</i>. \"Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage\". <i>Gastroenterology</i>. 2006. 131(4):1049-56.","subspecialties":"Gastroenterology;Infectious Disease","expansion":"","briefResultsDescription":"Ceftriaxone reduces the incidence of bacterial infection","published":"2006-10-01","pageName":"Antibiotics in Cirrhosis with Hemorrhage","diseases":"Cirrhosis;Gastrointestinal Hemorrhage","abbreviation":"","title":"Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage","pmid":"17030175"},{"timestamp":"2017-01-19T20:26:56Z","briefDesignDescription":"Low vs. traditional volumes in ARDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200005043421801","pageid":114,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200005043421801","trainingLevel":"Intern","citation":"Brower RG, <i>et al</i>. \"Ventilation With Lower Tidal Volumes As Compared With Traditional Tidal Volumes For Acute Lung Injury And The Acute Respiratory Distress Syndrome\". <i>The New England Journal of Medicine</i>. 2000. 342(18):1301-1308.","subspecialties":"Critical Care","expansion":"Acute Respiratory Distress Syndrome Network","briefResultsDescription":"Mortality benefit and more ventilator-free days with lung-protective strategy","published":"2000-05-04","pageName":"ARDSNet","diseases":"Acute Respiratory Distress Syndrome","abbreviation":"ARDSNet","title":"Ventilation With Lower Tidal Volumes As Compared With Traditional Tidal Volumes For Acute Lung Injury And The Acute Respiratory Distress Syndrome","pmid":"10793162"},{"timestamp":"2017-01-19T19:37:16Z","briefDesignDescription":"EGDT vs. usual care in sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1404380","pageid":2216,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1404380","trainingLevel":"Intern","citation":"ARISE and ANZICS writers. \"Goal-directed resuscitation for patients with early septic shock\". <i>The New England Journal of Medicine</i>. 2014. 371(16):1496-1506.","subspecialties":"Critical Care","expansion":"Australasian Resuscitation in Sepsis Evaluation","briefResultsDescription":"EGDT doesn't reduce mortality in sepsis","published":"2014-10-16","pageName":"ARISE","diseases":"Sepsis","abbreviation":"ARISE","title":"Goal-directed resuscitation for patients with early septic shock","pmid":"25272316"},{"timestamp":"2015-04-18T21:28:24Z","briefDesignDescription":"Apixaban vs. warfarin in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1107039","pageid":1497,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1107039","trainingLevel":"Intern","citation":"Granger CB, <i>et al</i>. \"Apixaban versus warfarin in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2011. 365(11):981-982.","subspecialties":"Cardiology;Neurology","expansion":"Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation","briefResultsDescription":"Apixaban better for CVA prevention in AF","published":"2011-09-15","pageName":"ARISTOTLE","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"ARISTOTLE","title":"Apixaban versus warfarin in patients with atrial fibrillation","pmid":"21870978"},{"timestamp":"2015-12-29T16:22:06Z","briefDesignDescription":"Pirfenidone in IPF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1402582","pageid":1825,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402582","trainingLevel":"Fellow","citation":"King TE, <i>et al</i>. \"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis\". <i>The New England Journal of Medicine</i>. 2014. 370(22):2083-2092.","subspecialties":"Pulmonology","expansion":"Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis","briefResultsDescription":"Pirfenidone reduces progression of IPF","published":"2014-05-29","pageName":"ASCEND","diseases":"Pulmonary Fibrosis","abbreviation":"ASCEND","title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","pmid":"24836312"},{"timestamp":"2016-02-16T16:43:30Z","briefDesignDescription":"Aspirin after VTE treatment","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1210384","pageid":1241,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210384","trainingLevel":"Intern","citation":"Brighton TA, <i>et al</i>. \"Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism\". <i>The New England Journal of Medicine</i>. 2012. 367(21):1979-1987.","subspecialties":"Hematology","expansion":"Aspirin to Prevent Recurrent Venous Thromboembolism","briefResultsDescription":"ASA probably reduces recurrent VTE","published":"2012-11-04","pageName":"ASPIRE","diseases":"Venous Thromboembolism","abbreviation":"ASPIRE","title":"Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism","pmid":"23121403"},{"timestamp":"2015-07-30T11:22:56Z","briefDesignDescription":"Revascularization in RAS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0905368","pageid":1684,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0905368","trainingLevel":"Resident","citation":"Wheatley K, <i>et al</i>. \"Revascularization versus medical therapy for renal-artery stenosis\". <i>The New England Journal of Medicine</i>. 2009. 361(20):1953-1962.","subspecialties":"Nephrology","expansion":"Angioplasty and Stenting for Renal Artery Lesions","briefResultsDescription":"Revascularization no better than medical therapy alone in RAS","published":"2009-11-12","pageName":"ASTRAL","diseases":"Renal Artery Stenosis;Hypertension","abbreviation":"ASTRAL","title":"Revascularization versus medical therapy for renal-artery stenosis","pmid":"19907042"},{"timestamp":"2016-03-24T19:03:50Z","briefDesignDescription":"10y vs. 5y tamoxifen in breast cancer","fulltexturl":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596060/","pageid":1581,"pdfurl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61963-1/fulltext","trainingLevel":"Fellow","citation":"Davies C, <i>et al</i>. \"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial\". <i>The Lancet</i>. 2013. 381(9869):805-16.","subspecialties":"Oncology","expansion":"Adjuvant Tamoxifen: Longer Against Shorter","briefResultsDescription":"10 years of tamoxifen reduces recurrence and mortality","published":"2013-03-09","pageName":"ATLAS","diseases":"Breast Cancer","abbreviation":"ATLAS","title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","pmid":"23219286"},{"timestamp":"2015-06-08T20:44:21Z","briefDesignDescription":"Rivaroxaban after ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1112277","pageid":174,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1112277","trainingLevel":"Resident","citation":"Mega JL, <i>et al</i>. \"Rivaroxaban in Patients with Recent Acute Coronary Syndrome\". <i>The New England Journal of Medicine</i>. 2012. 366(1):9-19.","subspecialties":"Cardiology","expansion":"Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51","briefResultsDescription":"Rivaroxaban reduces cardiovascular death, MI, and stroke, but increases nonfatal bleeding","published":"2012-01-05","pageName":"ATLAS ACS-2, TIMI 51","diseases":"Acute Coronary Syndrome;Coronary Artery Disease;Myocardial Infarction","abbreviation":"ATLAS ACS 2-TIMI 51","title":"Rivaroxaban in Patients with Recent Acute Coronary Syndrome","pmid":"22077192"},{"timestamp":"2017-01-19T20:30:33Z","briefDesignDescription":"RRT intensity in ATN","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0802639","pageid":2339,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802639","trainingLevel":"Resident","citation":"Palevsky PM, <i>et al</i>. \"Intensity of renal support in critically ill patients with acute kidney injury\". <i>The New England Journal of Medicine</i>. 2008. 359(1):7-20.","subspecialties":"Nephrology;Critical Care","expansion":"Acute Renal Failure Trial Network Study","briefResultsDescription":"Intensive RRT yields similar mortality as conventional RRT in critically ill patients with ATN","published":"2008-07-03","pageName":"ATN","diseases":"Acute Kidney Injury;Critical Illness","abbreviation":"ATN","title":"Intensity of renal support in critically ill patients with acute kidney injury","pmid":"18492867"},{"timestamp":"2014-10-23T16:02:26Z","briefDesignDescription":"Apixaban vs. ASA in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1007432","pageid":1718,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1007432","trainingLevel":"Intern","citation":"Connolly SJ, <i>et al</i>. \"Apixaban in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2011. 364(9):806-817.","subspecialties":"Cardiology;Neurology","expansion":"Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment","briefResultsDescription":"Apixaban better than ASA without increased bleeding in AF","published":"2011-03-03","pageName":"AVERROES","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"AVERROES","title":"Apixaban in patients with atrial fibrillation","pmid":"21309657"},{"timestamp":"2014-11-24T14:56:57Z","briefDesignDescription":"Zidovudine in HIV/AIDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198707233170401","pageid":1775,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198707233170401","trainingLevel":"Student","citation":"Fischl MA <i>et al</i>. \"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex\". <i>The New England Journal of Medicine</i>. 1987. 317(4):185-191.","subspecialties":"Infectious Disease","expansion":"","briefResultsDescription":"Zidovudine reduces mortality in HIV/AIDS","published":"1987-07-23","pageName":"AZT Trial","diseases":"HIV","abbreviation":"","title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex","pmid":"3299089"},{"timestamp":"2013-06-22T12:16:42Z","briefDesignDescription":"CABG/PCI vs. OMT in diabetes with CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0805796","pageid":1471,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805796","trainingLevel":"Resident","citation":"Frye RL, <i>et al</i>. \"A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 2009. 360(24):2503-2515.","subspecialties":"Cardiology;Endocrinology","expansion":"Bypass Angioplasty Revascularization Investigation 2 Diabetes","briefResultsDescription":"CABG is superior to OMT in diabetics with CAD","published":"2009-06-11","pageName":"BARI 2D","diseases":"Coronary Artery Disease;Diabetes Mellitus","abbreviation":"BARI 2D","title":"A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease","pmid":"19502645"},{"timestamp":"2015-03-27T18:54:17Z","briefDesignDescription":"Symptom-based asthma therapy","fulltexturl":"http://bit.ly/1FNk0v0","pageid":1864,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/24854/joc120069_987_997.pdf","trainingLevel":"Resident","citation":"Calhoun WJ, <i>et al</i>. \"Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: The BASALT randomized controlled trial\". <i>Journal of the American Medical Association</i>. 2012. 308(10):987-997.","subspecialties":"Pulmonology","expansion":"Best Adjustment Strategy for Asthma in the Long Term","briefResultsDescription":"Symptom-, biomarker-, and physician-based treatments are similar","published":"2012-09-12","pageName":"BASALT","diseases":"Asthma","abbreviation":"BASALT","title":"Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: The BASALT randomized controlled trial","pmid":"22968888"},{"timestamp":"2016-03-05T01:50:26Z","briefDesignDescription":"Benazepril in non-diabetic CKD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa053107","pageid":2674,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa053107","trainingLevel":"Resident","citation":"Hou FF, <i>et al</i>. \"Effect and Safety of Benazepril for Advanced Chronic Renal Insufficiency\". <i>The New England Journal of Medicine</i>. 2006. 354(2):131-140.","subspecialties":"Nephrology","expansion":"","briefResultsDescription":"Benazepril improves renal outcomes in non-diabetic CKD","published":"2006-01-12","pageName":"Benazepril in Severe CKD","diseases":"Chronic Kidney Disease","abbreviation":"","title":"Effect and Safety of Benazepril for Advanced Chronic Renal Insufficiency","pmid":"16407508"},{"timestamp":"2014-12-01T14:21:22Z","briefDesignDescription":"DMARD ± prednisone or infliximab in RA","fulltexturl":"http://onlinelibrary.wiley.com/doi/10.1002/art.21405/abstract","pageid":77,"pdfurl":"http://onlinelibrary.wiley.com/doi/10.1002/art.21405/pdf","trainingLevel":"Resident","citation":"Goekoop-Ruiterman YP, <i>et al</i>. \"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis\". <i>Arthritis & Rheumatism</i>. 2005. 52(11):3381-3390.","subspecialties":"Rheumatology","expansion":"Behandel-Strategeieën (\"treatment strategies\" in Dutch)","briefResultsDescription":"Combination therapy produces early functional improvement than DMARD alone","published":"2005-11-01","pageName":"BeSt","diseases":"Rheumatoid Arthritis","abbreviation":"BeSt","title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis","pmid":"16258899"},{"timestamp":"2016-09-13T14:01:06Z","briefDesignDescription":"LMWH bridging for surgery in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1501035","pageid":2402,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501035","trainingLevel":"Intern","citation":"Douketis JD, <i>et al</i>. \"Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2015. 373(9):823-33.","subspecialties":"Cardiology;Hematology","expansion":"Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for Elective Invasive Procedure or Surgery","briefResultsDescription":"LMWH bridging didn't reduce VTE but increased bleeding","published":"2015-06-22","pageName":"BRIDGE","diseases":"Atrial Fibrillation;Stroke","abbreviation":"BRIDGE","title":"Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation","pmid":"26095867"},{"timestamp":"2016-09-03T15:55:53Z","briefDesignDescription":"Vemurafenib in BRAF V600+ melanoma","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1103782","pageid":2391,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1103782","trainingLevel":"Fellow","citation":"Chapman BP, <i>et al</i>. \"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation\". <i>The New England Journal of Medicine</i>. 2011. 364(26):2507-2516.","subspecialties":"Oncology","expansion":"BRAF Inhibitor in Melanoma 3","briefResultsDescription":"Vemurafenib improves survival in BRAF V600-mutated melanoma","published":"2011-06-30","pageName":"BRIM-3","diseases":"Melanoma","abbreviation":"BRIM-3","title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","pmid":"21639808"},{"timestamp":"2016-04-02T00:34:31Z","briefDesignDescription":"Light therapy vs. SSRI for SAD","fulltexturl":"http://ajp.psychiatryonline.org/doi/full/10.1176/ajp.2006.163.5.805","pageid":2173,"pdfurl":"http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.2006.163.5.805","trainingLevel":"Intern","citation":"Lam RW, <i>et al</i>. \"The Can-SAD study: A randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder\". <i>The American Journal of Psychiatry</i>. 2006. 165(5):805-812.","subspecialties":"Psychiatry","expansion":null,"briefResultsDescription":"No difference between light therapy and SSRI in SAD","published":"2006-05-01","pageName":"Can-SAD","diseases":"Seasonal Affective Disorder;Depression","abbreviation":"Can-SAD","title":"The Can-SAD study: A randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder","pmid":"16648320"},{"timestamp":"2012-06-13T05:04:26Z","briefDesignDescription":"CT head rules for trauma","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)04561-X/fulltext","pageid":93,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS014067360004561X.pdf","trainingLevel":"resident","citation":"Stiell IG, <i>et al</i>. \"The Canadian CT Head Rule for patients with minor head trauma\". <i>The Lancet</i>. 2001. 357(9266):1391-96.","subspecialties":"Emergency Medicine;Neurology","expansion":"","briefResultsDescription":"GCS score, skull fracture, emesis, age, amnesia, and mechanism predict risk","published":"2001-05-05","pageName":"Canadian CT Head Rule","diseases":"Trauma","abbreviation":"","title":"The Canadian CT Head Rule for patients with minor head trauma","pmid":"11356436"},{"timestamp":"2016-03-07T04:51:24Z","briefDesignDescription":"Clopidogrel vs. aspirin in CV disease","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)09457-3/fulltext","pageid":7,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673696094573.pdf","trainingLevel":"Intern","citation":"Gent M, <i>et al</i>. \"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events\". <i>The Lancet</i>. 1996. 348(9038):1329-39.","subspecialties":"Neurology;Cardiology","expansion":"Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events","briefResultsDescription":"Clopidogrel reduces risk of cardiovascular events","published":"1996-11-16","pageName":"CAPRIE","diseases":"Stroke;Transient Ischemic Attack;Coronary Artery Disease","abbreviation":"CAPRIE","title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events","pmid":"8918275"},{"timestamp":"2016-01-31T02:54:18Z","briefDesignDescription":"Preop coronary revascularization if stable CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa041905","pageid":1332,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa041905","trainingLevel":"Resident","citation":"McFalls EO, <i>et al</i>. \"Coronary-artery revascularization before elective major vascular surgery\". <i>The New England Journal of Medicine</i>. 2004. 351(27):2795-2804.","subspecialties":"Cardiology;Preventive Medicine","expansion":"","briefResultsDescription":"Preop coronary revascularization doesn't reduce mortality","published":"2004-12-30","pageName":"CARP","diseases":"Coronary Artery Disease;Cardiac Risk Assessment","abbreviation":"CARP","title":"Coronary-artery revascularization before elective major vascular surgery","pmid":"15625331"},{"timestamp":"2014-06-13T04:19:04Z","briefDesignDescription":"Ultrafiltration in decompensated HF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1210357","pageid":1356,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210357","trainingLevel":"Resident","citation":"Bart BA, <i>et al</i>. \"Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome\". <i>The New England Journal of Medicine</i>. 2012. 367(24):2296-2304.","subspecialties":"Cardiology","expansion":"Cardiorenal Rescue Study in Acute Decompensated Heart Failure","briefResultsDescription":"Ultrafiltration worse then meds in acute HF","published":"2012-12-13","pageName":"CARRESS-HF","diseases":"Heart Failure","abbreviation":"CARRESS-HF","title":"Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome","pmid":"23131078"},{"timestamp":"2014-09-24T22:02:10Z","briefDesignDescription":"Antiarrhythmics post-MI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199103213241201","pageid":1110,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199103213241201","trainingLevel":"Resident","citation":"Echt DS, <i>et al</i>. \"Mortality and morbidity in patients receiving encainide, flecainide, or placebo\". <i>The New England Journal of Medicine</i>. 1991. 324(12):781-788.","subspecialties":"Cardiology","expansion":"Cardiac Arrhythmia Suppression Trial","briefResultsDescription":"Antiarrhythmics increase mortality","published":"1991-03-21","pageName":"CAST I","diseases":"Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"CAST I","title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo","pmid":"1900101"},{"timestamp":"2012-06-19T22:07:32Z","briefDesignDescription":"Antipsychotics in schizophrenia","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa051688","pageid":419,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa051688","trainingLevel":"Resident","citation":"Lieberman JA, <i>et al</i>. \"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia\". <i>The New England Journal of Medicine</i>. 2005. 353(12):1209-23.","subspecialties":"Psychiatry","expansion":"Clinical Antipsychotic Trials of Intervention Effectiveness","briefResultsDescription":"Olanzapine ↓discontinuations but ↑metabolic syndrome, and perphenazine ˜ atypicals","published":"2005-09-22","pageName":"CATIE","diseases":"Schizophrenia","abbreviation":"CATIE","title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","pmid":"16172203"},{"timestamp":"2016-04-05T21:06:33Z","briefDesignDescription":"Antipsychotics in dementia with psychosis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa061240","pageid":2724,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa061240","trainingLevel":"Intern","citation":"Schneider LS, <i>et al</i>. \"Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease\". <i>The New England Journal of Medicine</i>. 2006. 355(15):1525-38.","subspecialties":"Psychiatry","expansion":"Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer's Disease","briefResultsDescription":"Antipsychotics no better than placebo","published":"2006-10-12","pageName":"CATIE-AD","diseases":"Dementia;Alzheimer Disease;Psychosis","abbreviation":"CATIE-AD","title":"Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease","pmid":"17035647"},{"timestamp":"2014-10-20T00:30:55Z","briefDesignDescription":"Ranibizumab vs. bevacizumab for macular degeneration","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1102673","pageid":2250,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1102673","trainingLevel":"Resident","citation":"The CATT Research Group Writers. \"Ranibizumab and bevacizumab for neovascular age-related macular degeneration\". <i>The New England Journal of Medicine</i>. 2011. 364(20):1897-1908.","subspecialties":"Ophthalmology","expansion":"Comparison of Age-Related Macular Degeneration Treatment Trails","briefResultsDescription":"Ranibizumab vs. bevacizumab similar even when comparing monthly vs. PRN scheduling","published":"2011-05-19","pageName":"CATT","diseases":"Macular Degeneration","abbreviation":"CATT","title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","pmid":"21526923"},{"timestamp":"2016-03-07T04:48:21Z","briefDesignDescription":"ASA/clopidogrel vs. ASA in TIA/stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1215340","pageid":1530,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1215340","trainingLevel":"Resident","citation":"Wang Y, <i>et al</i>. \"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack\". <i>The New England Journal of Medicine</i>. 2013. 369(1):11-19.","subspecialties":"Neurology","expansion":"Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events","briefResultsDescription":"ASA/clopidogrel decreases stroke rates compared to ASA alone in TIA and high-risk CVA","published":"2013-07-04","pageName":"CHANCE","diseases":"Stroke;Transient Ischemic Attack","abbreviation":"CHANCE","title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","pmid":"23803136"},{"timestamp":"2016-03-07T04:57:52Z","briefDesignDescription":"Aspirin/clopidogrel vs. aspirin for CV prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa060989","pageid":2175,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa060989","trainingLevel":"Resident","citation":"Bhatt DL, <i>et al</i>. \"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events\". <i>The New England Journal of Medicine</i>. 2006. 354(16):1706-1717.","subspecialties":"Cardiology","expansion":"Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance","briefResultsDescription":"Combination therapy no better than aspirin alone, more bleeding","published":"2006-04-20","pageName":"CHARISMA","diseases":"Cardiovascular Disease;Stroke;Myocardial Infarction;Acute Coronary Syndrome","abbreviation":"CHARISMA","title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","pmid":"16531616"},{"timestamp":"2014-08-29T20:13:54Z","briefDesignDescription":"ARB plus ACE-I in HF","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2914283-3/fulltext","pageid":2126,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673603142833.pdf","trainingLevel":"Intern","citation":"McMurray JJ, <i>et al</i>. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial\". <i>The Lancet</i>. 2003. 362(9386):767-771.","subspecialties":"Cardiology","expansion":null,"briefResultsDescription":"Adding ARB to ACE-I reduces CV events and HF hospitalizations","published":"2003-09-06","pageName":"CHARM-Added","diseases":"Heart Failure","abbreviation":"Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Added","title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial","pmid":"13678869"},{"timestamp":"2015-07-02T06:27:35Z","briefDesignDescription":"ARBs in HFpEF","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14285-7/fulltext","pageid":2381,"pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)14285-7.pdf","trainingLevel":"Intern","citation":"Yusuf S, <i>et al</i>. \"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial\". <i>The Lancet</i>. 2003. 362(9386):777-781.","subspecialties":"Cardiology","expansion":"Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved","briefResultsDescription":"Candesartan modestly reduces HF admissions but does not affect CV mortality","published":"2003-09-06","pageName":"CHARM-Preserved","diseases":"Heart Failure","abbreviation":"CHARM-Preserved","title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial","pmid":"13678871"},{"timestamp":"2015-04-12T06:08:58Z","briefDesignDescription":"Nivolumab in solid tumors","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1200690","pageid":2220,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200690","trainingLevel":"Resident","citation":"Topalian SL, <i>et al</i>. \"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer\". <i>The New England Journal of Medicine</i>. 2012. 366(26):2443-54.","subspecialties":"Oncology","expansion":"","briefResultsDescription":"Nivolumab was well tolerated, yielded durable remissions in about 30% of patients","published":"2012-06-28","pageName":"CheckMate-003","diseases":"Melanoma;Lung Cancer;Renal Cell Carcinoma","abbreviation":"","title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","pmid":"22658127"},{"timestamp":"2016-01-03T13:47:49Z","briefDesignDescription":"Free long-acting reversible contraception in teens","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1400506","pageid":2233,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1400506","trainingLevel":"Student","citation":"Secura GM, <i>et al</i>. \"Provision of no-cost, long-acting contraception and teenage pregnancy\". <i>The New England Journal of Medicine</i>. 2014. 371(14):1316-1326.","subspecialties":"Gynecology;Preventive Medicine;Obstetrics","expansion":null,"briefResultsDescription":"LARC reduced pregnancy, live births, and abortions","published":"2014-10-02","pageName":"CHOICE","diseases":"Unplanned Pregnancy","abbreviation":"CHOICE","title":"Provision of no-cost, long-acting contraception and teenage pregnancy","pmid":"25271604"},{"timestamp":"2015-03-09T17:47:38Z","briefDesignDescription":"EPO in CKD with anemia","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa065485","pageid":422,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa065485","trainingLevel":"Resident","citation":"Singh, AK <i>et al</i>. \"Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease\". <i>The New England Journal of Medicine</i>. 2006. 355(20):2085-2098.","subspecialties":"Nephrology;Hematology","expansion":"Correction of Hemoglobin and Outcomes in Renal Insufficiency","briefResultsDescription":"Increased morbidity/mortality with higher hgb targets","published":"2006-11-16","pageName":"CHOIR","diseases":"Chronic Kidney Disease;Anemia","abbreviation":"CHOIR","title":"Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease","pmid":"17108343"},{"timestamp":"2013-08-15T18:51:46Z","briefDesignDescription":"PFO closure in cryptogenic stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1009639","pageid":1093,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009639","trainingLevel":"Fellow","citation":"Furlan AJ, <i>et al</i>. \"Closure or medical therapy for cryptogenic stroke with patent foramen ovale\". <i>The New England Journal of Medicine</i>. 2012. 366(11):991-999.","subspecialties":"Neurology;Cardiology","expansion":"Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient Ischemic Attack due to Presumed Paradoxical Embolism through a Patent Foramen Ovale","briefResultsDescription":"PFO closure does not reduce recurrent stroke","published":"2012-03-15","pageName":"CLOSURE I","diseases":"Stroke;Patent Foramen Ovale;Transient Ischemic Attack","abbreviation":"CLOSURE I","title":"Closure or medical therapy for cryptogenic stroke with patent foramen ovale","pmid":"22417252"},{"timestamp":"2016-02-16T16:44:29Z","briefDesignDescription":"LMWH vs. warfarin in cancer VTE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa025313","pageid":13,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa025313","trainingLevel":"Intern","citation":"Lee AY, <i>et al</i>. \"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer\". <i>The New England Journal of Medicine</i>. 2003. 349(2):146-53.","subspecialties":"Hematology;Oncology","expansion":"Comparison of Low Molecular Weight Heparin Versus Oral Anticoagulant Therapy for Long Term Anticoagulation in Cancer Patients With Venous Thromboembolism","briefResultsDescription":"LMWH reduces VTE recurrence in cancer VTE without increasing bleeding risk","published":"2003-07-10","pageName":"CLOT","diseases":"Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism","abbreviation":"CLOT","title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","pmid":"12853587"},{"timestamp":"2015-06-28T14:04:10Z","briefDesignDescription":"PPI plus clopidogrel in CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1007964","pageid":313,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1007964","trainingLevel":"Resident","citation":"Bhatt DL, <i>et al</i>. \"Clopidogrel with or without omeprazole in coronary artery disease\". <i>The New England Journal of Medicine</i>. 2010. 363(20):1909-17.","subspecialties":"Cardiology","expansion":"Clopidogrel and the Optimization of Gastrointestinal Events Trial","briefResultsDescription":"PPIs reduce bleeding but do not increase CV events when given with clopidogrel","published":"2010-11-11","pageName":"COGENT","diseases":"Coronary Artery Disease","abbreviation":"COGENT","title":"Clopidogrel with or without omeprazole in coronary artery disease","pmid":"20925534"},{"timestamp":"2016-07-07T20:56:39Z","briefDesignDescription":"FIT vs. colonoscopy for colon cancer screening","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1108895","pageid":2393,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1108895","trainingLevel":"Resident","citation":"Quintero E, <i>et al</i>. \"Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening\". <i>The New England Journal of Medicine</i>. 2012. 366(8):697-706.","subspecialties":"Preventive Medicine;Gastroenterology;Oncology","expansion":null,"briefResultsDescription":"FIT is noninferior to colonoscopy for detecting colon cancer","published":"2012-02-23","pageName":"COLONPREV","diseases":"Colon Cancer","abbreviation":"COLONPREV","title":"Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening","pmid":"22356323"},{"timestamp":"2015-08-24T04:36:50Z","briefDesignDescription":"Carvedilol vs. metoprolol in HFrEF","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)13800-7/fulltext","pageid":121,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673603138007.pdf","trainingLevel":"Resident","citation":"Poole-Wilson PA, <i>et al</i>. \"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial\". <i>The Lancet</i>. 2003. 362(9377):7-13.","subspecialties":"Cardiology","expansion":"Carvedilol Or Metoprolol European Trial","briefResultsDescription":"Carvedilol extends survival in HFrEF","published":"2003-07-05","pageName":"COMET","diseases":"Heart Failure","abbreviation":"COMET","title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial","pmid":"12853193"},{"timestamp":"2014-09-24T20:08:16Z","briefDesignDescription":"Metoprolol in acute MI","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67661-1/fulltext","pageid":1451,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673605676611.pdf","trainingLevel":"Student","citation":"Chen ZM, <i>et al</i>. \"Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial\". <i>The Lancet</i>. 2005. 366(9497):1622-1632.","subspecialties":"Cardiology","expansion":"ClOpidogrel and Metoprolol in Myocardial Infarction Trial / Second Chinese Cardiac Study","briefResultsDescription":"High-dose IV and PO metoprolol increases cardiogenic shock","published":"2005-11-05","pageName":"COMMIT","diseases":"Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"COMMIT/CCS-2","title":"Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial","pmid":"16271643"},{"timestamp":"2014-06-13T04:30:42Z","briefDesignDescription":"Enalapril in severe HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198706043162301","pageid":18,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198706043162301","trainingLevel":"Intern","citation":"CONSENSUS Trial Study Group. \"Effects of enalapril on mortality in severe congestive heart failure, results of the cooperative north Scandinavian enalapril survival study\". <i>The New England Journal of Medicine</i>. 1987. 316(23):1429-35.","subspecialties":"Cardiology","expansion":"Cooperative North Scandinavian Enalapril Survival Study","briefResultsDescription":"Enalapril ↓mortality in NYHA class IV HFrEF","published":"1987-06-04","pageName":"CONSENSUS","diseases":"Heart Failure","abbreviation":"CONSENSUS","title":"Effects of enalapril on mortality in severe congestive heart failure, results of the cooperative north Scandinavian enalapril survival study","pmid":"2883575"},{"timestamp":"2014-06-13T04:33:43Z","briefDesignDescription":"Carvedilol in HFrEF","fulltexturl":"http://circ.ahajournals.org/content/106/17/2194.full","pageid":42,"pdfurl":"http://circ.ahajournals.org/content/106/17/2194.full.pdf","trainingLevel":"Intern","citation":"Packer M, <i>et al</i>. \"Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure\". <i>Circulation</i>. 2002. 106(17):2194-9.","subspecialties":"Cardiology","expansion":"Carvedilol Prospective Randomized Cumulative Survival","briefResultsDescription":"Carvedilol reduces mortality and HF hospitalizations in severe NYHA class III-IV HFrEF","published":"2002-10-22","pageName":"COPERNICUS","diseases":"Heart Failure","abbreviation":"COPERNICUS","title":"Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure","pmid":"12390947"},{"timestamp":"2014-06-13T04:37:32Z","briefDesignDescription":"Rosuvastatin in ischemic HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0706201","pageid":524,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0706201","trainingLevel":"Resident","citation":"Kjekshus J, <i>et al</i>. \"Rosuvastatin in Older Patients with Systolic Heart Failure\". <i>The New England Journal of Medicine</i>. 2007. 357(22):2248-61.","subspecialties":"Cardiology","expansion":"Controlled Rosuvastatin Multinational Trial in Heart Failure","briefResultsDescription":"Statins confer no survival benefit but may reduce hospitalizations in ischemic HFrEF","published":"2007-11-29","pageName":"CORONA","diseases":"Heart Failure;Hyperlipidemia","abbreviation":"CORONA","title":"Rosuvastatin in Older Patients with Systolic Heart Failure","pmid":"17984166"},{"timestamp":"2017-01-19T19:41:25Z","briefDesignDescription":"Hydrocortisone in septic shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa071366","pageid":4,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa071366","trainingLevel":"Student","citation":"Sprung CL, <i>et al</i>. \"Hydrocortisone therapy for patients with septic shock\". <i>New England Journal of Medicine</i>. 2008. 358(2):111-24.","subspecialties":"Critical Care;Endocrinology","expansion":"Corticosteroid Therapy of Septic Shock","briefResultsDescription":"Improved survival of hydrocortisone in septic shock","published":"2008-01-10","pageName":"CORTICUS","diseases":"Sepsis;Shock","abbreviation":"CORTICUS","title":"Hydrocortisone therapy for patients with septic shock","pmid":"18184957"},{"timestamp":"2015-12-05T21:37:40Z","briefDesignDescription":"PCI vs. medical therapy in CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa070829","pageid":21,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa070829","trainingLevel":"Student","citation":"Boden WE, <i>et al</i>. \"Optimal medical therapy with or without PCI for stable coronary disease\". <i>The New England Journal of Medicine</i>. 2007. 356:1503-16.","subspecialties":"Cardiology","expansion":"Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation","briefResultsDescription":"No difference between PCI and OMT in stable CAD","published":"2007-04-12","pageName":"COURAGE","diseases":"Coronary Artery Disease","abbreviation":"COURAGE","title":"Optimal medical therapy with or without PCI for stable coronary disease","pmid":"17387127"},{"timestamp":"2013-08-31T18:14:13Z","briefDesignDescription":"Tranexamic acid in trauma","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960835-5/fulltext","pageid":490,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673610608355.pdf","trainingLevel":"resident","citation":"Shakur H, <i>et al</i>. \"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage\". <i>The Lancet</i>. 2010. 376(9734):23-32.","subspecialties":"Emergency Medicine;Surgery","expansion":"Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 2","briefResultsDescription":"Tranexamic acid reduces 4-week mortality","published":"2010-07-03","pageName":"CRASH-2","diseases":"Trauma","abbreviation":"CRASH-2","title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage","pmid":"20554319"},{"timestamp":"2013-08-15T18:50:20Z","briefDesignDescription":"Stenting vs. CEA in carotid stenosis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0912321","pageid":492,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0912321","trainingLevel":"Intern","citation":"Brott TG, <i>et al</i>. \"Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis\". <i>The New England Journal of Medicine</i>. 2010. 363(1):11-23.","subspecialties":"Surgery;Neurology;Cardiology","expansion":"Carotid Revascularization Endarterectomy vs. Stenting Trial","briefResultsDescription":"No difference in stroke/MI/death; stenting ↑perioperative stroke but ↓perioperative MI","published":"2010-07-01","pageName":"CREST","diseases":"Carotid Stenosis;Stroke;Transient Ischemic Attack","abbreviation":"CREST","title":"Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis","pmid":"20505173"},{"timestamp":"2017-01-19T19:57:16Z","briefDesignDescription":"Colloids vs. crystalloids in shock","fulltexturl":"http://bit.ly/1kLbQWJ","pageid":1768,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/928522/joi130081.pdf","trainingLevel":"resident","citation":"Annane D, <i>et al</i>. \"Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock\". <i>The Journal of the American Medical Association</i>. 2013. 310(17):1809-1817.","subspecialties":"Critical Care","expansion":"Colloids Versus Crystalloids for the Resuscitation of the Critically Ill","briefResultsDescription":"Colloids no different from crystalloids in mortality","published":"2013-11-06","pageName":"CRISTAL","diseases":"Shock","abbreviation":"CRISTAL","title":"Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock","pmid":"24108515"},{"timestamp":"2013-08-07T13:19:01Z","briefDesignDescription":"Captopril in T1DM nephropathy","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199311113292004","pageid":1591,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199311113292004","trainingLevel":"Student","citation":"Lewis EJ, <i>et al</i>. \"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.\". <i>The New England Journal of Medicine</i>. 1993. 329(20):1456-1462.","subspecialties":"Nephrology;Endocrinology","expansion":"Collaborative Study Group Captopril Trial","briefResultsDescription":"Captopril reduces T1DM nephropathy progression","published":"1993-11-11","pageName":"CSG Captopril Trial","diseases":"Diabetic Nephropathy;Diabetes Mellitus","abbreviation":"CSG Captopril Trial","title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.","pmid":"8413456"},{"timestamp":"2014-09-24T20:43:54Z","briefDesignDescription":"Clopidogrel in UA/NSTEMI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa010746","pageid":921,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa010746","trainingLevel":"Resident","citation":"Yusuf S, <i>et al</i>. \"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation\". <i>The New England Journal of Medicine</i>. 2001. 345(7):494-502.","subspecialties":"Cardiology","expansion":"Clopidogrel in Unstable Angina to Prevent Recurrent Events","briefResultsDescription":"Clopidogrel reduces CV events but increases bleeding in UA/NSTEMI","published":"2001-08-16","pageName":"CURE","diseases":"Acute Coronary Syndrome","abbreviation":"CURE","title":"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation","pmid":"11519503"},{"timestamp":"2017-02-01T18:13:16Z","briefDesignDescription":"Culprit lesion-only vs. complete revascularization","fulltexturl":"http://www.onlinejacc.org/content/65/10/963","pageid":2880,"pdfurl":"http://www.onlinejacc.org/content/accj/65/10/963.full.pdf?download","trainingLevel":"Resident","citation":"Gershlick <i>et al</i>. \"Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease\". <i>J Am Coll Cardiol</i>. 2015. 65(10):963-72.","subspecialties":"Cardiology","expansion":"Complete Versus Lesion-Only Primary PCI Trial","briefResultsDescription":"Complete revascularization superior to culprit lesion-only revascularization","published":"2015-03-17","pageName":"CvLPRIT","diseases":"Coronary Artery Disease","abbreviation":"CvLPRIT","title":"Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease","pmid":"25766941"},{"timestamp":"2015-03-15T03:05:51Z","briefDesignDescription":"Pulse cyclophosphamide for ANCA vasculitis","fulltexturl":null,"pageid":2338,"pdfurl":"http://annals.org/data/Journals/AIM/20182/0000605-200905190-00004.pdf","trainingLevel":"Fellow","citation":"de Groot K, <i>et al</i>. \"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial\". <i>Annals of Internal Medicine</i>. 2009. 150(10):670-680.","subspecialties":"Rheumatology;Nephrology","expansion":null,"briefResultsDescription":"Pulse no worse than daily cyclophosphamide","published":"2009-05-19","pageName":"CYCLOPS","diseases":"Vasculitis","abbreviation":"CYCLOPS","title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial","pmid":"19451574"},{"timestamp":"2015-04-12T06:11:46Z","briefDesignDescription":"Cytisine vs. NRT for tobacco abuse","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1407764","pageid":2319,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1407764","trainingLevel":"Intern","citation":"Walker N, <i>et al</i>. \"Cytisine versus nicotine for smoking cessation\". <i>The New England Journal of Medicine</i>. 2014. 371(25):2353-2362.","subspecialties":"Pulmonology;Preventive Medicine","expansion":null,"briefResultsDescription":"Cytisine superior to NRT for abstinence at 1 month","published":"2014-12-18","pageName":"Cytisine for Smoking Cessation","diseases":"Tobacco Abuse","abbreviation":null,"title":"Cytisine versus nicotine for smoking cessation","pmid":"25517706"},{"timestamp":"2016-03-01T06:42:36Z","briefDesignDescription":"Hematocrit thresholds in PV","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1208500","pageid":2709,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208500","trainingLevel":"Fellow","citation":"Marchioli R, <i>et al</i>. \"Cardiovascular events and intensity of treatment in polycythemia vera\". <i>The New England Journal of Medicine</i>. 2013. 368(1):22-33.","subspecialties":"Hematology;Cardiology","expansion":"Cytoreductive Therapy in Polycythemia Vera","briefResultsDescription":"Fewer vascular events with hematocrit <45% compared to 45-50%","published":"2013-01-03","pageName":"CYTO-PV","diseases":"Polycythemia Vera;Myeloproliferative Neoplasms","abbreviation":"CYTO-PV","title":"Cardiovascular events and intensity of treatment in polycythemia vera","pmid":"23216616"},{"timestamp":"2017-01-19T20:34:41Z","briefDesignDescription":"Scheduled daily sedation holidays in intubated patients","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200005183422002","pageid":1554,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200005183422002","trainingLevel":"Intern","citation":"Kress JP, <i>et al</i>. \"Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation\". <i>The New England Journal of Medicine</i>. 2000. 342(20):1471-1477.","subspecialties":"Critical Care;Pulmonology","expansion":"","briefResultsDescription":"Sedation holidays reduce intubated, ICU, hospital days","published":"2000-05-18","pageName":"Daily ICU Sedation Holidays","diseases":"Respiratory Failure","abbreviation":"","title":"Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation","pmid":"10816184"},{"timestamp":"2016-10-04T15:42:32Z","briefDesignDescription":"ICD vs. standard care in NICM and LVEF ≤35%","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1608029","pageid":2815,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1608029","trainingLevel":"Resident","citation":"Kober L, <i>et al</i>. \"Defibrillator implantation in patients with nonischemic systolic heart failure\". <i>The New England Journal of Medicine</i>. 2016. epub 2016-08-28:1-10.","subspecialties":"Cardiology","expansion":"Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality","briefResultsDescription":"ICD not better than standard of care in NICM and LVEF ≤35%","published":"2016-08-28","pageName":"DANISH","diseases":"Ventricular Tachycardia","abbreviation":"DANISH","title":"Defibrillator implantation in patients with nonischemic systolic heart failure","pmid":"27571011"},{"timestamp":"2016-09-08T20:11:08Z","briefDesignDescription":"Aspirin/clopidogrel duration after PCI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1409312","pageid":2264,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1409312","trainingLevel":"Intern","citation":"Mauri L, <i>et al</i>. \"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents\". <i>The New England Journal of Medicine</i>. 2014. 371(23):2155-2166.","subspecialties":"Cardiology","expansion":"Dual Antiplatelet Therapy","briefResultsDescription":"Longer duration reduces stent thrombosis, MI, stroke, but increases mortality/bleeding","published":"2014-11-16","pageName":"DAPT","diseases":"Coronary Artery Disease;Myocardial Infarction;Stroke","abbreviation":"DAPT","title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","pmid":"25399658"},{"timestamp":"2015-10-07T14:21:01Z","briefDesignDescription":"DASH diet in HTN","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199704173361601","pageid":90,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199704173361601","trainingLevel":"Student","citation":"Appel LJ, <i>et al</i>. \"A clinical trial of the effects of dietary patterns on blood pressure\". <i>The New England Journal of Medicine</i>. 1997. 336(16):1117-1124.","subspecialties":"Cardiology;Nephrology","expansion":"Dietary Approaches to Stop Hypertension","briefResultsDescription":"DASH diet reduces SBP and DBP","published":"1997-04-17","pageName":"DASH","diseases":"Hypertension","abbreviation":"DASH","title":"A clinical trial of the effects of dietary patterns on blood pressure","pmid":"9099655"},{"timestamp":"2016-08-06T18:08:26Z","briefDesignDescription":"Dual-chamber vs. ventricular backup pacing in ICD patients","fulltexturl":"http://jama.jamanetwork.com/article.aspx?volume","pageid":2713,"pdfurl":null,"trainingLevel":"Resident","citation":"Wilkoff BL, <i>et al</i>. \"Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator\". <i>Journal of the American Medical Association</i>. 2002. 288(24):3115-3123.","subspecialties":"Cardiology","expansion":"Dual-chamber pacing or ventricular backup pacing in ICD patients","briefResultsDescription":"Ventricular backup pacemaker superior to dual-chamber pacemaker","published":"2002-12-25","pageName":"DAVID","diseases":"Bradycardia","abbreviation":"DAVID","title":"Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator","pmid":"12495391"},{"timestamp":"2012-09-16T11:23:12Z","briefDesignDescription":"Intensive glycemic therapy in T1DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199309303291401","pageid":135,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199309303291401","trainingLevel":"Student","citation":"DCCT Research Group. \"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus\". <i>The New England Journal of Medicine</i>. 1993. 329(14):977-986.","subspecialties":"Endocrinology","expansion":"Diabetes Control and Complications Trial","briefResultsDescription":"Intensive therapy delays microvascular but not macrovascular complications in T1DM","published":"1993-09-30","pageName":"DCCT","diseases":"Diabetes Mellitus","abbreviation":"DCCT","title":"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus","pmid":"8366922"},{"timestamp":"2014-06-13T04:45:33Z","briefDesignDescription":"ICD vs. medical therapy in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa033088","pageid":84,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa033088","trainingLevel":"Resident","citation":"Kadish A, <i>et al</i>. \"Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy\". <i>The New England Journal of Medicine</i>. 2004. 350(21):2151-2158.","subspecialties":"Cardiology","expansion":"Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation","briefResultsDescription":"ICD reduced risk of arrhythmogenic sudden death, but not overall mortality","published":"2004-05-20","pageName":"DEFINITE","diseases":"Heart Failure","abbreviation":"DEFINITE","title":"Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy","pmid":"15152060"},{"timestamp":"2014-06-13T04:50:56Z","briefDesignDescription":"Digoxin in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199702203360801","pageid":89,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199702203360801","trainingLevel":"Resident","citation":"Gorlin R, <i>et al</i>. \"The effect of digoxin on mortality and morbidity in patients with heart failure\". <i>The New England Journal of Medicine</i>. 1997. 336(8):525-533.","subspecialties":"Cardiology","expansion":"Digitalis Investigation Group","briefResultsDescription":"Reduced hospitalizations, no mortality benefit","published":"1997-02-20","pageName":"DIG","diseases":"Heart Failure","abbreviation":"DIG","title":"The effect of digoxin on mortality and morbidity in patients with heart failure","pmid":"9036306"},{"timestamp":"2016-04-13T01:29:00Z","briefDesignDescription":"ICD for ICM shortly after MI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa041489","pageid":1743,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa041489","trainingLevel":"Resident","citation":"Hohnloser SH, <i>et al</i>. \"Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction\". <i>The New England Journal of Medicine</i>. 2004. 351(24):2481-2488.","subspecialties":"Cardiology","expansion":"Defibrillator in Acute Myocardial Infarction Trial","briefResultsDescription":"ICD reduces arrhythmia but not mortality","published":"2004-12-09","pageName":"DINAMIT","diseases":"Heart Failure;Myocardial Infarction","abbreviation":"DINAMIT","title":"Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction","pmid":"15590950"},{"timestamp":"2014-12-14T18:13:00Z","briefDesignDescription":"Diuretic dosing in acute HF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1005419","pageid":1457,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005419","trainingLevel":"Intern","citation":"Felker GM, <i>et al</i>. \"Diuretic strategies in patients with acute decompensated heart failure\". <i>The New England Journal of Medicine</i>. 2011. 364(9):797-805.","subspecialties":"Cardiology","expansion":"Diuretic Optimization Strategies Evaluation","briefResultsDescription":"High-dose better than low-dose, continuous infusions no better than intermittent IV boluses","published":"2011-03-03","pageName":"DOSE","diseases":"Heart Failure","abbreviation":"DOSE","title":"Diuretic strategies in patients with acute decompensated heart failure","pmid":"21366472"},{"timestamp":"2013-07-29T21:18:41Z","briefDesignDescription":"Duct tape vs. cryotherapy for warts","fulltexturl":"","pageid":1579,"pdfurl":"http://archpedi.jamanetwork.com/data/Journals/PEDS/5052/POA20075.pdf","trainingLevel":"Student","citation":"Focht DR, <i>et al</i>. \"The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart)\". <i>Archives of Pediatric and Adolescent Medicine</i>. 2002. 156:971-974.","subspecialties":"Pediatrics;Dermatology","expansion":"","briefResultsDescription":"Duct tape superior to cryotherapy for wart resolution","published":"2002-10-01","pageName":"Duct Tape for Treatment of the Common Wart","diseases":"Warts","abbreviation":"","title":"The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart)","pmid":"12361440"},{"timestamp":"2015-11-09T17:39:12Z","briefDesignDescription":"Palliative care in NSCLC","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1000678","pageid":466,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000678","trainingLevel":"Intern","citation":"Temel JS, <i>et al</i>. \"Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer\". <i>The New England Journal of Medicine</i>. 2010. 363(8):733-742.","subspecialties":"Oncology;Palliative Care","expansion":null,"briefResultsDescription":"Palliative care ↑mood, ↑QOL, ↑survival, ↓aggressive care","published":"2010-08-19","pageName":"Early Palliative Care","diseases":"Lung Cancer","abbreviation":null,"title":"Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer","pmid":"20818875"},{"timestamp":"2016-04-02T00:33:53Z","briefDesignDescription":"Alteplase 3-4.5h after stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0804656","pageid":115,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0804656","trainingLevel":"Intern","citation":"Hacke W, <i>et al</i>. \"Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke\". <i>The New England Journal of Medicine</i>. 2008. 359(13):1317-1329.","subspecialties":"Neurology","expansion":"European Cooperative Acute Stroke Study III","briefResultsDescription":"Alteplase improves neurological outcomes at 3 months","published":"2008-09-25","pageName":"ECASS III","diseases":"Stroke","abbreviation":"ECASS III","title":"Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke","pmid":"18815396"},{"timestamp":"2015-09-01T05:00:13Z","briefDesignDescription":"CEA in symptomatic carotid stenosis","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2897%2909292-1","pageid":2354,"pdfurl":"","trainingLevel":"Intern","citation":"ECST Writers. \"Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST)\". <i>The Lancet</i>. 1998. 351(9113):1379-1387.","subspecialties":"Surgery;Neurology","expansion":"European Carotid Surgery Trial","briefResultsDescription":"CEA improves outcomes in patients with ≥80% symptomatic carotid stenosis","published":"1998-05-09","pageName":"ECST","diseases":"Carotid Stenosis;Stroke","abbreviation":"ECST","title":"Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST)","pmid":"9593407"},{"timestamp":"2013-03-12T08:18:42Z","briefDesignDescription":"Intensive glycemic therapy in T1DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa052187","pageid":136,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa052187","trainingLevel":"intern","citation":"Nathan DM, <i>et al</i>. \"Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes\". <i>The New England Journal of Medicine</i>. 2005. 353(25):2643-2653.","subspecialties":"Endocrinology","expansion":"Epidemiology of Diabetes Interventions and Complications","briefResultsDescription":"Intensive therapy associated with fewer cardiovascular complications","published":"2005-12-22","pageName":"EDIC","diseases":"Diabetes Mellitus","abbreviation":"EDIC","title":"Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes","pmid":"16371630"},{"timestamp":"2016-02-15T17:18:58Z","briefDesignDescription":"Rivaroxaban vs. warfarin in PE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1113572","pageid":1519,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113572","trainingLevel":"Student","citation":"Büller HR, <i>et al</i>. \"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism\". <i>The New England Journal of Medicine</i>. 2012. 366(14):1287-1297.","subspecialties":"Hematology;Pulmonology","expansion":"","briefResultsDescription":"Rivaroxaban is noninferior to warfarin in PE treatment","published":"2012-04-05","pageName":"EINSTEIN-PE","diseases":"Pulmonary Embolism;Venous Thromboembolism","abbreviation":"EINSTEIN-PE","title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","pmid":"22449293"},{"timestamp":"2015-03-03T14:43:13Z","briefDesignDescription":"Immunosuppression after kidney transplant","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa067411","pageid":2324,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa067411","trainingLevel":"Resident","citation":"Ekberg H, <i>et al</i>. \"Reduced exposure to calcineurin inhibitors in renal transplantation\". <i>The New England Journal of Medicine</i>. 2007. 357(25):2562-2575.","subspecialties":"Nephrology","expansion":"Efficacy Limiting Toxicity Elimination-Symphony","briefResultsDescription":"Daclizumab, mycophenolate, steroids, and tacrolimus beneficial","published":"2007-12-20","pageName":"ELITE-Symphony","diseases":"Kidney Transplant","abbreviation":"ELITE-Symphony","title":"Reduced exposure to calcineurin inhibitors in renal transplantation","pmid":"18094377"},{"timestamp":"2013-06-27T17:49:25Z","briefDesignDescription":"T-DM1 in metastatic breast cancer","fulltexturl":"http://www.nejm.org/doi/abs/10.1056/NEJMoa1209124","pageid":1257,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209124","trainingLevel":"fellow","citation":"Verma S, <i>et al</i>. \"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer\". <i>The New England Journal of Medicine</i>. 2012. 367(19):1783-1791.","subspecialties":"Oncology","expansion":"Emtansine vs. Capecitabine+Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer","briefResultsDescription":"T-DM1 prolongs PFS in metastatic breast cancer","published":"2012-11-08","pageName":"EMILIA","diseases":"Breast Cancer","abbreviation":"EMILIA","title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","pmid":"23020162"},{"timestamp":"2016-10-25T16:05:49Z","briefDesignDescription":"Empagliflozin for CV outcomes in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1504720","pageid":2448,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1504720","trainingLevel":"intern","citation":"Zinman B, <i>et al</i>. \"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2015. 373(22):2117-28.","subspecialties":"Cardiology;Endocrinology","expansion":"","briefResultsDescription":"Empagliflozin reduces mortality compared to placebo in patients with type 2 diabetes","published":"2015-09-17","pageName":"EMPA-REG OUTCOME","diseases":"Diabetes Mellitus","abbreviation":"EMPA-REG OUTCOME","title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","pmid":"26378978"},{"timestamp":"2014-06-13T05:16:42Z","briefDesignDescription":"Eplerenone in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1009492","pageid":120,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009492","trainingLevel":"Resident","citation":"Zannad F, <i>et al</i>. \"Eplerenone in patients with systolic heart failure and mild symptoms\". <i>The New England Journal of Medicine</i>. 2011. 364(1):11-21.","subspecialties":"Cardiology","expansion":"Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure","briefResultsDescription":"Eplerenone reduces CV deaths and HF hospitalizations","published":"2011-01-06","pageName":"EMPHASIS-HF","diseases":"Heart Failure","abbreviation":"EMPHASIS-HF","title":"Eplerenone in patients with systolic heart failure and mild symptoms","pmid":"21073363"},{"timestamp":"2017-03-05T05:35:28Z","briefDesignDescription":"Edoxaban vs. warfarin in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1310907","pageid":2471,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310907","trainingLevel":"resident","citation":"Guigliano RP, <i>et al</i>. \"Edoxaban versus warfarin in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2013. 369(22):2093-2104.","subspecialties":"Cardiology","expansion":"Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48","briefResultsDescription":"Edoxaban  is noninferior to warfarin to prevent stroke or thromboembolism","published":"2013-11-28","pageName":"ENGAGE AF-TIMI 48","diseases":"Atrial Fibrillation","abbreviation":"ENGAGE AF-TIMI 48","title":"Edoxaban versus warfarin in patients with atrial fibrillation","pmid":"24251359"},{"timestamp":"2015-12-24T15:08:03Z","briefDesignDescription":"Eplerenone post-MI with HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa030207","pageid":16,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa030207","trainingLevel":"Resident","citation":"Pitt B, <i>et al</i>. \"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction\". <i>The New England Journal of Medicine</i>. 2003. 348(14):1309-21.","subspecialties":"Cardiology","expansion":"Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study","briefResultsDescription":"Mortality benefit of eplerenone post MI with HFrEF","published":"2003-04-03","pageName":"EPHESUS","diseases":"Heart Failure;Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"EPHESUS","title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","pmid":"12668699"},{"timestamp":"2016-07-14T21:52:30Z","briefDesignDescription":"PSA screening q4y for prostate cancer","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0810084","pageid":2796,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0810084","trainingLevel":"Intern","citation":"Schröder FH, <i>et al</i>. \"Screening and Prostate-Cancer Mortality in a Randomized European Study\". <i>The New England Journal of Medicine</i>. 2009. 360(13):1320-1328.","subspecialties":"Urology;Oncology;Preventive Medicine","expansion":"European Randomized Study of Screening for Prostate Cancer","briefResultsDescription":"Decrease in prostate cancer mortality but increased risk of overdiagnosis and overtreatment","published":"2009-07-09","pageName":"ERSPC","diseases":"Prostate Cancer","abbreviation":"ERSPC","title":"Screening and Prostate-Cancer Mortality in a Randomized European Study","pmid":"19297566"},{"timestamp":"2014-06-13T05:31:57Z","briefDesignDescription":"PA catheters in acute HF management","fulltexturl":null,"pageid":1407,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/4994/JOC50108.pdf","trainingLevel":"Resident","citation":"Binanay C, <i>et al</i>. \"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness\". <i>JAMA</i>. 2005. 294(13):1625-1633.","subspecialties":"Cardiology;Critical Care","expansion":"Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness","briefResultsDescription":"Routine PA catheters no better than clinical assessment","published":"2005-10-05","pageName":"ESCAPE","diseases":"Heart Failure","abbreviation":"ESCAPE","title":"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness","pmid":"16204662"},{"timestamp":"2014-05-11T10:19:18Z","briefDesignDescription":"ASA+dipyridamole in secondary stroke prevention","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2806%2968734-5/fulltext","pageid":1726,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673606687345.pdf","trainingLevel":"Intern","citation":"Halkes PH, <i>et al</i>. \"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial\". <i>The Lancet</i>. 2006. 367(9523):1665-1673.","subspecialties":"Neurology","expansion":"European/Australasian Stroke Prevention in Reversible Ischaemia Trial","briefResultsDescription":"ASA+dipyridamole better than ASA for secondary stroke prevention","published":"2006-05-20","pageName":"ESPRIT","diseases":"Stroke;Transient Ischemic Attack","abbreviation":"ESPRIT","title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial","pmid":"16714187"},{"timestamp":"2014-09-26T17:56:38Z","briefDesignDescription":"LMWH vs. UFH in UA/NSTEMI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199708143370702","pageid":1443,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199708143370702","trainingLevel":"Intern","citation":"Cohen M, <i>et al</i>. \"A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 1997. 337(7):447-452.","subspecialties":"Cardiology","expansion":"Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events Study Group","briefResultsDescription":"LMWH reduces 14-day mortality, MI, or recurrent angina in UA/NSTEMI","published":"1997-08-14","pageName":"ESSENCE","diseases":"Acute Coronary Syndrome","abbreviation":"ESSENCE","title":"A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease","pmid":"9250846"},{"timestamp":"2017-01-16T23:26:38Z","briefDesignDescription":"Ticagrelor vs. clopidogrel in symptomatic PAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1611688","pageid":2878,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611688","trainingLevel":"Resident","citation":"Hiatt WR <i>et al</i>. \"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease\". <i>New Engl J Med</i>. 2017. 376(1):32-40.","subspecialties":"Cardiology","expansion":"Examining use of ticagrelor in peripheral artery disease","briefResultsDescription":"Ticagrelor not superior to clopidogrel in symptomatic PAD","published":"2017-01-05","pageName":"EUCLID (Ticagrelor)","diseases":"Peripheral Arterial Disease","abbreviation":"EUCLID","title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","pmid":"27959717"},{"timestamp":"2013-03-12T08:23:06Z","briefDesignDescription":"Dexamethasone in meningitis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa021334","pageid":306,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa021334","trainingLevel":"Resident","citation":"de Gans JD, <i>et al</i>. \"Dexamethasone in Adults with Bacterial Meningitis\". <i>The New England Journal of Medicine</i>. 2002. 347(20):1549-1556.","subspecialties":"Infectious Disease;Neurology","expansion":"European Dexamethasone Study","briefResultsDescription":"Dexamethasone reduces mortality in bacterial meningitis","published":"2002-11-14","pageName":"European Dexamethasone Study","diseases":"Meningitis","abbreviation":"EDS","title":"Dexamethasone in Adults with Bacterial Meningitis","pmid":"12432041"},{"timestamp":"2015-09-23T06:42:25Z","briefDesignDescription":"Tolvaptan in acute HF in HFrEF","fulltexturl":null,"pageid":1345,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/5131/joc70029_1319_1331.pdf","trainingLevel":"Resident","citation":"Konstam MA, <i>et al</i>. \"The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure\". <i>The Journal of the American Medical Association</i>. 2007. 297(12):1319-1331.","subspecialties":"Cardiology","expansion":"Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan","briefResultsDescription":"No benefit from tolvaptan when given for 60 days after acute HF episode","published":"2007-03-28","pageName":"EVEREST-Outcomes","diseases":"Heart Failure","abbreviation":"EVEREST","title":"The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure","pmid":"17384437"},{"timestamp":"2015-10-18T16:29:54Z","briefDesignDescription":"Cinacalcet in ESRD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1205624","pageid":2426,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205624","trainingLevel":"Resident","citation":"Chertow GM, <i>et al</i>. \"Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis\". <i>The New England Journal of Medicine</i>. 2012. 367(26):2482-2494.","subspecialties":"Nephrology","expansion":"Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis","briefResultsDescription":"Cinecalcet did not reduce CV events in ESRD","published":"2012-12-27","pageName":"EVOLVE","diseases":"Chronic Kidney Disease;Cardiovascular Disease","abbreviation":"EVOLVE","title":"Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis","pmid":"23121374"},{"timestamp":"2017-01-28T20:49:49Z","briefDesignDescription":"CABG vs. PCI in left main CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1610227","pageid":2868,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1610227","trainingLevel":"Resident","citation":"Stone GW, <i>et al</i>. \"Everolimus-eluting stents or bypass surgery for left main coronary artery disease\". <i>The New England Journal of Medicine</i>. 2016. 375(23):2223-35.","subspecialties":"Cardiology","expansion":"XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL)","briefResultsDescription":"PCI noninferior to CABG in left main CAD with low-intermediate anatomic complexity","published":"2016-12-08","pageName":"EXCEL","diseases":"Coronary Artery Disease","abbreviation":"EXCEL","title":"Everolimus-eluting stents or bypass surgery for left main coronary artery disease","pmid":"27797291"},{"timestamp":"2016-04-01T01:03:52Z","briefDesignDescription":"Omalizumab in severe allergic asthma","fulltexturl":null,"pageid":1434,"pdfurl":"http://annals.org/data/Journals/AIM/20231/0000605-201105030-00002.pdf","trainingLevel":"Fellow","citation":"Hanania NA, <i>et al</i>. \"Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial\". <i>Annals of Internal Medicine</i>. 2011. 154(9):573-582.","subspecialties":"Allergy and Immunology;Pulmonology;Pediatrics","expansion":"A Study of Omalizumab/Xolair in Subjects With Moderate to Severe Persistent Asthma","briefResultsDescription":"Omalizumab reduces asthma exacerbations","published":"2011-05-03","pageName":"EXTRA","diseases":"Asthma","abbreviation":"EXTRA","title":"Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial","pmid":"21536936"},{"timestamp":"2013-02-20T06:44:13Z","briefDesignDescription":"FFR-guided PCI in stable CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0807611","pageid":998,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807611","trainingLevel":"resident","citation":"Tonino PAL, <i>et al</i>. \"Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention\". <i>The New England Journal of Medicine</i>. 2009. 360(3):213-224.","subspecialties":"Cardiology","expansion":"Fractional Flow Reserve versus Angiography for Multivessel Evaluation","briefResultsDescription":"FFR reduces composite of death, nonfatal MI, urgent revascularization","published":"2009-01-15","pageName":"FAME","diseases":"Coronary Artery Disease","abbreviation":"FAME","title":"Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention","pmid":"19144937"},{"timestamp":"2014-10-07T16:18:34Z","briefDesignDescription":"FFR-guided PCI vs. OMT in CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1205361","pageid":1003,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205361","trainingLevel":"Resident","citation":"De Bruyne B, <i>et al</i>. \"Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease\". <i>The New England Journal of Medicine</i>. 2012. 367(11):991-1001.","subspecialties":"Cardiology","expansion":"FFR vs. Angiographyfor Multivessel Evaluation 2","briefResultsDescription":"FFR-guided PCI reduces urgent revascularization","published":"2012-09-13","pageName":"FAME 2","diseases":"Coronary Artery Disease","abbreviation":"FAME 2","title":"Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease","pmid":"22924638"},{"timestamp":"2014-11-28T20:04:58Z","briefDesignDescription":"Fluid resuscitation in Sub-Saharan Africa","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1101549","pageid":1860,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1101549","trainingLevel":"Resident","citation":"Maitland K, <i>et al</i>. \"Mortality after fluid bolus in African children with severe infection\". <i>The New England Journal of Medicine</i>. 2011. 364(26):2483-2495.","subspecialties":"Pediatrics;Critical Care","expansion":"Fluid Expansion as Supportive Therapy","briefResultsDescription":"Albumin and saline increase mortality when compared to no fluids in this patient population","published":"2011-06-30","pageName":"FEAST","diseases":"Shock","abbreviation":"FEAST","title":"Mortality after fluid bolus in African children with severe infection","pmid":"21615299"},{"timestamp":"2013-10-07T20:50:13Z","briefDesignDescription":"Fidaxomicin in C. difficile","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0910812","pageid":255,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910812","trainingLevel":"Resident","citation":"Louie TJ, <i>et al</i>. \"Fidaxomicin versus Vancomycin for Clostridium difficile Infection\". <i>The New England Journal of Medicine</i>. 2011. 365(5):422-431.","subspecialties":"Infectious Disease;Gastroenterology","expansion":null,"briefResultsDescription":"Fidaxomicin noninferior to vancomycin for cure, and resulted in 45% fewer recurrences","published":"2011-02-03","pageName":"Fidaxomicin in C. difficile Diarrhea","diseases":"Clostridium difficile","abbreviation":null,"title":"Fidaxomicin versus Vancomycin for Clostridium difficile Infection","pmid":"21288078"},{"timestamp":"2016-12-01T04:56:21Z","briefDesignDescription":"Cryoablation vs. RF ablation in pAF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1602014","pageid":2795,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1602014","trainingLevel":"Resident","citation":"Kuck K, <i>et al</i>. \"Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2016. 374(23):2235-45.","subspecialties":"Cardiology","expansion":"","briefResultsDescription":"Cryoablation equivalent to RF ablation in pAF","published":"2016-06-09","pageName":"FIRE AND ICE","diseases":"Atrial Fibrillation","abbreviation":"FIRE AND ICE","title":"Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation","pmid":"27042964"},{"timestamp":"2017-02-08T16:37:01Z","briefDesignDescription":"LABA+LAMA vs. LABA+ICS in COPD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1516385","pageid":2871,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1516385","trainingLevel":"Resident","citation":"Wedzicha JA, <i>et al</i>. \"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD\". <i>The New England Journal of Medicine</i>. 2016. 374(23):2222-2234.","subspecialties":"Pulmonology","expansion":"Effect of Indacaterol Glycopyronium Vs. Fluticasone Salmeterol on COPD Exacerbations","briefResultsDescription":"LABA+LAMA reduces COPD exacerbations","published":"2016-06-09","pageName":"FLAME (COPD)","diseases":"Emphysema;Chronic Bronchitis;Chronic Obstructive Pulmonary Disease","abbreviation":"FLAME COPD","title":"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD","pmid":"27181606"},{"timestamp":"2017-02-01T03:34:51Z","briefDesignDescription":"SSRI after CVA for motor recovery","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S1474-4422(10)70314-8","pageid":2370,"pdfurl":"","trainingLevel":"Resident","citation":"Chollet F, <i>et al</i>. \"Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial\". <i>The Lancet Neurology</i>. 2011. 10(2):123-130.","subspecialties":"Neurology","expansion":"Fluoxetine for Motor Recovery after Acute Ischaemic Stroke","briefResultsDescription":"Early fluoxetine improved motor outcomes post stroke","published":"2011-02-01","pageName":"FLAME (Stroke)","diseases":"Stroke","abbreviation":"FLAME","title":"Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial","pmid":"21216670"},{"timestamp":"2017-03-29T01:17:07Z","briefDesignDescription":"Evolocumab for CVD events if atherosclerotic disease","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1615664","pageid":2891,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1615664","trainingLevel":"Resident","citation":"Sabatine MS, <i>et al</i>. \"Evolocumab and clinical outcomes in patients with cardiovascular disease\". <i>The New England Journal of Medicine</i>. 2017. epub 2017-03-17:1-10.","subspecialties":"Cardiology","expansion":"Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk","briefResultsDescription":"Evolocumab reduces CV events in patients with atherosclerotic disease","published":"2017-03-17","pageName":"FOURIER","diseases":"Coronary Artery Disease","abbreviation":"FOURIER","title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","pmid":"28304224"},{"timestamp":"2016-04-18T04:27:26Z","briefDesignDescription":"CABG vs. PCI for CAD in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1211585","pageid":2314,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1211585","trainingLevel":"Resident","citation":"Farkouh ME, <i>et al</i>. \"Strategies for multivessel revascularization in patients with diabetes\". <i>The New England Journal of Medicine</i>. 2012. 367(25):2375-2384.","subspecialties":"Cardiology;Endocrinology","expansion":"Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease","briefResultsDescription":"CABG reduces death and revascularization rates but causes more strokes","published":"2012-12-20","pageName":"FREEDOM","diseases":"Coronary Artery Disease;Diabetes Mellitus","abbreviation":"FREEDOM","title":"Strategies for multivessel revascularization in patients with diabetes","pmid":"23121323"},{"timestamp":"2015-11-10T22:57:39Z","briefDesignDescription":"Early invasive strategy in UA/NSTEMI","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)07349-3/fulltext","pageid":2451,"pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(99)07349-3.pdf","trainingLevel":"Resident","citation":"FRISC Investigators. \"Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study\". <i>The Lancet</i>. 1999. 354(9180):708-15.","subspecialties":"Cardiology","expansion":"","briefResultsDescription":"Fewer recurrent MIs with early invasive strategy in high-risk patients","published":"1999-08-28","pageName":"FRISC-II","diseases":"Coronary Artery Disease;Myocardial Infarction;Acute Coronary Syndrome","abbreviation":"FRISC-II","title":"Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study","pmid":"10475181"},{"timestamp":"2016-04-01T01:05:22Z","briefDesignDescription":"Risk factors for GI bleeds in ICU patients","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199402103300601","pageid":391,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199402103300601","trainingLevel":"Intern","citation":"Cook DJ, <i>et al</i>. \"Risk factors for gastrointestinal bleeding in critically ill patients\". <i>The New England Journal of Medicine</i>. 1994. 330(6):337-381.","subspecialties":"Critical Care;Gastroenterology","expansion":null,"briefResultsDescription":"Greatest risk for GI bleed with coagulopathy and mechanical ventilation","published":"1994-02-10","pageName":"GI bleeding in ICU patients","diseases":"Gastrointestinal Hemorrhage","abbreviation":null,"title":"Risk factors for gastrointestinal bleeding in critically ill patients","pmid":"8284001"},{"timestamp":"2014-09-24T22:28:37Z","briefDesignDescription":"Lisinopril in acute MI","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2990232-1/abstract","pageid":258,"pdfurl":"","trainingLevel":"Resident","citation":"GISSI-3 Group. \"Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction\". <i>The Lancet</i>. 1994. 343(8906):1115-22.","subspecialties":"Cardiology","expansion":"Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico","briefResultsDescription":"Lisinopril improves 6-week mortality","published":"1994-05-07","pageName":"GISSI-3","diseases":"Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"GISSI-3","title":"Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction","pmid":"7910229"},{"timestamp":"2015-10-05T15:11:02Z","briefDesignDescription":"tPA in ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199309023291001","pageid":2177,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199309023291001","trainingLevel":"Student","citation":"Topol E, <i>et al</i>. \"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction\". <i>The New England Journal of Medicine</i>. 1993. 329(10):673-682.","subspecialties":"Cardiology","expansion":"Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries","briefResultsDescription":"tPA reduces mortality in ACS","published":"1993-09-03","pageName":"GUSTO","diseases":"Myocardial Infarction;Acute Coronary Syndrome","abbreviation":"GUSTO","title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","pmid":"8204123"},{"timestamp":"2014-09-19T10:30:21Z","briefDesignDescription":"Hypothermia for cardiac arrest","fulltexturl":"http://www.nejm.org/doi/full/10.1056/nejmoa012689","pageid":410,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/nejmoa012689","trainingLevel":"Resident","citation":"Holzer M, <i>et al</i>. \"Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest\". <i>The New England Journal of Medicine</i>. 2002. 346(8):549-556.","subspecialties":"Critical Care;Neurology;Cardiology","expansion":"Hypothermia After Cardiac Arrest","briefResultsDescription":"Hypothermia improves neurologic outcomes and reduces mortality","published":"2002-02-21","pageName":"HACA","diseases":"Cardiac Arrest","abbreviation":"HACA","title":"Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest","pmid":"11856793"},{"timestamp":"2016-09-03T01:37:44Z","briefDesignDescription":"Continuous-flow LVAD in heart failure","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0909938#t","pageid":2808,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0909938","trainingLevel":"Fellow","citation":"Slaughter MS, <i>et al</i>. \"Advanced heart failure treated with continuous-flow left ventricular assist device\". <i>The New England Journal of Medicine</i>. 2009. 361(23):2241-2251.","subspecialties":"Cardiology","expansion":"Advanced heart failure treated with continuous-flow left ventricular assist device","briefResultsDescription":"Continuous-flow LVAD improved survival free from stroke and device failure","published":"2009-12-03","pageName":"HEARTMATE II","diseases":"Heart Failure","abbreviation":"HEARTMATE II","title":"Advanced heart failure treated with continuous-flow left ventricular assist device","pmid":"19920051"},{"timestamp":"2013-10-09T17:11:02Z","briefDesignDescription":"Trastuzumab in breast cancer","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa052306","pageid":440,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa052306","trainingLevel":"Resident","citation":"Piccart-Gebhart MJ, <i>et al</i>. \"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer\". <i>The New England Journal of Medicine</i>. 2005. 353(16):1659-72.","subspecialties":"Oncology","expansion":"Herceptin Adjuvant Trial","briefResultsDescription":"Trastuzumab improves survival","published":"2005-10-20","pageName":"HERA","diseases":"Breast Cancer","abbreviation":"HERA","title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","pmid":"16236737"},{"timestamp":"2013-08-15T18:50:04Z","briefDesignDescription":"Ramipril in patients with high CV risk","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200001203420301","pageid":1165,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200001203420301","trainingLevel":"intern","citation":"Yusuf S, <i>et al</i>. \"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients\". <i>The New England Journal of Medicine</i>. 2000. 342(3):145-153.","subspecialties":"Cardiology;Neurology","expansion":"Heart Outcomes Prevention Evaluation","briefResultsDescription":"Ramipril reduces death, MI, and stroke","published":"2000-01-20","pageName":"HOPE","diseases":"Coronary Artery Disease;Stroke;Transient Ischemic Attack","abbreviation":"HOPE","title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","pmid":"10639539"},{"timestamp":"2015-04-18T20:54:22Z","briefDesignDescription":"Niacin in atherosclerotic disease","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1300955","pageid":2329,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300955","trainingLevel":"Intern","citation":"Landray MJ <i>et al</i>. \"Effects of extended-release niacin with laropiprant in high-risk patients\". <i>The New England Journal of Medicine</i>. 2014. 371(3):203-212.","subspecialties":"Cardiology","expansion":"Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events","briefResultsDescription":"Niacin is poorly tolerated, doesn't reduce major vascular events","published":"2014-07-17","pageName":"HPS2-THRIVE","diseases":"Coronary Artery Disease;Peripheral Vascular Disease","abbreviation":"HPS2-THRIVE","title":"Effects of extended-release niacin with laropiprant in high-risk patients","pmid":"25014686"},{"timestamp":"2014-11-24T14:57:45Z","briefDesignDescription":"Early ART in HIV","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1105243","pageid":1010,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1105243","trainingLevel":"Resident","citation":"Cohen MS, <i>et al</i>. \"Prevention of HIV-1 Infection with Early Antiretroviral Therapy\". <i>The New England Journal of Medicine</i>. 2011. 365(6):493-505.","subspecialties":"Infectious Disease","expansion":"HIV Prevention Trials Network 052 Study","briefResultsDescription":"Reduced morbidity and HIV transmission","published":"2011-08-11","pageName":"HPTN 052","diseases":"HIV","abbreviation":"HPTN 052","title":"Prevention of HIV-1 Infection with Early Antiretroviral Therapy","pmid":"21767103"},{"timestamp":"2016-10-28T14:45:04Z","briefDesignDescription":"High sensitivity troponin for acute chest pain","fulltexturl":"http://www.sciencedirect.com/science/article/pii/S0735109714017264","pageid":2343,"pdfurl":null,"trainingLevel":"Intern","citation":"Bandstein N, <i>et al</i>. \"Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction\". <i>Journal of the American College of Cardiology</i>. 2014. 63(23):2569-2578.","subspecialties":"Emergency Medicine;Cardiology","expansion":null,"briefResultsDescription":"HS troponin-T is associated with high NPV for MI at 30 days","published":"2014-06-17","pageName":"HS troponin-T to rule out MI","diseases":"Acute Coronary Syndrome;Myocardial Infarction","abbreviation":null,"title":"Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction","pmid":"24694529"},{"timestamp":"2014-12-05T14:52:27Z","briefDesignDescription":"Perinatal vitamins to prevent neural tube defects","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199212243272602","pageid":2142,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199212243272602","trainingLevel":"Student","citation":"Czeizel AE and Dudas I. \"Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation\". <i>The New England Journal of Medicine</i>. 1992. 327(26):1832-1835.","subspecialties":"Obstetrics;Preventive Medicine","expansion":null,"briefResultsDescription":"Perinatal vitamins reduce neural tube defects","published":"1992-12-24","pageName":"Hungarian Prenatal Vitamin Trial","diseases":"Neural Tube Defects","abbreviation":null,"title":"Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation","pmid":"1307234"},{"timestamp":"2016-11-14T00:03:37Z","briefDesignDescription":"Hydrocortisone vs. placebo in severe sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMsa1410639","pageid":2860,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMsa1410639","trainingLevel":"Resident","citation":"Keh D, <i>et al</i>. \"Effect of hydrocortisone on development of shock among patients with severe sepsis\". <i>Journal of the American Medical Association</i>. 2016. 316(17):1775-1785.","subspecialties":"Critical Care","expansion":"","briefResultsDescription":"Hydrocortisone not superior to placebo in severe sepsis","published":"2016-10-03","pageName":"HYPRESS","diseases":"Sepsis","abbreviation":"HYPRESS","title":"Effect of hydrocortisone on development of shock among patients with severe sepsis","pmid":"27695824"},{"timestamp":"2016-04-01T01:04:48Z","briefDesignDescription":"Elderly HTN treatment","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0801369","pageid":2349,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0801369","trainingLevel":"Intern","citation":"Beckett NS, <i>et al</i>. \"Treatment of hypertension in patients 80 years of age or older\". <i>The New England Journal of Medicine</i>. 2008. 358(18):1887-1898.","subspecialties":"Nephrology;Cardiology;Geriatrics","expansion":"Hypertension in the Very Elderly Trial","briefResultsDescription":"Trend towards reduction in stroke with treatment (P","published":"2008-05-01","pageName":"HYVET","diseases":"Hypertension","abbreviation":"HYVET","title":"Treatment of hypertension in patients 80 years of age or older","pmid":"18378519"},{"timestamp":"2014-06-13T05:59:23Z","briefDesignDescription":"IABP in MI and cardiogenic shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1208410","pageid":1065,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208410","trainingLevel":"Fellow","citation":"Thiele H, <i>et al</i>. \"Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock\". <i>The New England Journal of Medicine</i>. 2012. 367(14):1287-1296.","subspecialties":"Cardiology;Critical Care","expansion":"Intraaortic Balloon Pump in Cardiogenic Shock II","briefResultsDescription":"IABP did not reduce mortality at 30 days","published":"2012-10-10","pageName":"IABP-SHOCK II","diseases":"Acute Coronary Syndrome;Myocardial Infarction;Shock","abbreviation":"IABP-SHOCK II","title":"Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock","pmid":"22920912"},{"timestamp":"2016-01-07T06:34:16Z","briefDesignDescription":"Second-line ibrutinib in WM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1501548","pageid":2660,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501548","trainingLevel":"Fellow","citation":"Treon SP, <i>et al</i>. \"Ibrutinib in Previously Treated Waldenstrom Macroglobulinemia\". <i>The New England Journal of Medicine</i>. 2015. 372(15):1430-1440.","subspecialties":"Hematology","expansion":null,"briefResultsDescription":"Ibrutinib is safe and effective in previously treated WM","published":"2015-04-09","pageName":"Ibrutinib in Waldenstrom macroglobulinemia","diseases":"Lymphoma;Waldenström Macroglobulinemia","abbreviation":null,"title":"Ibrutinib in Previously Treated Waldenstrom Macroglobulinemia","pmid":"25853747"},{"timestamp":"2014-12-10T17:26:18Z","briefDesignDescription":"Colchicine in the first episode of acute pericarditis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1208536","pageid":1729,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208536","trainingLevel":"Intern","citation":"Imazio M, <i>et al</i>. \"A Randomized Trial of Colchicine for Acute Pericarditis\". <i>The New England Journal of Medicine</i>. 2013. 369(16):1522-1528.","subspecialties":"Cardiology","expansion":"Evaluation of additive benefit of colchicine to conventional therapy in acute pericarditis","briefResultsDescription":"Colchicine reduces incessant or recurrent acute pericarditis when used in first episode","published":"2013-10-17","pageName":"ICAP","diseases":"Pericarditis","abbreviation":"ICAP","title":"A Randomized Trial of Colchicine for Acute Pericarditis","pmid":"23992557"},{"timestamp":"2015-03-09T17:55:21Z","briefDesignDescription":"Early vs. late dialysis in CKD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1000552","pageid":1020,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000552","trainingLevel":"Resident","citation":"Cooper BA, <i>et al</i>. \"A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis\". <i>The New England Journal of Medicine</i>. 2010. 363(7):609-619.","subspecialties":"Nephrology","expansion":"Initiating Dialysis Early and Late","briefResultsDescription":"No difference in survival or clinical outcomes","published":"2010-08-12","pageName":"IDEAL","diseases":"Chronic Kidney Disease","abbreviation":"IDEAL","title":"A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis","pmid":"20581422"},{"timestamp":"2016-04-01T23:27:03Z","briefDesignDescription":"ARBs in diabetic nephropathy","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa011303","pageid":2670,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa011303","trainingLevel":"Resident","citation":"Lewis EJ, <i>et al</i>. \"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2001. 345(12):851-860.","subspecialties":"Nephrology;Endocrinology","expansion":"Irbesartan Diabetic Nephropathy Trial","briefResultsDescription":"ARBs prevent progression of T2DM nephropathy","published":"2001-09-20","pageName":"IDNT","diseases":"Diabetic Nephropathy;Diabetes Mellitus","abbreviation":"IDNT","title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","pmid":"11565517"},{"timestamp":"2016-02-01T10:43:04Z","briefDesignDescription":"Early vs. delayed ART in HIV","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1506816","pageid":2468,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506816","trainingLevel":"Student","citation":"INSIGHT START Writers. \"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection\". <i>The New England Journal of Medicine</i>. 2015. 373(9):795-807.","subspecialties":"Infectious Disease","expansion":null,"briefResultsDescription":"Less complications with early ART","published":"2015-08-27","pageName":"INSIGHT START","diseases":"HIV","abbreviation":"START","title":"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection","pmid":"26192873"},{"timestamp":"2015-12-05T21:34:41Z","briefDesignDescription":"ART in primary HIV prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1011205","pageid":1100,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1011205","trainingLevel":"intern","citation":"Grant RM, <i>et al</i>. \"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men\". <i>The New England Journal of Medicine</i>. 2010. 363(27):2587-2599.","subspecialties":"Infectious Disease;Preventive Medicine","expansion":"Iniciativa Profilaxis Pre Exposicion (\"Preexposure Prophylaxis Initiative\")","briefResultsDescription":"ART reduces tranmission of HIV among MSM","published":"2010-12-30","pageName":"IPrEx","diseases":"HIV","abbreviation":"iPrEx","title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","pmid":"21091279"},{"timestamp":"2016-03-01T14:04:38Z","briefDesignDescription":"Imatinib vs. IFNα/cytarabine in CML","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa022457","pageid":1076,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa022457","trainingLevel":"Student","citation":"O'Brien SG, <i>et al</i>. \"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia\". <i>The New England Journal of Medicine</i>. 2003. 384(11):994-1004.","subspecialties":"Hematology;Oncology","expansion":"International Randomized Study of Interferon and STI571","briefResultsDescription":"Imatinib delays disease progression","published":"2003-03-13","pageName":"IRIS","diseases":"Chronic Myeloid Leukemia;Myeloproliferative Neoplasms","abbreviation":"IRIS","title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","pmid":"12637609"},{"timestamp":"2017-01-25T21:25:48Z","briefDesignDescription":"Triple therapy for 6w vs. 6m after DES","fulltexturl":"http://content.onlinejacc.org/article.aspx?articleID","pageid":2812,"pdfurl":"http://content.onlinejacc.org/data/Journals/JAC/933764/02050.pdf","trainingLevel":"Intern","citation":"Fiedler KA <i>et al</i>. \"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation\". <i>J Am Coll Cardiol</i>. 2015. 65(16):1619-30.","subspecialties":"Cardiology","expansion":"Triple therapy in Patients who Require Oral Anticoagulation After Drug-Eluting Stent Implantation","briefResultsDescription":"Triple therapy for 6 weeks not superior to 6 months in regards to net clinical outcome","published":"2015-04-28","pageName":"ISAR-TRIPLE","diseases":"Coronary Artery Disease;Atrial Fibrillation","abbreviation":"ISAR-TRIPLE","title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation","pmid":"25908066"},{"timestamp":"2016-10-30T14:54:03Z","briefDesignDescription":"Aspirin ± streptokinase in acute MI","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)92833-4/abstract","pageid":133,"pdfurl":"","trainingLevel":"Resident","citation":"ISIS-2 Collaborative Group. \"Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither among 17187 Cases of Suspected Acute Myocardial Infarction\". <i>The Lancet</i>. 1988. 332(8607):349-360.","subspecialties":"Cardiology","expansion":"Second International Study of Infarct Survival","briefResultsDescription":"Mortality benefit of aspirin within 24 hours of acute MI","published":"1988-08-13","pageName":"ISIS-2","diseases":"Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"ISIS-2","title":"Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither among 17187 Cases of Suspected Acute Myocardial Infarction","pmid":"2899772"},{"timestamp":"2016-03-07T04:46:48Z","briefDesignDescription":"Aspirin in acute ischemic stroke","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)04011-7/fulltext","pageid":132,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673697040117.pdf","trainingLevel":"Intern","citation":"IST Collaborative Group. \"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke\". <i>The Lancet</i>. 1997. 349(9065):1569-1581.","subspecialties":"Neurology","expansion":"International Stroke Trial","briefResultsDescription":"Mortality benefit with aspirin","published":"1997-05-31","pageName":"IST","diseases":"Stroke","abbreviation":"IST","title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke","pmid":"9174558"},{"timestamp":"2014-12-12T19:36:46Z","briefDesignDescription":"Rosuvastatin for primary CV prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0807646","pageid":445,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807646","trainingLevel":"resident","citation":"Ridker PM, <i>et al</i>. \"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein\". <i>The New England Journal of Medicine</i>. 2008. 359(21):2195-2207.","subspecialties":"Cardiology;Preventive Medicine","expansion":"Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin","briefResultsDescription":"Rosuvastatin delays major CV events","published":"2008-11-20","pageName":"JUPITER","diseases":"Hyperlipidemia;Coronary Artery Disease;Stroke;Transient Ischemic Attack","abbreviation":"JUPITER","title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","pmid":"18997196"},{"timestamp":"2016-11-28T21:35:41Z","briefDesignDescription":"Pembrolizumab vs. chemotherapy in NSCLC","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1606774","pageid":2846,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1606774","trainingLevel":"Resident","citation":"Reck M, <i>et al</i>. \"Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer\". <i>The New England Journal of Medicine</i>. 2016. 375(19):1824-1833.","subspecialties":"Oncology","expansion":"","briefResultsDescription":"Pembrolizumab improves survival in advanced NSCLC over chemotherapy","published":"2016-11-10","pageName":"KEYNOTE-024","diseases":"Lung Cancer","abbreviation":"KEYNOTE-024","title":"Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer","pmid":"27718847"},{"timestamp":"2016-09-06T21:17:09Z","briefDesignDescription":"Liraglutide and CVD endpoints in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1603827","pageid":2803,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1603827","trainingLevel":"Resident","citation":"Marso SP, <i>et al</i>. \"Liraglutide and cardiovascular outcomes in type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2016. 375(4):311-322.","subspecialties":"Cardiology;Endocrinology","expansion":"Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results","briefResultsDescription":"Liraglutide reduces CV mortality in T2DM","published":"2016-06-28","pageName":"LEADER","diseases":"Diabetes Mellitus;Cardiovascular Disease","abbreviation":"LEADER","title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","pmid":"27295427"},{"timestamp":"2016-01-31T19:13:00Z","briefDesignDescription":"Epidural steroids in spinal stenosis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1313265","pageid":1883,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1313265","trainingLevel":"Resident","citation":"Friedly JL, <i>et al</i>. \"A randomized trial of epidural glucocorticoid injections for spinal stenosis\". <i>The New England Journal of Medicine</i>. 2014. 371(1):11-21.","subspecialties":"Pain Medicine;Physical Medicine and Rehabilitation;Radiology","expansion":"Lumbar Epidural Steroid Injections for Spinal Stenosis","briefResultsDescription":"Epidural steroids don't improve pain or disability at six weeks","published":"2014-07-03","pageName":"LESS","diseases":"Spinal Stenosis","abbreviation":"LESS","title":"A randomized trial of epidural glucocorticoid injections for spinal stenosis","pmid":"24988555"},{"timestamp":"2017-01-19T20:18:41Z","briefDesignDescription":"Intensive glycemic therapy in the surgical ICU","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa011300","pageid":139,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa011300","trainingLevel":"Resident","citation":"Van den Berghe G, <i>et al</i>. \"Intensive Insulin Therapy in Critically Ill Patients\". <i>The New England Journal of Medicine</i>. 2001. 345(19):1359-1367.","subspecialties":"Critical Care;Endocrinology","expansion":"","briefResultsDescription":"Intensive glycemic control reduces mortality","published":"2001-11-08","pageName":"Leuven Surgical Trial","diseases":"Stress Hyperglycemia","abbreviation":"Leuven Surgical Trial","title":"Intensive Insulin Therapy in Critically Ill Patients","pmid":"11794168"},{"timestamp":"2016-08-13T14:15:04Z","briefDesignDescription":"ATRA-ATO vs. ATRA-chemotherapy in APL","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1300874","pageid":2285,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300874","trainingLevel":"Fellow","citation":"Lo-Coco F, <i>et al</i>. \"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia\". <i>The New England Journal of Medicine</i>. 2013. 369(2):111-21.","subspecialties":"Hematology;Oncology","expansion":"","briefResultsDescription":"ATRA-ATO is noninferior, possibly superior to ATRA-chemotherapy in APL","published":"2013-07-11","pageName":"Lo-Coco 2013","diseases":"Leukemia","abbreviation":"","title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","pmid":"23841729"},{"timestamp":"2016-04-01T00:50:48Z","briefDesignDescription":"Colchicine for stable CAD","fulltexturl":"http://www.sciencedirect.com/science/article/pii/S0735109712054782","pageid":1583,"pdfurl":null,"trainingLevel":"Resident","citation":"Nidorf SM, <i>et al</i>. \"Low-dose colchicine for secondary prevention of cardiovascular disease\". <i>Journal of the American College of Cardiology</i>. 2013. 61(4):404-410.","subspecialties":"Cardiology","expansion":"Low-Dose Colchicine","briefResultsDescription":"Colcicine may reduce complications in stable CAD","published":"2013-01-29","pageName":"LoDoCo","diseases":"Coronary Artery Disease","abbreviation":"LoDoCo","title":"Low-dose colchicine for secondary prevention of cardiovascular disease","pmid":"23265346"},{"timestamp":"2016-10-24T14:24:59Z","briefDesignDescription":"Weight loss and exercise in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1212914","pageid":1546,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1212914","trainingLevel":"Intern","citation":"Wing RR, <i>et al</i>. \"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2013. 369(2):145-154.","subspecialties":"Endocrinology;Cardiology","expansion":"Look Action for HEAlth in Diabetes","briefResultsDescription":"No reduction of CVD with weight loss and exercise in T2DM","published":"2013-07-11","pageName":"Look AHEAD","diseases":"Diabetes Mellitus;Cardiovascular Disease","abbreviation":"Look AHEAD","title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","pmid":"23796131"},{"timestamp":"2015-10-17T12:47:53Z","briefDesignDescription":"CRT in HFrEF with QRS ≥130 msec and mild symptoms","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0906431","pageid":1780,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0906431","trainingLevel":"Resident","citation":"Moss AJ, <i>et al</i>. \"Cardiac-resynchronization therapy for the prevention of heart-failure events\". <i>The New England Journal of Medicine</i>. 2009. 361(14):1329-1338.","subspecialties":"Cardiology","expansion":"Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy","briefResultsDescription":"CRT reduces mortality or HF complications in mildly symptomatic HFrEF with prolonged QRS","published":"2009-10-01","pageName":"MADIT-CRT","diseases":"Heart Failure","abbreviation":"MADIT-CRT","title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","pmid":"19723701"},{"timestamp":"2015-08-24T04:47:14Z","briefDesignDescription":"ICD in post-MI patients with HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa013474","pageid":385,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa013474","trainingLevel":"Resident","citation":"Moss AJ, <i>et al</i>. \"Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction\". <i>The New England Journal of Medicine</i>. 2002. 346(12):877-883.","subspecialties":"Cardiology","expansion":"Multicenter Automatic Defibrillator Implantation Trial II","briefResultsDescription":"ICD improves survival in post-MI patients with LVEF≤30%","published":"2002-03-21","pageName":"MADIT-II","diseases":"Heart Failure;Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"MADIT-II","title":"Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction","pmid":"11907286"},{"timestamp":"2015-04-12T06:49:08Z","briefDesignDescription":"Rivaroxaban vs. LMWH for VTE prophylaxis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1111096","pageid":1272,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1111096","trainingLevel":"Resident","citation":"Cohen AT, <i>et al</i>. \"Rivaroxaban for thromboprophylaxis in acutely ill medical patients\". <i>The New England Journal of Medicine</i>. 2013. 368(6):513-523.","subspecialties":"Hematology","expansion":"Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban with Enoxaparin","briefResultsDescription":"Rivaroxaban similar to LMWH for prophylaxis, caused more bleeding","published":"2013-02-07","pageName":"MAGELLAN","diseases":"Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","abbreviation":"MAGELLAN","title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","pmid":"23388003"},{"timestamp":"2015-10-29T05:08:46Z","briefDesignDescription":"US screening for AAA in men","fulltexturl":"http://www.bmj.com/content/338/bmj.b2307.long","pageid":2397,"pdfurl":"http://www.bmj.com/content/338/bmj.b2307.full.pdf","trainingLevel":"Intern","citation":"Thompson SG, <i>et al</i>. \"Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study\". <i>BMJ</i>. 2009. 338:b2307.","subspecialties":"Preventive Medicine;Radiology","expansion":"Multicentre Aneurysm Screening Study","briefResultsDescription":"US screening reduces AAA mortality in men","published":"2009-06-24","pageName":"MASS","diseases":"Abdominal Aortic Aneurysm","abbreviation":"MASS","title":"Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study","pmid":"19553269"},{"timestamp":"2016-03-07T04:48:46Z","briefDesignDescription":"ASA/clopidogrel vs. clopidogrel in stroke","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16721-4/fulltext","pageid":1125,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673604167214.pdf","trainingLevel":"student","citation":"Diener HC, <i>et al</i>. \"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial\". <i>The Lancet</i>. 2004. 364(9431):331-337.","subspecialties":"Neurology","expansion":"Management of Atherothrombosis with Clopidogrel in High-risk patients","briefResultsDescription":"More major bleeding but no greater efficacy with combination therapy","published":"2004-07-24","pageName":"MATCH","diseases":"Stroke","abbreviation":"MATCH","title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","pmid":"15276392"},{"timestamp":"2015-08-24T03:51:03Z","briefDesignDescription":"Metoprolol in HFrEF","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140673699044402","pageid":130,"pdfurl":"","trainingLevel":"Resident","citation":"Fagerberg B, <i>et al</i>. \"Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure\". <i>The Lancet</i>. 1999. 353(9169):2001-7.","subspecialties":"Cardiology","expansion":"Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure","briefResultsDescription":"Metoprolol improves survival in NYHA II-IV HFrEF","published":"1999-06-12","pageName":"MERIT-HF","diseases":"Heart Failure","abbreviation":"MERIT-HF","title":"Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure","pmid":"10376614"},{"timestamp":"2015-04-18T20:55:54Z","briefDesignDescription":"Surgery vs. PT in OA with meniscal tear","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1301408","pageid":1429,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1301408","trainingLevel":"Student","citation":"Katz JN, <i>et al</i>. \"Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis\". <i>The New England Journal of Medicine</i>. 2013. 368(18):1675-1684.","subspecialties":"Surgery;Physical Medicine and Rehabilitation","expansion":"Meniscal Tear in Osteoarthritis Research","briefResultsDescription":"Surgery no better than PT alone","published":"2013-05-02","pageName":"METEOR","diseases":"Meniscal Tear;Osteoarthritis","abbreviation":"METEOR","title":"Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis","pmid":"23506518"},{"timestamp":"2014-05-16T18:12:22Z","briefDesignDescription":"Early surgery for MR","fulltexturl":"","pageid":1787,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/927436/joi130034.pdf","trainingLevel":"Resident","citation":"Suri RM, <i>et al</i>. \"Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets\". <i>JAMA</i>. 2013. 310(6):609-616.","subspecialties":"Cardiology","expansion":"Mitral Regurgitation International Database","briefResultsDescription":"Early surgery reduces mortality in MR","published":"2013-08-14","pageName":"MIDA","diseases":"Mitral Regurgitation","abbreviation":"MIDA","title":"Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets","pmid":"23942679"},{"timestamp":"2015-06-21T20:25:46Z","briefDesignDescription":"Atorvastatin in UA/NSTEMI","fulltexturl":"http://jama.ama-assn.org/content/285/13/1711.long","pageid":432,"pdfurl":"http://jama.ama-assn.org/content/285/13/1711.full.pdf","trainingLevel":"Resident","citation":"Schwartz GG, <i>et al</i>. \"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes\". <i>Journal of the American Medical Association</i>. 2001. 285(13):1711-1718.","subspecialties":"Cardiology","expansion":"Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering","briefResultsDescription":"Atorvastatin reduced rate of CV events after UA/NSTEMI","published":"2001-04-04","pageName":"MIRACL","diseases":"Coronary Artery Disease;Acute Coronary Syndrome;Hyperlipidemia","abbreviation":"MIRACL","title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes","pmid":"11277825"},{"timestamp":"2017-02-23T15:15:18Z","briefDesignDescription":"Low-dose tPA for submassive PE","fulltexturl":"http://www.ajconline.org/article/S0002-9149%2812%2902205-9/fulltext","pageid":1785,"pdfurl":"http://download.journals.elsevierhealth.com/pdfs/journals/0002-9149/PIIS0002914912022059.pdf","trainingLevel":"Intern","citation":"Sharifi M, <i>et al</i>. \"Moderate pulmonary embolism treated with thrombolysis\". <i>The American Journal of Cardiology</i>. 2013. 111(2):273-277.","subspecialties":"Critical Care;Pulmonology;Cardiology","expansion":"Moderate Pulmonary Embolism Treated with Thrombolysis","briefResultsDescription":"Low-dose tPA reduces pulmonary HTN in submassive PE","published":"2013-01-15","pageName":"MOPETT","diseases":"Pulmonary Embolism;Venous Thromboembolism","abbreviation":"MOPETT","title":"Moderate pulmonary embolism treated with thrombolysis","pmid":"23102885"},{"timestamp":"2014-06-08T03:15:16Z","briefDesignDescription":"Arthroscopy in knee OA","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa013259","pageid":1055,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa013259","trainingLevel":"Resident","citation":"Moseley JB, <i>et al</i>. \"A controlled trial of arthroscopic surgery for osteoarthritis of the knee\". <i>The New England Journal of Medicine</i>. 2002. 347(2):81-88.","subspecialties":"Surgery;Physical Medicine and Rehabilitation","expansion":"","briefResultsDescription":"No difference between groups at 2 years","published":"2002-07-11","pageName":"Moseley Trial","diseases":"Osteoarthritis","abbreviation":"","title":"A controlled trial of arthroscopic surgery for osteoarthritis of the knee","pmid":"12110735"},{"timestamp":"2016-11-12T21:01:49Z","briefDesignDescription":"Gemcitabine/nab-paclitaxel in pancreatic cancer","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1304369","pageid":2816,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1304369","trainingLevel":"Resident","citation":"Von Hoff DD, <i>et al</i>. \"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine\". <i>The New England Journal of Medicine</i>. 2013. 369(18):1691-1703.","subspecialties":"Oncology","expansion":"Metastatic Pancreatic Adenocarcinoma Clinical Trial","briefResultsDescription":"Gemcicabine/nab-paclitaxel improves OS in metastatic pancreatic cancer compared to gemcitabine","published":"2013-10-31","pageName":"MPACT","diseases":"Pancreatic Cancer","abbreviation":"MPACT","title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","pmid":"24131140"},{"timestamp":"2016-03-10T04:00:44Z","briefDesignDescription":"IA therapy for proximal large artery strokes","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1411587","pageid":2373,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1411587","trainingLevel":"Intern","citation":"Berkhemer OA, <i>et al</i>. \"A randomized trial of intraarterial treatment for acute ischemic stroke\". <i>The New England Journal of Medicine</i>. 2015. 372(1):11-20.","subspecialties":"Neurology","expansion":"","briefResultsDescription":"IA therapy improves outcome without increased mortality or ICH","published":"2015-01-01","pageName":"MR CLEAN","diseases":"Stroke","abbreviation":"MR CLEAN","title":"A randomized trial of intraarterial treatment for acute ischemic stroke","pmid":"25517348"},{"timestamp":"2015-07-02T09:31:21Z","briefDesignDescription":"Thrombectomy vs. standard care in stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1212793","pageid":2363,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1212793","trainingLevel":"Fellow","citation":"Kidwell CS, <i>et al</i>. \"A trial of imaging selection and endovascular treatment for ischemic stroke\". <i>The New England Journal of Medicine</i>. 2013. 368(10):914-923.","subspecialties":"Neurology","expansion":"","briefResultsDescription":"Imaging did not id pts who would benefit from endovascular thrombectomy for acute ischemic stroke.","published":"2013-03-07","pageName":"MR RESCUE","diseases":"Stroke","abbreviation":"MR RESCUE","title":"A trial of imaging selection and endovascular treatment for ischemic stroke","pmid":"23394476"},{"timestamp":"2016-07-19T22:28:36Z","briefDesignDescription":"Hydroxyurea in sickle-cell disease","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199505183322001","pageid":2797,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199505183322001","trainingLevel":"Student","citation":"Charache S, <i>et al</i>. \"Effect of hydroxyurea on the frequency of painful crises in sickle-cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle-Cell Anemia\". <i>The New England Journal of Medicine</i>. 1995. 332(20):1317-1322.","subspecialties":"Hematology","expansion":"Multicenter Study of Hydroxyurea in Sickle-Cell Anemia","briefResultsDescription":"Hydroxyurea ↓frequency of painful crises in SCD","published":"1995-05-18","pageName":"MSH","diseases":"Sickle-Cell Disease","abbreviation":"MSH","title":"Effect of hydroxyurea on the frequency of painful crises in sickle-cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle-Cell Anemia","pmid":"7715639"},{"timestamp":"2017-01-28T21:54:59Z","briefDesignDescription":"ICD vs. antiarrhythmics vs. neither in mild HF and VT at EPS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199912163412503","pageid":2872,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199912163412503","trainingLevel":"Resident","citation":"Buxton AE <i>et al</i>. \"A randomized study of the prevention of sudden death in patients with coronary artery disease\". <i>New Engl J Med</i>. 1999. 341(25):1882-90.","subspecialties":"Cardiology;Electrophysiology","expansion":"Multicenter Unsustained Tachycardia Trial","briefResultsDescription":"EPS guided ICD placement in patients with mild LV systolic dysfunction superior to antiarrhythmic therapy or no treatment","published":"1999-12-16","pageName":"MUSTT","diseases":"Ventricular Tachycardia","abbreviation":"MUSTT","title":"A randomized study of the prevention of sudden death in patients with coronary artery disease","pmid":"10601507"},{"timestamp":"2016-04-02T00:31:14Z","briefDesignDescription":"Early vs. delayed ART in HIV","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0807252","pageid":1039,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807252","trainingLevel":"Resident","citation":"Kitahata MM, <i>et al</i>. \"Effect of Early vs. Deferred Antiretroviral therapy for HIV on Survival\". <i>The New England Journal of Medicine</i>. 2009. 360(18):1815-1826.","subspecialties":"Infectious Disease","expansion":"North American AIDS Cohort Collaboration on Research and Design","briefResultsDescription":"Early ART in HIV improves survival","published":"2009-04-30","pageName":"NA-ACCORD","diseases":"HIV","abbreviation":"NA-ACCORD","title":"Effect of Early vs. Deferred Antiretroviral therapy for HIV on Survival","pmid":"19339714"},{"timestamp":"2013-04-16T20:36:00Z","briefDesignDescription":"CEA in symptomatic carotid stenosis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199811123392002","pageid":128,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199811123392002","trainingLevel":"Intern","citation":"Barnett HJ, <i>et al</i>. \"Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis\". <i>The New England Journal of Medicine</i>. 1998. 339(20):1415-25.","subspecialties":"Surgery;Neurology","expansion":"North American Symptomatic Carotid Endarterectomy Trial","briefResultsDescription":"CEA reduces the risk of death or stroke in symptomatic 50-69% carotid stenosis","published":"1998-11-12","pageName":"NASCET","diseases":"Carotid Stenosis;Stroke","abbreviation":"NASCET","title":"Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis","pmid":"9811916"},{"timestamp":"2016-02-24T17:48:30Z","briefDesignDescription":"Dialysis prescriptions in ESRD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198111123052003","pageid":504,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198111123052003","trainingLevel":"Fellow","citation":"Lowrie EG, <i>et al</i>. \"Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study\". <i>The New England Journal of Medicine</i>. 1981. 305(20):1176-1181.","subspecialties":"Nephrology","expansion":"The National Cooperative Dialysis Study","briefResultsDescription":"Low BUN better tolerated, fewer hospitalizations","published":"1981-11-12","pageName":"NCDS","diseases":"Chronic Kidney Disease","abbreviation":"NCDS","title":"Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study","pmid":"7027040"},{"timestamp":"2016-04-04T13:24:11Z","briefDesignDescription":"Nitrates for activity tolerance in HFpEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1510774","pageid":2668,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1510774","trainingLevel":"Resident","citation":"Redfield MM, <i>et al</i>. \"Isosorbide mononitrate in heart failure with preserved ejection fraction\". <i>New England Journal of Medicine</i>. 2015. 373(24):2314-2324.","subspecialties":"Cardiology","expansion":"Nitrate’s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction","briefResultsDescription":"Nitrates do not improve activity tolerance in HFpEF","published":"2015-12-10","pageName":"NEAT-HFpEF","diseases":"Heart Failure","abbreviation":"NEAT-HFpEF","title":"Isosorbide mononitrate in heart failure with preserved ejection fraction","pmid":"26549714"},{"timestamp":"2014-09-29T20:08:35Z","briefDesignDescription":"Lung volume reduction in COPD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa030287","pageid":1604,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa030287","trainingLevel":"Resident","citation":"Fishman A, <i>et al</i>. \"A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema\". <i>The New England Journal of Medicine</i>. 2003. 348(21):2059-2073.","subspecialties":"Surgery;Pulmonology","expansion":"National Emphysema Treatment Trial","briefResultsDescription":"LVRS benefits apical emphysema and those with low exercise function","published":"2003-05-22","pageName":"NETT","diseases":"Chronic Obstructive Pulmonary Disease;Emphysema","abbreviation":"NETT","title":"A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema","pmid":"12759479"},{"timestamp":"2017-01-19T20:18:26Z","briefDesignDescription":"Intensive glycemic therapy in ICU","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0810625","pageid":26,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0810625","trainingLevel":"Intern","citation":"Finfer S, <i>et al</i>. \"Intensive versus conventional glucose control in critically ill patients\". <i>The New England Journal of Medicine</i>. 2009. 360(13):1283-1297.","subspecialties":"Critical Care;Endocrinology","expansion":"Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation","briefResultsDescription":"Increased mortality targeting euglycemia","published":"2009-03-26","pageName":"NICE-SUGAR","diseases":"Stress Hyperglycemia","abbreviation":"NICE-SUGAR","title":"Intensive versus conventional glucose control in critically ill patients","pmid":"19318384"},{"timestamp":"2015-08-24T19:41:34Z","briefDesignDescription":"tPA in ischemic stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199512143332401","pageid":131,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199512143332401","trainingLevel":"MedicalStudent","citation":"Marler JR, <i>et al</i>. \"Tissue Plasminogen Activator for Acute Ischemic Stroke\". <i>The New England Journal of Medicine</i>. 1995. 333(24):1581-1587.","subspecialties":"Neurology;Critical Care","expansion":"National Institute of Neurological Disorders and Stroke rt-PA Stroke Study","briefResultsDescription":"tPA within 3 hours improved outcomes","published":"1995-12-14","pageName":"NINDS","diseases":"Stroke","abbreviation":"NINDS","title":"Tissue Plasminogen Activator for Acute Ischemic Stroke","pmid":"7477192"},{"timestamp":"2015-09-10T15:14:05Z","briefDesignDescription":"CT vs. CXR in lung cancer screening","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1102873","pageid":980,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1102873","trainingLevel":"Resident","citation":"Berg CD, <i>et al</i>. \"Reduced lung cancer mortality with low-dose computed tomographic screening\". <i>The New England Journal of Medicine</i>. 2011. 365(5):395-409.","subspecialties":"Pulmonology;Oncology;Preventive Medicine","expansion":"National Lung Screening Trial","briefResultsDescription":"Low-dose CT reduces lung cancer mortality compared to CXR","published":"2011-08-04","pageName":"NLST","diseases":"Lung Cancer","abbreviation":"NLST","title":"Reduced lung cancer mortality with low-dose computed tomographic screening","pmid":"21714641"},{"timestamp":"2016-10-18T21:05:11Z","briefDesignDescription":"Drug-eluting stent vs. bare-metal stent in CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1607991","pageid":2832,"pdfurl":null,"trainingLevel":"Resident","citation":"Bonaa KH, <i>et al</i>. \"Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 2016. 375:1242-1252.","subspecialties":"Cardiology","expansion":"Drug-Eluting or Bare-Metal Stents for Percutaneous Coronary Intervention in Stable or Unstable Coronary Artery Disease","briefResultsDescription":"Drug-eluting stent superior to bare-metal stent in CAD","published":"2016-08-30","pageName":"NORSTENT","diseases":"Coronary Artery Disease","abbreviation":"NORSTENT","title":"Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease","pmid":"27572953"},{"timestamp":"2014-07-24T19:49:48Z","briefDesignDescription":"Continuous vs. nocturnal oxygen in COPD","fulltexturl":"http://annals.org/article.aspx?articleid","pageid":1788,"pdfurl":"","trainingLevel":"Student","citation":"NOTT Group. \"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group\". <i>Annals of Internal Medicine</i>. 1980. 93(3):91-398.","subspecialties":"Pulmonology","expansion":"Nocturnal Oxygen Therapy Trial","briefResultsDescription":"Continuous oxygen reduces mortality in COPD with hypoxemia","published":"1980-09-01","pageName":"NOTT","diseases":"Chronic Obstructive Pulmonary Disease","abbreviation":"NOTT","title":"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group","pmid":"6776858"},{"timestamp":"2015-11-09T16:32:43Z","briefDesignDescription":"Sentinel LN biopsy in breast cancer","fulltexturl":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041644/","pageid":1167,"pdfurl":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041644/pdf/nihms-250175.pdf","trainingLevel":"Student","citation":"Krag DN, <i>et al</i>. \"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial\". <i>Lancet Oncology</i>. 2010. 11(10):927-933.","subspecialties":"Oncology","expansion":"National Surgical Adjuvant Breast and Bowel Project Trial B-32","briefResultsDescription":"Sentinel lymph node biopsy is equally efficacious but has fewer side effects than ALND","published":"2010-10-01","pageName":"NSABP B-32","diseases":"Breast Cancer","abbreviation":"NSABP B-32","title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","pmid":"20863759"},{"timestamp":"2014-12-05T14:53:26Z","briefDesignDescription":"Tamoxifen in breast cancer prevention","fulltexturl":"http://jnci.oxfordjournals.org/content/90/18/1371.long","pageid":1049,"pdfurl":"http://jnci.oxfordjournals.org/content/90/18/1371.full.pdf+html","trainingLevel":"resident","citation":"Fisher B, <i>et al</i>. \"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study\". <i>Journal of the National Cancer Institute</i>. 1998. 90(18):1371-1388.","subspecialties":"Oncology;Preventive Medicine","expansion":"National Surgical Adjuvant Breast and Bowel Project, Prevention-1","briefResultsDescription":"Tamoxifen reduces breast cancer incidence by 48%","published":"1998-09-16","pageName":"NSABP P-1","diseases":"Breast Cancer","abbreviation":"NSABP P-1","title":"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","pmid":"9747868"},{"timestamp":"2016-06-20T01:57:25Z","briefDesignDescription":"PCI+OMT vs. OMT 3-28 days after MI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa066139","pageid":2676,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa066139","trainingLevel":"Intern","citation":"Hochman J.S., <i>et al</i>. \"Coronary Intervention for Persistent Occlusion after Myocardial Infarction\". <i>The New England Journal of Medicine</i>. 2006. 355(23):2395-2407.","subspecialties":"Cardiology","expansion":"Occluded Artery Trial","briefResultsDescription":"PCI+OMT no better than OMT 3-28 days after MI","published":"2006-12-07","pageName":"OAT","diseases":"Acute Coronary Syndrome;Coronary Artery Disease;Myocardial Infarction","abbreviation":"OAT","title":"Coronary Intervention for Persistent Occlusion after Myocardial Infarction","pmid":"17105759"},{"timestamp":"2015-10-01T02:45:33Z","briefDesignDescription":"PCSK9 inhibitor alirocumab for HLD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1501031","pageid":2423,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501031","trainingLevel":"Student","citation":"Robinson JG, <i>et al</i>. \"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events\". <i>The New England Journal of Medicine</i>. 2015. 372(16):1489-1499.","subspecialties":"Cardiology","expansion":"Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not\nAdequately Controlled with Their Lipid Modifying Therapy","briefResultsDescription":"Alirocumab lowers LDL, reduces non-fatal MI","published":"2015-04-16","pageName":"ODYSSEY LONG TERM","diseases":"Hyperlipidemia","abbreviation":"ODYSSEY LONG TERM","title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","pmid":"25773378"},{"timestamp":"2016-04-01T23:27:21Z","briefDesignDescription":"IV PPI for GI bleeds","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200008033430501","pageid":247,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200008033430501","trainingLevel":"Resident","citation":"Lau JYW, <i>et al</i>. \"Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer\". <i>The New England Journal of Medicine</i>. 2000. 343(5):310-316.","subspecialties":"Gastroenterology","expansion":null,"briefResultsDescription":"IV omeprazole reduced 30-day rebleeding","published":"2000-08-03","pageName":"Omeprazole in Peptic Ulcer Bleeding","diseases":"Gastrointestinal Hemorrhage","abbreviation":null,"title":"Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer","pmid":"10922420"},{"timestamp":"2014-08-11T16:05:12Z","briefDesignDescription":"Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0801317","pageid":1776,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0801317","trainingLevel":"Resident","citation":"Yusuf S, <i>et al</i>. \"Telmisartan, ramipril, or both in patients at high risk for vascular events\". <i>The New England Journal of Medicine</i>. 2008. 358(15):1547-1559.","subspecialties":"Cardiology;Nephrology;Endocrinology","expansion":"Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial","briefResultsDescription":"No difference in CV complications, combination ACE-inhibitor and ARB poorly tolerated","published":"2008-04-10","pageName":"ONTARGET","diseases":"Cardiovascular Disease;Diabetes Mellitus;Stroke","abbreviation":"ONTARGET","title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","pmid":"18378520"},{"timestamp":"2016-09-24T17:52:15Z","briefDesignDescription":"ASA/warfarin vs. warfarin in AF","fulltexturl":"http://circ.ahajournals.org/content/128/7/721.long","pageid":1769,"pdfurl":"http://circ.ahajournals.org/content/128/7/721.full.pdf","trainingLevel":"Fellow","citation":"Steinberg BA, <i>et al</i>. \"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry\". <i>Circulation</i>. 2013. 128(7):721-8.","subspecialties":"Cardiology;Neurology","expansion":"Outcomes Registry for Better Informed Treatment of Atrial Fibrillation","briefResultsDescription":"ASA/warfarin associated with more bleeding, fewer CV events","published":"2013-08-13","pageName":"ORBIT-AF","diseases":"Atrial Fibrillation;Stroke","abbreviation":"ORBIT-AF","title":"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry","pmid":"23861512"},{"timestamp":"2015-02-25T23:57:13Z","briefDesignDescription":"Fish oil for high-risk CVD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1203859","pageid":2330,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1203859","trainingLevel":"Intern","citation":"Bosch J, <i>et al</i>. \"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia\". <i>The New England Journal of Medicine</i>. 2012. 367(4):309-318.","subspecialties":"Cardiology;Neurology","expansion":"Investigators in the outcome Reduction with an Initial Glargine Intervention","briefResultsDescription":"n-3 fatty acids don't reduce CVD","published":"2012-07-26","pageName":"ORIGIN n-3 Fatty Acids","diseases":"Cardiovascular Disease;Coronary Artery Disease;Stroke","abbreviation":"ORIGIN n-3 Fatty Acids","title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","pmid":"22686415"},{"timestamp":"2017-01-19T20:19:35Z","briefDesignDescription":"High-frequency oscillatory vent in early ARDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1215554","pageid":1254,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1215554","trainingLevel":"Resident","citation":"Ferguson ND, <i>et al</i>. \"High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome\". <i>The New England Journal of Medicine</i>. 2013. 368(9):795-805.","subspecialties":"Critical Care;Pulmonology","expansion":"Oscillation for Acute Respiratory Distress Syndrome Treated Early","briefResultsDescription":"High-frequency oscillatory vent may harm in early ARDS","published":"2013-02-28","pageName":"OSCILLATE","diseases":"Acute Respiratory Distress Syndrome","abbreviation":"Oscillate","title":"High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome","pmid":"23339639"},{"timestamp":"2016-04-02T00:30:47Z","briefDesignDescription":"Step-up approach to pancreatitis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0908821","pageid":398,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0908821","trainingLevel":"Fellow","citation":"van Santvoort HC, <i>et al</i>. \"A Step-up Approach or Open Necrosectomy for Necrotizing Pancreatitis\". <i>The New England Journal of Medicine</i>. 2010. 362(16):1491-502.","subspecialties":"Surgery;Gastroenterology","expansion":"Minimally Invasive Step Up Approach versus Maximal Necrosectomy in Patients with Acute Necrotising Pancreatitis","briefResultsDescription":"Step-up approach reduces major complications and death","published":"2010-04-22","pageName":"PANTER","diseases":"Pancreatitis","abbreviation":"PANTER","title":"A Step-up Approach or Open Necrosectomy for Necrotizing Pancreatitis","pmid":"20410514"},{"timestamp":"2017-01-09T19:22:15Z","briefDesignDescription":"ARNI vs. enalapril in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1409077","pageid":2163,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1409077","trainingLevel":"Resident","citation":"McMurray JJV, <i>et al</i>. \"Angiotensin-neprilysin inhibition versus enalapril in heart failure\". <i>The New England Journal of Medicine</i>. 2014. 371(11):993-1004.","subspecialties":"Cardiology","expansion":"Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure","briefResultsDescription":"ARNI reduces mortality in HFrEF","published":"2014-08-30","pageName":"PARADIGM-HF","diseases":"Heart Failure","abbreviation":"PARADIGM-HF","title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","pmid":"25176015"},{"timestamp":"2014-05-11T22:03:58Z","briefDesignDescription":"Maintenance pemetrexed in lung cancer","fulltexturl":"http://jco.ascopubs.org/content/31/23/2895.long","pageid":1606,"pdfurl":"http://jco.ascopubs.org/content/31/23/2895.full.pdf","trainingLevel":"Fellow","citation":"Paz-Ares LG, <i>et al</i>. \"PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer\". <i>Journal of Clinical Oncology</i>. 2013. 31(23):2895-902.","subspecialties":"Oncology","expansion":"","briefResultsDescription":"Maintenance pemetrexed improves PFS and OS following induction with cisplatin/pemetrexed","published":"2013-08-10","pageName":"PARAMOUNT","diseases":"Lung Cancer","abbreviation":"PARAMOUNT","title":"PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer","pmid":"23835707"},{"timestamp":"2016-05-29T18:58:41Z","briefDesignDescription":"TAVI for AS in intermediate-risk surgical candidates","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1514616","pageid":2753,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1514616","trainingLevel":"Resident","citation":"Leon MB, <i>et al</i>. \"Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients\". <i>The New England Journal of Medicine</i>. 2016. 374(17):1609-20.","subspecialties":"Cardiology","expansion":"Placement of Aortic Transcatheter Valves, Cohort A","briefResultsDescription":"TAVI noninferior to surgical AVR in intermediate-risk surgical candidates","published":"2016-04-28","pageName":"PARTNER 2","diseases":"Aortic Stenosis","abbreviation":"PARTNER 2","title":"Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients","pmid":"27040324"},{"timestamp":"2016-05-03T14:59:54Z","briefDesignDescription":"TAVI for AS in high-risk surgical candidates","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1103510","pageid":2741,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1103510","trainingLevel":"Intern","citation":"Smith CR, <i>et al</i>. \"Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients\". <i>The New England Journal of Medicine</i>. 2011. 364(23):2187-98.","subspecialties":"Cardiology","expansion":"Placement of Aortic Transcatheter Valves, Cohort A","briefResultsDescription":"TAVI noninferior to surgical AVR in high-risk surgical candidates","published":"2011-06-09","pageName":"PARTNER A","diseases":"Aortic Stenosis","abbreviation":"PARTNER A","title":"Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients","pmid":"21639811"},{"timestamp":"2015-08-20T12:21:54Z","briefDesignDescription":"TAVI for AS in poor surgical candidates","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1008232","pageid":1674,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1008232","trainingLevel":"Intern","citation":"Leon MB, <i>et al</i>. \"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery\". <i>The New England Journal of Medicine</i>. 2010. 363(17):1597-1607.","subspecialties":"Cardiology","expansion":"Placement of Aortic Transcatheter Valves, Cohort B","briefResultsDescription":"TAVI reduces all-cause mortality ± rehospitalization, increased stroke","published":"2010-10-21","pageName":"PARTNER B","diseases":"Aortic Stenosis","abbreviation":"PARTNER B","title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","pmid":"20961243"},{"timestamp":"2014-10-13T21:17:38Z","briefDesignDescription":"Finasteride for prostate cancer prophylaxis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa030660","pageid":1786,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa030660","trainingLevel":"Intern","citation":"Thompson IM, <i>et al</i>. \"The influence of finasteride on the development of prostate cancer\". <i>The New England Journal of Medicine</i>. 2003. 349(3):215-224.","subspecialties":"Urology;Oncology","expansion":"Prostate Cancer Prevention Trial","briefResultsDescription":"Finasteride reduces all-grade prostate cancer risk, increases high-grade disease","published":"2003-07-13","pageName":"PCPT","diseases":"Prostate Cancer","abbreviation":"PCPT","title":"The influence of finasteride on the development of prostate cancer","pmid":"12824459"},{"timestamp":"2016-01-01T13:52:14Z","briefDesignDescription":"Extended ticagrelor+ASA after MI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1500857","pageid":2469,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1500857","trainingLevel":"Intern","citation":"Bonaca MP, <i>et al</i>. \"Long-term use of ticagrelor in patients with prior myocardial infarction\". <i>The New England Journal of Medicine</i>. 2015. 372(19):1791-1800.","subspecialties":"Cardiology","expansion":"","briefResultsDescription":"Extended ticagrelor+ASA reduces CVD events after MI","published":"2015-05-07","pageName":"PEGASUS-TIMI 54","diseases":"Coronary Artery Disease;Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"PEGASUS-TIMI 54","title":"Long-term use of ticagrelor in patients with prior myocardial infarction","pmid":"25773268"},{"timestamp":"2016-11-07T11:52:09Z","briefDesignDescription":"tPA for submassive PE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1302097","pageid":1778,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1302097","trainingLevel":"resident","citation":"Meyer G, <i>et al</i>. \"Fibrinolysis for patients with intermediate-risk pulmonary embolism\". <i>The New England Journal of Medicine</i>. 2014. 370(15):1402-1411.","subspecialties":"Critical Care;Pulmonology;Hematology","expansion":"Pulmonary Embolism Thrombolysis trial","briefResultsDescription":"tPA reduces hemodynamic decomp, not mortality, also increases bleeding in submassive PE","published":"2014-04-10","pageName":"PEITHO","diseases":"Pulmonary Embolism;Venous Thromboembolism","abbreviation":"PEITHO","title":"Fibrinolysis for patients with intermediate-risk pulmonary embolism","pmid":"24716681"},{"timestamp":"2015-07-06T21:57:52Z","briefDesignDescription":"Pentoxifylline in alcoholic hepatitis","fulltexturl":"http://www.gastrojournal.org/article/S0016-5085(00)51183-4/fulltext","pageid":53,"pdfurl":"http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508500511834.pdf","trainingLevel":"Resident","citation":"Akriviadis E, <i>et al</i>. \"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial\". <i>Gastroenterology</i>. 2000. 119(6):1637-48.","subspecialties":"Gastroenterology","expansion":"","briefResultsDescription":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis","published":"2000-12-20","pageName":"Pentoxifylline in Severe Alcoholic Hepatitis","diseases":"Alcoholic Hepatitis","abbreviation":"","title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","pmid":"11113085"},{"timestamp":"2016-12-01T02:06:08Z","briefDesignDescription":"Prevalence of PE in syncope","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1602172","pageid":2843,"pdfurl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1602172","trainingLevel":"Resident","citation":"Sapp JL, <i>et al</i>. \"Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope\". <i>The New England Journal of Medicine</i>. 2016. 375(16):1524-31.","subspecialties":"Hematology","expansion":"Pulmonary Embolism in Syncope Italian Trial","briefResultsDescription":"PE found in 1 of 6 patients with syncope","published":"2016-10-20","pageName":"PESIT","diseases":"Pulmonary Embolism;Venous Thromboembolism;Syncope","abbreviation":"PESIT","title":"Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope","pmid":"27797317"},{"timestamp":"2016-12-15T02:48:45Z","briefDesignDescription":"DOAC, VKA, antiplatelets after PCI with stent","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1611594","pageid":2861,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611594","trainingLevel":"Resident","citation":"Gibson CM, <i>et al</i>. \"Prevention of bleeding in patients with AF undergoing PCI\". <i>The New England Journal of Medicine</i>. 2016. epub 2016-11-14:1-12.","subspecialties":"Cardiology","expansion":"Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with AF who Undergo Percutaneous Coronary Intervention","briefResultsDescription":"Rivaroxaban with lower bleeding","published":"2016-11-14","pageName":"PIONEER AF-PCI","diseases":"Acute Coronary Syndrome;Coronary Artery Disease;Myocardial Infarction","abbreviation":"PIONEER AF-PCI","title":"Prevention of bleeding in patients with AF undergoing PCI","pmid":"27959713"},{"timestamp":"2016-04-05T13:46:19Z","briefDesignDescription":"Accuracy of CT for PE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa052367#t","pageid":161,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa052367#t","trainingLevel":"MedicalStudent","citation":"Stein PD, <i>et al</i>. \"Multidetector Computed Tomography for Acute Pulmonary Embolism\". <i>The New England Journal of Medicine</i>. 2006. 354(22):2317-2327.","subspecialties":"Pulmonology;Hematology","expansion":"Prospective Investigation of Pulmonary Embolism Diagnosis II","briefResultsDescription":"CT sensitive and specific in detecting acute PE","published":"2006-06-01","pageName":"PIOPED II","diseases":"Pulmonary Embolism;Venous Thromboembolism","abbreviation":"PIOPED II","title":"Multidetector Computed Tomography for Acute Pulmonary Embolism","pmid":"16738268"},{"timestamp":"2015-04-18T21:08:45Z","briefDesignDescription":"Probiotics to prevent CDAD","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961218-0/abstract","pageid":1770,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673613612180.pdf","trainingLevel":"Resident","citation":"Allen SJ, <i>et al</i>. \"Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial\". <i>The Lancet</i>. 2013. 382(9900):1249-1257.","subspecialties":"Gastroenterology;Infectious Disease;Preventive Medicine","expansion":"","briefResultsDescription":"Probiotics do not reduce diarrhea including C. diff with antibiotics","published":"2013-10-12","pageName":"PLACIDE","diseases":"Clostridium difficile","abbreviation":"PLACIDE","title":"Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial","pmid":"23932219"},{"timestamp":"2016-09-24T19:59:13Z","briefDesignDescription":"Ticagrelor vs. clopidogrel in ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0904327","pageid":1629,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0904327","trainingLevel":"Resident","citation":"Wallentin L, <i>et al</i>. \"Ticagrelor versus clopidogrel in patients with acute coronary syndromes\". <i>The New England Journal of Medicine</i>. 2009. 361(11):1045-1057.","subspecialties":"Cardiology","expansion":"Platelet Inhibition and Patient Outcomes","briefResultsDescription":"Ticagrelor reduces mortality, increases bleeding","published":"2009-09-10","pageName":"PLATO","diseases":"Acute Coronary Syndrome;Coronary Artery Disease","abbreviation":"PLATO","title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","pmid":"19717846"},{"timestamp":"2012-05-07T02:36:42Z","briefDesignDescription":"8 vs. 15 days of antibiotics in VAP","fulltexturl":"http://jama.ama-assn.org/content/290/19/2588.long","pageid":118,"pdfurl":"http://jama.ama-assn.org/content/290/19/2588.full.pdf","trainingLevel":"Intern","citation":"Chastre J. \"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial\". <i>Journal of the American Medical Association</i>. 2003. 290(19):2588-98.","subspecialties":"Critical Care;Infectious Disease;Pulmonology","expansion":"","briefResultsDescription":"8 days of antibiotics are equivalent to 15 days","published":"2003-11-19","pageName":"PneumA","diseases":"Pneumonia","abbreviation":"PneumA","title":"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","pmid":"14625336"},{"timestamp":"2014-10-17T07:39:25Z","briefDesignDescription":"Perioperative metoprolol","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60601-7/fulltext","pageid":173,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673608606017.pdf","trainingLevel":"Intern","citation":"Devereaux PJ, <i>et al</i>. \"Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery: a Randomised Controlled Trial\". <i>The Lancet</i>. 2008. 371(9627):1839-1847.","subspecialties":"Surgery;Cardiology","expansion":"PeriOperative ISchemic Evaluation","briefResultsDescription":"Perioperative metoprolol reduces MI risk but increases risk of mortality and stroke","published":"2008-05-31","pageName":"POISE","diseases":"Cardiac Risk Assessment;Coronary Artery Disease","abbreviation":"POISE","title":"Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery: a Randomised Controlled Trial","pmid":"18479744"},{"timestamp":"2015-02-01T13:07:10Z","briefDesignDescription":"Perioperative ASA","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1401105","pageid":1777,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401105","trainingLevel":"Intern","citation":"Devereaux PJ, <i>et al</i>. \"Aspirin in patients undergoing noncardiac surgery\". <i>The New England Journal of Medicine</i>. 2014. 370(16):1494-1503.","subspecialties":"Cardiology;Surgery","expansion":"Perioperative ischemic evaluation 2 aspirin arm","briefResultsDescription":"Perioperative ASA doesn't modify MI rates but increases major bleeding","published":"2014-03-31","pageName":"POISE-2 ASA","diseases":"Cardiac Risk Assessment","abbreviation":"POISE-2 ASA","title":"Aspirin in patients undergoing noncardiac surgery","pmid":"24679062"},{"timestamp":"2013-11-26T10:47:19Z","briefDesignDescription":"PCI to high-risk non-infarct arteries in STEMI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1305520","pageid":1748,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1305520","trainingLevel":"Resident","citation":"Wald DS, <i>et al</i>. \"Randomized trial of preventative angioplasty in myocardial infarction\". <i>The New England Journal of Medicine</i>. 2013. 369(12):1115-1123.","subspecialties":"Cardiology","expansion":"Preventative Angioplasty in Acute Myocardial Infarction","briefResultsDescription":"PCI to high-risk non infarct arteries in STEMI improves CV outcomes","published":"2013-09-19","pageName":"PRAMI","diseases":"Myocardial Infarction","abbreviation":"PRAMI","title":"Randomized trial of preventative angioplasty in myocardial infarction","pmid":"23991625"},{"timestamp":"2017-03-05T12:20:54Z","briefDesignDescription":"Celecoxib, naproxen, or ibuprofen for CV safety in arthritis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1611593","pageid":2888,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611593","trainingLevel":"Resident","citation":"Nissen SE, <i>et al</i>. \"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis\". <i>The New England Journal of Medicine</i>. 2016. 375(26):2519-2529.","subspecialties":"Cardiology;Rheumatology;Neurology","expansion":"Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen","briefResultsDescription":"Celecoxib noninferior to ibuprofen or naproxen with regard to CV safety","published":"2016-12-29","pageName":"PRECISION","diseases":"Coronary Artery Disease;Rheumatoid Arthritis;Osteoarthritis;Stroke","abbreviation":"PRECISION","title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","pmid":"27959716"},{"timestamp":"2014-09-19T15:33:46Z","briefDesignDescription":"Mediterranean diet in CVD prevention","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1200303","pageid":1247,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200303","trainingLevel":"Student","citation":"Estruch R, <i>et al</i>. \"Primary prevention of cardiovascular disease with a mediterranean diet\". <i>The New England Journal of Medicine</i>. 2013. 368(14):1279-1290.","subspecialties":"Cardiology","expansion":"Prevención con Dieta Mediterránea","briefResultsDescription":"Mediterranean diet reduces composite rate of MI/CVA/CV death","published":"2013-02-25","pageName":"PREDIMED","diseases":"Coronary Artery Disease;Stroke;Transient Ischemic Attack","abbreviation":"PREDIMED","title":"Primary prevention of cardiovascular disease with a mediterranean diet","pmid":"23432189"},{"timestamp":"2015-07-06T21:57:28Z","briefDesignDescription":"Prednisolone vs. placebo in alcoholic hepatitis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199202203260802","pageid":1113,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199202203260802","trainingLevel":"Intern","citation":"Ramond MJ, <i>et al</i>. \"A randomized trial of prednisolone in patients with severe alcoholic hepatitis\". <i>The New England Journal of Medicine</i>. 1992. 362(8):507-512.","subspecialties":"Gastroenterology","expansion":"","briefResultsDescription":"Prednisolone improves short-term survival","published":"1992-02-20","pageName":"Prednisolone in Severe Alcoholic Hepatitis","diseases":"Alcoholic Hepatitis","abbreviation":"","title":"A randomized trial of prednisolone in patients with severe alcoholic hepatitis","pmid":"1531090"},{"timestamp":"2016-03-23T20:23:57Z","briefDesignDescription":"IVC filters for proximal DVT","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199802123380701","pageid":2697,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199802123380701","trainingLevel":"Resident","citation":"Decousus H, <i>et al</i>. \"A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis\". <i>The New England Journal of Medicine</i>. 1998. 338(7):409-416.","subspecialties":"Pulmonology;Hematology","expansion":"Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group","briefResultsDescription":"IVC filters reduce future PE risk but increase DVT risk","published":"1998-02-12","pageName":"PREPIC","diseases":"Deep Vein Thrombosis;Venous Thromboembolism;Pulmonary Embolism","abbreviation":"PREPIC","title":"A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis","pmid":"9459643"},{"timestamp":"2015-10-18T16:28:48Z","briefDesignDescription":"IVC filters for high-risk PE","fulltexturl":"http://bit.ly/1Jti6Ct","pageid":2405,"pdfurl":"http://bit.ly/1ONs0iA","trainingLevel":"Intern","citation":"Mismetti P, <i>et al</i>. \"Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial\". <i>The Journal of the American Medical Association</i>. 2015. 313(16):1627-35.","subspecialties":"Hematology;Pulmonology;Interventional Radiology","expansion":"Prevention du Risque d'Embolie Pulmonaire par Interruption Cave 2","briefResultsDescription":"IVC filters do not improve outcomes in acute high-risk PE","published":"2015-04-28","pageName":"PREPIC 2","diseases":"Venous Thromboembolism","abbreviation":"PREPIC 2","title":"Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial","pmid":"25919526"},{"timestamp":"2013-03-21T00:59:25Z","briefDesignDescription":"Rifapentine/isoniazid in latent TB","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1104875","pageid":928,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1104875","trainingLevel":"fellow","citation":"Sterling TR, <i>et al</i>. \"Three months of rifapentine and isoniazid for latent tuberculosis infection.\". <i>The New England Journal of Medicine</i>. 2011. 365(23):2155-66.","subspecialties":"Infectious Disease","expansion":null,"briefResultsDescription":"Rifapentine/isoniazid x3 months is noninferior to isoniazid x9 months","published":"2011-12-08","pageName":"PREVENT TB","diseases":"Tuberculosis","abbreviation":"PREVENT TB","title":"Three months of rifapentine and isoniazid for latent tuberculosis infection.","pmid":"22150035"},{"timestamp":"2017-01-19T19:37:00Z","briefDesignDescription":"EGDT in septic shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1401602","pageid":1782,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401602","trainingLevel":"Intern","citation":"Angus DC, <i>et al</i>. \"A randomized trial of protocol-based care for early septic shock\". <i>The New England Journal of Medicine</i>. 2014. 370(10):1683-1693.","subspecialties":"Critical Care","expansion":"Protocolized Care for Early Septic Shock","briefResultsDescription":"No difference for EGDT vs. standard protocol vs. usual care for septic shock","published":"2014-05-01","pageName":"ProCESS","diseases":"Sepsis","abbreviation":"ProCESS","title":"A randomized trial of protocol-based care for early septic shock","pmid":"24635773"},{"timestamp":"2016-09-12T23:33:10Z","briefDesignDescription":"FOLFIRINOX in pancreatic cancer","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1011923","pageid":2819,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1011923","trainingLevel":"Resident","citation":"Conroy T, <i>et al</i>. \"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer\". <i>The New England Journal of Medicine</i>. 2011. 364(19):1817-1825.","subspecialties":"Oncology","expansion":"PRODIGE 4 Actions concertées dans les Cancers COloRectaux et Digestifs","briefResultsDescription":"FOLFIRINOX improves OS in metastatic pancreatic cancer compared to gemcitabine","published":"2011-05-12","pageName":"PRODIGE 4 ACCORD 11","diseases":"Pancreatic Cancer","abbreviation":"PRODIGE 4 ACCORD 11","title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","pmid":"21561347"},{"timestamp":"2013-03-25T00:56:44Z","briefDesignDescription":"ASA-dipyridamole vs. clopidogrel in stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0805002","pageid":1082,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805002","trainingLevel":"Resident","citation":"Sacco RL, <i>et al</i>. \"Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke\". <i>The New England Journal of Medicine</i>. 2008. 359(12):1238-1251.","subspecialties":"Neurology","expansion":"Prevention Regimen for Effectively Avoiding Second Strokes","briefResultsDescription":"Similar efficacy but less bleeding with clopidogrel","published":"2008-09-18","pageName":"PRoFESS","diseases":"Stroke","abbreviation":"PROFESS","title":"Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke","pmid":"18753638"},{"timestamp":"2017-01-19T20:12:06Z","briefDesignDescription":"Procalcitonin-guided antibiotics","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61879-1/fulltext","pageid":434,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673609618791.pdf","trainingLevel":"resident","citation":"Bouadma L, <i>et al</i>. \"Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units\". <i>The Lancet</i>. 2010. 375(9713):463-74.","subspecialties":"Critical Care;Infectious Disease","expansion":"Procalcitonin to Reduce Antibiotic Treatments in Acutely ill patients","briefResultsDescription":"Procalcitonin noninferior and led to fewer days on antibiotics","published":"2010-02-06","pageName":"PRORATA","diseases":"Critical Illness","abbreviation":"PRORATA","title":"Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units","pmid":"20097417"},{"timestamp":"2017-01-19T20:23:00Z","briefDesignDescription":"Prone ventilation in ARDS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1214103","pageid":1479,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214103","trainingLevel":"fellow","citation":"Guérin C, <i>et al</i>. \"Prone positioning in severe acute respiratory distress syndrome\". <i>The New England Journal of Medicine</i>. 2013. 368(23):2159-2168.","subspecialties":"Critical Care","expansion":"Proning Severe ARDS Patients","briefResultsDescription":"Intermittent prone positioning improves survival in severe ARDS","published":"2013-06-06","pageName":"PROSEVA","diseases":"Acute Respiratory Distress Syndrome","abbreviation":"PROSEVA","title":"Prone positioning in severe acute respiratory distress syndrome","pmid":"23688302"},{"timestamp":"2014-12-12T19:48:34Z","briefDesignDescription":"Pravastatin vs. atorvastatin after ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa040583","pageid":1338,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa040583","trainingLevel":"Intern","citation":"Cannon CP, <i>et al</i>. \"Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2004. 350(15):1495-1504.","subspecialties":"Cardiology","expansion":"Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22","briefResultsDescription":"High-dose atorvastatin is superior to moderate-dose pravastatin at reducing CV events after ACS","published":"2004-04-08","pageName":"PROVE IT-TIMI 22","diseases":"Acute Coronary Syndrome;Hyperlipidemia","abbreviation":"PROVE IT-TIMI 22","title":"Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes","pmid":"15007110"},{"timestamp":"2014-09-17T23:33:52Z","briefDesignDescription":"Activated protein C in severe sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200103083441001","pageid":983,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200103083441001","trainingLevel":"Resident","citation":"Bernard GR, <i>et al</i>. \"Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis\". <i>The New England Journal of Medicine</i>. 2001. 344(10):699-709.","subspecialties":"Critical Care","expansion":"Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis","briefResultsDescription":"Improved survival with APC but not seen in subsequent larger PROWESS-SHOCK trial","published":"2001-03-08","pageName":"PROWESS","diseases":"Sepsis;Shock","abbreviation":"PROWESS","title":"Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis","pmid":"11236773"},{"timestamp":"2014-09-17T23:34:32Z","briefDesignDescription":"Activated protein C in septic shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1202290","pageid":977,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1202290","trainingLevel":"Resident","citation":"Ranieri VM, <i>et al</i>. \"Drotrecogin Alfa (Activated) in Adults with Septic Shock\". <i>The New England Journal of Medicine</i>. 2012. 366(22):2055-2064.","subspecialties":"Critical Care","expansion":"Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis and Septic Shock","briefResultsDescription":"No survival benefit at 28 or 90 days, in contrast to PROWESS","published":"2012-05-31","pageName":"PROWESS-SHOCK","diseases":"Sepsis;Shock","abbreviation":"PROWESS-SHOCK","title":"Drotrecogin Alfa (Activated) in Adults with Septic Shock","pmid":"22616830"},{"timestamp":"2014-05-22T00:30:05Z","briefDesignDescription":"Lenient vs. strict rate control in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1001337","pageid":181,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001337","trainingLevel":"Resident","citation":"Van Gelder IC, <i>et al</i>. \"Lenient versus Strict Rate Control in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2010. 362(15):1363-73.","subspecialties":"Cardiology","expansion":"Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II","briefResultsDescription":"Lenient rate control is as effective as strict rate control","published":"2010-04-15","pageName":"RACE II","diseases":"Atrial Fibrillation","abbreviation":"RACE II","title":"Lenient versus Strict Rate Control in Patients with Atrial Fibrillation","pmid":"20231232"},{"timestamp":"2016-09-04T00:32:44Z","briefDesignDescription":"CRT+ICD for mild-moderate HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1009540","pageid":2731,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009540","trainingLevel":"Resident","citation":"Tang AS, <i>et al</i>. \"Cardiac-resynchronization therapy for mild-to-moderate heart failure\". <i>The New England Journal of Medicine</i>. 2010. 363(25):2385-2395.","subspecialties":"Cardiology","expansion":"Resynchronization–Defibrillation for Ambulatory Heart Failure","briefResultsDescription":"CRT+ICD reduces mortality but increased the rate of adverse events","published":"2010-12-16","pageName":"RAFT","diseases":"Heart Failure","abbreviation":"RAFT","title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","pmid":"21073365"},{"timestamp":"2015-08-24T04:40:44Z","briefDesignDescription":"Spironolactone in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199909023411001","pageid":11,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199909023411001","trainingLevel":"Intern","citation":"Pitt B, <i>et al</i>. \"The effect of spironolactone on morbidity and mortality in patients with severe heart failure\". <i>New England Journal of Medicine</i>. 1999. 341(10):709-717.","subspecialties":"Cardiology","expansion":"Randomized Aldactone Evaluation Study","briefResultsDescription":"Spironolactone reduces all-cause mortality by 30% in severe HFrEF","published":"1999-09-02","pageName":"RALES","diseases":"Heart Failure","abbreviation":"RALES","title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","pmid":"10471456"},{"timestamp":"2013-03-05T21:39:54Z","briefDesignDescription":"Rituximab vs. cyclophosphamide in ANCA-associated vasculitis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0909905","pageid":1214,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0909905","trainingLevel":"Fellow","citation":"Stone JH, <i>et al</i>. \"Rituximab versus cyclophosphamide for ANCA-associated vasculitis\". <i>The New England Journal of Medicine</i>. 2010. 363(3):221-232.","subspecialties":"Rheumatology","expansion":"Rituximab in ANCA-Associated Vasculitis","briefResultsDescription":"Rituximab noninferior to cyclophosphamide in ANCA-associated vasculitis","published":"2010-07-15","pageName":"RAVE","diseases":"Vasculitis","abbreviation":"RAVE","title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","pmid":"20647199"},{"timestamp":"2014-10-23T16:27:56Z","briefDesignDescription":"Dabigatran in mechanical heart valves","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1300615","pageid":1707,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300615","trainingLevel":"Resident","citation":"Eikelboom JW, <i>et al</i>. \"Dabigatran versus warfarin in patients with mechanical heart valves\". <i>The New England Journal of Medicine</i>. 2013. 369(13):1206-1214.","subspecialties":"Cardiology;Hematology","expansion":"Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement","briefResultsDescription":"Dabigatran has more thromboembolism and bleeding than warfarin","published":"2013-09-26","pageName":"RE-ALIGN","diseases":"Valvular Disease","abbreviation":"RE-ALIGN","title":"Dabigatran versus warfarin in patients with mechanical heart valves","pmid":"23991661"},{"timestamp":"2016-02-15T17:20:10Z","briefDesignDescription":"Dabigatran vs. warfarin in VTE","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0906598","pageid":973,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0906598","trainingLevel":"fellow","citation":"Schulman S, <i>et al</i>. \"Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism\". <i>New England Journal of Medicine</i>. 2009. 361(24):2342-52.","subspecialties":"Hematology;Pulmonology","expansion":"Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism","briefResultsDescription":"Dabigatran non-inferior to warfarin for VTE recurrence, but dabigatran yielded less bleeding","published":"2009-12-10","pageName":"RE-COVER","diseases":"Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism","abbreviation":"RE-COVER","title":"Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism","pmid":"19966341"},{"timestamp":"2015-04-18T21:22:31Z","briefDesignDescription":"Dabigatran vs. warfarin in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0905561","pageid":178,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0905561","trainingLevel":"Resident","citation":"Connolly SJ, <i>et al</i>. \"Dabigatran versus warfarin in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2009. 361(12):1139-51.","subspecialties":"Cardiology;Neurology","expansion":"Randomized Evaluation of Long-Term Anticoagulation Therapy","briefResultsDescription":"High-dose dabigatran reduces stroke risk without increasing major bleeding in atrial fibrillation","published":"2009-09-17","pageName":"RE-LY","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"RE-LY","title":"Dabigatran versus warfarin in patients with atrial fibrillation","pmid":"19717844"},{"timestamp":"2016-06-03T10:57:27Z","briefDesignDescription":"Idarucizumab for dabigatran reversal","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1502000","pageid":2421,"pdfurl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1502000","trainingLevel":"Intern","citation":"Pollack CV, <i>et al</i>. \"Idarucizumab for Dabigatran Reversal\". <i>The New England Journal of Medicine</i>. 2015. 373(6):511-520.","subspecialties":"Hematology","expansion":"","briefResultsDescription":"Idarucizumab reversed the dabigatran effect in minutes","published":"2015-08-06","pageName":"RE-VERSE AD","diseases":"Hemorrhage","abbreviation":"RE-VERSE AD","title":"Idarucizumab for Dabigatran Reversal","pmid":"26095746"},{"timestamp":"2015-04-24T14:27:53Z","briefDesignDescription":"5d vs. 14d steroids in acute COPD","fulltexturl":"http://bit.ly/1BQhpuy","pageid":1615,"pdfurl":null,"trainingLevel":"Intern","citation":"Leuppi JD, <i>et al</i>. \"Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial\". <i>JAMA</i>. 2013. 309(21):2223-2231.","subspecialties":"Pulmonology","expansion":"Reduction in the Use of Corticosteroids in Exacerbated COPD","briefResultsDescription":"5d steroids noninferior to 14d in acute COPD","published":"2013-06-05","pageName":"REDUCE","diseases":"Chronic Obstructive Pulmonary Disease","abbreviation":"REDUCE","title":"Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial","pmid":"23695200"},{"timestamp":"2016-01-28T22:47:55Z","briefDesignDescription":"ARBs in diabetic nephropathy","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa011161","pageid":1030,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa011161","trainingLevel":"Intern","citation":"Brenner BM, <i>et al</i>. \"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy\". <i>The New England Journal of Medicine</i>. 2001. 345(12):861-869.","subspecialties":"Endocrinology;Nephrology","expansion":"Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan","briefResultsDescription":"ARBs reduce progression to","published":"2001-09-20","pageName":"RENAAL","diseases":"Diabetes Mellitus;Chronic Kidney Disease","abbreviation":"RENAAL","title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","pmid":"11565518"},{"timestamp":"2013-08-15T18:48:57Z","briefDesignDescription":"PFO closure in cryptogenic stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1301440","pageid":1334,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1301440","trainingLevel":"Intern","citation":"Carroll JD, <i>et al</i>. \"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke\". <i>The New England Journal of Medicine</i>. 2013. 368(12):1092-1100.","subspecialties":"Neurology;Cardiology","expansion":"Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment","briefResultsDescription":"PFO closure does not reduce recurrent CVA after cryptogenic CVA","published":"2013-03-21","pageName":"RESPECT","diseases":"Stroke;Patent Foramen Ovale;Transient Ischemic Attack","abbreviation":"RESPECT","title":"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke","pmid":"23514286"},{"timestamp":"2016-11-08T16:03:35Z","briefDesignDescription":"Rifaximin/lactulose vs. lactulose for acute HE","fulltexturl":"http://www.nature.com/ajg/journal/v108/n9/full/ajg2013219a.html","pageid":1784,"pdfurl":"http://www.nature.com/ajg/journal/v108/n9/pdf/ajg2013219a.pdf","trainingLevel":"Intern","citation":"Sharma BC, <i>et al</i>. \"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy\". <i>The American Journal of Gastroenterology</i>. 2013. 108(9):1458-1463.","subspecialties":"Gastroenterology","expansion":"","briefResultsDescription":"Rifaximin/lactulose improved rates of HE reversal and survival, reduced hospital LOS","published":"2013-09-01","pageName":"Rifaximin and Lactulose for HE","diseases":"Hepatic Encephalopathy","abbreviation":"","title":"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy","pmid":"23877348"},{"timestamp":"2017-01-19T19:36:24Z","briefDesignDescription":"Early goal-directed therapy in sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa010307","pageid":60,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa010307","trainingLevel":"Student","citation":"Rivers E, <i>et al</i>. \"Early Goal Directed Therapy in the Treatment of Severe Sepsis and Septic Shock\". <i>The New England Journal of Medicine</i>. 2001. 345(19):1368-1377.","subspecialties":"Critical Care;Emergency Medicine","expansion":"","briefResultsDescription":"Early goal-directed therapy decreased mortality and morbiditiy in sepsis","published":"2001-11-08","pageName":"Rivers Trial","diseases":"Sepsis;Shock","abbreviation":"","title":"Early Goal Directed Therapy in the Treatment of Severe Sepsis and Septic Shock","pmid":"11794169"},{"timestamp":"2015-04-18T21:28:53Z","briefDesignDescription":"Rivaroxaban vs. warfarin in AF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1009638","pageid":1358,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009638","trainingLevel":"Student","citation":"Patel MR, <i>et al</i>. \"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2011. 365(10):883-891.","subspecialties":"Cardiology;Neurology","expansion":"Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation","briefResultsDescription":"Rivaroxaban is noninferior to warfarin for stroke/embolization prevention in nonvalvular AF","published":"2011-09-08","pageName":"ROCKET AF","diseases":"Atrial Fibrillation;Stroke;Transient Ischemic Attack","abbreviation":"ROCKET AF","title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","pmid":"21830957"},{"timestamp":"2014-09-24T22:15:54Z","briefDesignDescription":"Sertraline for depression post-ACS","fulltexturl":"http://jama.ama-assn.org/content/288/6/701.full","pageid":423,"pdfurl":"http://jama.ama-assn.org/content/288/6/701.full.pdf","trainingLevel":"Resident","citation":"Glassman AH, <i>et al</i>. \"Sertraline treatment of major depression in patients with acute MI or unstable angina\". <i>Journal of the American Medical Association</i>. 2002. 288(6):701-709.","subspecialties":"Psychiatry;Cardiology","expansion":"Sertraline Antidepressant Heart Attack Randomized Trial","briefResultsDescription":"Sertraline improves symptoms without adverse CV effects","published":"2002-08-14","pageName":"SADHART","diseases":"Depression;Acute Coronary Syndrome","abbreviation":"SADHAT","title":"Sertraline treatment of major depression in patients with acute MI or unstable angina","pmid":"12169073"},{"timestamp":"2017-01-19T20:07:27Z","briefDesignDescription":"Albumin vs. saline in ICU","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa040232","pageid":285,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa040232","trainingLevel":"Intern","citation":"Finfer S, <i>et al</i>. \"A comparison of albumin and saline for fluid resuscitation in the intensive care unit\". <i>The New England Journal of Medicine</i>. 2004. 350(22):2247-2256.","subspecialties":"Critical Care","expansion":"Saline versus Albumin Fluid Evaluation","briefResultsDescription":"No mortality difference (except worse mortality with albumin for TBI)","published":"2004-05-27","pageName":"SAFE","diseases":"Critical Illness","abbreviation":"SAFE","title":"A comparison of albumin and saline for fluid resuscitation in the intensive care unit","pmid":"15163774"},{"timestamp":"2016-04-01T12:57:20Z","briefDesignDescription":"Stenting in intracranial stenosis","fulltexturl":"http://www.nejm.org/doi/pdf/10.1056/nejmoa1105335","pageid":2420,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/nejmoa1105335","trainingLevel":"Intern","citation":"Chimowitz MI, <i>et al</i>. \"Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis\". <i>The New England Journal of Medicine</i>. 2015. 365(11):993-1003.","subspecialties":"Neurology;Interventional Radiology","expansion":"","briefResultsDescription":"Medical therapy superior to stenting in IC stenosis","published":"2011-09-15","pageName":"SAMMPRIS","diseases":"Stroke","abbreviation":"SAMMPRIS","title":"Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis","pmid":"24168957"},{"timestamp":"2015-08-24T04:52:18Z","briefDesignDescription":"Captopril in MI with LV dysfunction","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199209033271001","pageid":150,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199209033271001","trainingLevel":"Resident","citation":"Pfeffer MA, <i>et al</i>. \"Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction — Results of the Survival and Ventricular Enlargement Trial\". <i>The New England Journal of Medicine</i>. 1992. 327(10):669-677.","subspecialties":"Cardiology","expansion":"Survival and Ventricular Enlargement Trial","briefResultsDescription":"Captopril improves survival","published":"1992-09-03","pageName":"SAVE","diseases":"Acute Coronary Syndrome;Myocardial Infarction;Heart Failure","abbreviation":"SAVE","title":"Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction — Results of the Survival and Ventricular Enlargement Trial","pmid":"1386652"},{"timestamp":"2014-06-13T06:22:51Z","briefDesignDescription":"Amiodarone or ICD in severe HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa043399","pageid":40,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa043399","trainingLevel":"Intern","citation":"Bardy GH, <i>et al</i>. \"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure\". <i>The New England Journal of Medicine</i>. 2005. 252(3):225-37.","subspecialties":"Cardiology","expansion":"Sudden Cardiac Death in Heart Failure Trial","briefResultsDescription":"ICD reduces mortality by 23% in class II-III HFrEF","published":"2005-01-20","pageName":"SCD-HeFT","diseases":"Heart Failure","abbreviation":"SCD-HeFT","title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","pmid":"15659722"},{"timestamp":"2014-05-27T04:59:32Z","briefDesignDescription":"Dexmedetomidine vs. midazolam for sedation","fulltexturl":"http://jama.ama-assn.org/content/301/5/489.long","pageid":353,"pdfurl":"http://jama.ama-assn.org/content/301/5/489.full.pdf","trainingLevel":"Resident","citation":"Riker RR, <i>et al</i>. \"Dexmedetomidine vs. Midazolam for Sedation of Critically Ill Patients\". <i>Journal of American Medical Association</i>. 2009. 301(5):489-499.","subspecialties":"Critical Care","expansion":"Safety and Efficacy of Dexmedetomidine Compared with Midazolam","briefResultsDescription":"↓ delirium, ↓ ventilator days with dexmedetomidine","published":"2009-02-04","pageName":"SEDCOM","diseases":"Critical Illness","abbreviation":"SEDCOM","title":"Dexmedetomidine vs. Midazolam for Sedation of Critically Ill Patients","pmid":"19188334"},{"timestamp":"2017-01-19T19:50:00Z","briefDesignDescription":"MAP 65-70 vs. 80-85 mmHg in sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1312173","pageid":1779,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1312173","trainingLevel":"Resident","citation":"Asfar P, <i>et al</i>. \"High versus low blood-pressure target in patients with septic shock\". <i>The New England Journal of Medicine</i>. 2014. 370(17):1583-1593.","subspecialties":"Critical Care","expansion":"Sepsis and Mean Arterial Pressure","briefResultsDescription":"No difference for higher MAP in sepsis except renal protection in vascular disease","published":"2014-04-23","pageName":"SEPSISPAM","diseases":"Sepsis;Shock","abbreviation":"SEPSISPAM","title":"High versus low blood-pressure target in patients with septic shock","pmid":"24635770"},{"timestamp":"2016-04-20T19:51:38Z","briefDesignDescription":"Ivabradine in HFrEF","fulltexturl":"http://www.sciencedirect.com/science/article/pii/S0140673610611981","pageid":2735,"pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(10)61198-1.pdf","trainingLevel":"Resident","citation":"Swedberg K <i>et al</i>. \"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study\". <i>Lancet</i>. 2010. 376(10):875-885.","subspecialties":"Cardiology","expansion":"Systolic Heart failure treatment with the If inhibitor ivabradine Trial","briefResultsDescription":"Ivabradine improves mortality and heart failure hospitalization in HFrEF","published":"2010-09-11","pageName":"SHIFT","diseases":"Heart Failure","abbreviation":"SHIFT","title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","pmid":"20801500"},{"timestamp":"2014-09-24T21:56:53Z","briefDesignDescription":"Early PCI/CABG in MI + shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199908263410901","pageid":388,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199908263410901","trainingLevel":"Resident","citation":"Hochman JS, <i>et al</i>. \"Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock\". <i>The New England Journal of Medicine</i>. 1999. 341(9):625-634.","subspecialties":"Cardiology;Critical Care","expansion":"SHould we emergently revascularize Occluded Coronaries for Cardiogenic shocK","briefResultsDescription":"Early PCI/CABG improves survival in acute MI and cardiogenic shock","published":"1999-08-26","pageName":"SHOCK","diseases":"Acute Coronary Syndrome;Myocardial Infarction;Shock","abbreviation":"SHOCK","title":"Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock","pmid":"10460813"},{"timestamp":"2015-10-14T20:09:26Z","briefDesignDescription":"Salmeterol in asthma","fulltexturl":"http://bit.ly/1VSBfoL","pageid":512,"pdfurl":"http://journal.publications.chestnet.org/data/Journals/CHEST/22038/15.pdf","trainingLevel":"intern","citation":"Nelson HS, <i>et al</i>. \"The salmeterol multicenter asthma research trial\". <i>Chest</i>. 2006. 129(1):15-26.","subspecialties":"Pulmonology","expansion":"Salmeterol Multicenter Asthma Research Trial","briefResultsDescription":"Salmeterol increases death in subgroups","published":"2006-01-01","pageName":"SMART","diseases":"Asthma","abbreviation":"SMART","title":"The salmeterol multicenter asthma research trial","pmid":"16424409"},{"timestamp":"2017-01-19T19:50:29Z","briefDesignDescription":"Dopamine vs. norepinephrine in shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0907118","pageid":113,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907118","trainingLevel":"Intern","citation":"De Backer D, <i>et al</i>. \"Comparison of dopamine and norepinephrine in the treatment of shock\". <i>The New England Journal of Medicine</i>. 2010. 362(9):779-89.","subspecialties":"Critical Care;Emergency Medicine","expansion":"Sepsis Occurrence in Acutely Ill Patients II","briefResultsDescription":"Norepinephrine reduces mortality","published":"2010-03-04","pageName":"SOAP II","diseases":"Sepsis;Shock","abbreviation":"SOAP II","title":"Comparison of dopamine and norepinephrine in the treatment of shock","pmid":"20200382"},{"timestamp":"2016-08-06T20:15:49Z","briefDesignDescription":"Ticagrelor vs. aspirin in acute stroke or TIA","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1603060","pageid":2809,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1603060","trainingLevel":"Resident","citation":"Johnston SC, <i>et al</i>. \"Ticagrelor versus aspirin in acute stroke or transient ischemic attack\". <i>New Engl J Med</i>. 2016. 365(1):35-43.","subspecialties":"Neurology","expansion":"Ticagrelor versus aspirin in stroke/TIA","briefResultsDescription":"Ticagrelor not superior to aspirin in acute stroke or TIA","published":"2016-07-07","pageName":"SOCRATES","diseases":"Stroke","abbreviation":"SOCRATES","title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","pmid":"27160892"},{"timestamp":"2014-06-13T07:07:04Z","briefDesignDescription":"Enalapril in moderate-severe HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199108013250501","pageid":394,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199108013250501","trainingLevel":"Resident","citation":"Yusuf S, <i>et al</i>. \"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure\". <i>The New England Journal of Medicine</i>. 1991. 325(5):293-302.","subspecialties":"Cardiology","expansion":"Studies of Left Ventricular Dysfunction","briefResultsDescription":"Enalapril reduces mortality and HF hospitalizations in HFrEF","published":"1991-08-01","pageName":"SOLVD","diseases":"Heart Failure","abbreviation":"SOLVD","title":"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure","pmid":"2057034"},{"timestamp":"2016-02-02T23:48:43Z","briefDesignDescription":"Infliximab ± azathioprine induction in Crohn disease","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0904492","pageid":1863,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0904492","trainingLevel":"Intern","citation":"Colombel JF, <i>et al</i>. \"Infliximab, azathioprine, or combination therapy for Crohn's disease\". <i>The New England Journal of Medicine</i>. 2010. 362(15):1383-1395.","subspecialties":"Gastroenterology","expansion":"Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease","briefResultsDescription":"Combination therapy better than infliximab or azathioprine for Crohn disease induction therapy","published":"2010-04-15","pageName":"SONIC","diseases":"Inflammatory Bowel Disease;Crohn Disease","abbreviation":"SONIC","title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","pmid":"20393175"},{"timestamp":"2017-01-25T13:51:33Z","briefDesignDescription":"Aspirin and wafarin in AF","fulltexturl":"http://circ.ahajournals.org/content/84/2/527.long","pageid":2340,"pdfurl":"http://circ.ahajournals.org/content/84/2/527.full.pdf","trainingLevel":"Resident","citation":"SPAF Investigators. \"Stroke Prevention in Atrial Fibrillation Study. Final results\". <i>Circulation</i>. 1991. 84(2):527-39.","subspecialties":"Cardiology;Neurology","expansion":"Stroke Prevention in Atrial Fibrillation","briefResultsDescription":"Aspirin and warfarin reduce stroke incidence in AF","published":"1991-08-01","pageName":"SPAF","diseases":"Atrial Fibrillation;Stroke","abbreviation":"SPAF","title":"Stroke Prevention in Atrial Fibrillation Study. Final results","pmid":"1860198"},{"timestamp":"2015-08-27T02:57:38Z","briefDesignDescription":"Atorvastatin after stroke","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa061894","pageid":461,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa061894","trainingLevel":"intern","citation":"Amarenco P, <i>et al</i>. \"High-dose atorvastatin after stroke or transient ischemic attack\". <i>The New England Journal of Medicine</i>. 2006. 355(6):549-559.","subspecialties":"Neurology","expansion":"Stroke Prevention by Aggressive Reduction in Cholesterol Levels","briefResultsDescription":"Atorvastatin ↓stroke risk in general but slightly ↑hemorrhagic strokes","published":"2006-08-10","pageName":"SPARCL","diseases":"Stroke;Hyperlipidemia;Transient Ischemic Attack","abbreviation":"SPARCL","title":"High-dose atorvastatin after stroke or transient ischemic attack","pmid":"16899775"},{"timestamp":"2017-03-13T09:55:52Z","briefDesignDescription":"BP targets in high-risk patients","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1511939","pageid":2487,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1511939","trainingLevel":"Student","citation":"The SPRINT Research Group. \"A randomized trial of intensive versus standard blood-pressure control\". <i>The New England Journal of Medicine</i>. 2015. 373(22):2103-2116.","subspecialties":"Cardiology;Preventive Medicine","expansion":"Systolic Blood Pressure Intervention Trial","briefResultsDescription":"SBP <120 improves CV outcomes with increased risks","published":"2015-11-09","pageName":"SPRINT","diseases":"Hypertension","abbreviation":"SPRINT","title":"A randomized trial of intensive versus standard blood-pressure control","pmid":"26551272"},{"timestamp":"2016-09-02T15:46:28Z","briefDesignDescription":"Clopidogrel+ASA for lacunar strokes","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1204133","pageid":2678,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1204133","trainingLevel":"Intern","citation":"SPS3 Study Group writers. \"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke\". <i>New England Journal of Medicine</i>. 2012. 367(9):817-825.","subspecialties":"Neurology","expansion":"Secondary Prevention of Small Subcortical Strokes clopidogrel+ASA","briefResultsDescription":"Clopidogrel+ASA increased all cause mortality compared to ASA alone","published":"2012-08-30","pageName":"SPS3 Clopidogrel-ASA","diseases":"Stroke;Transient Ischemic Attack","abbreviation":"SPS3-Clopidogrel+ASA","title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","pmid":"22931315"},{"timestamp":"2016-03-09T05:25:39Z","briefDesignDescription":"SBP <130 vs. SBP 130-150 after lacunar strokes","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60852-1/abstract","pageid":2671,"pdfurl":"http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(13)60852-1.pdf","trainingLevel":"Intern","citation":"SPS3 Study Group. \"Blood-pressure targets in patients with recent lacunar stroke\". <i>The Lancet</i>. 2013. 382(9891):507-515.","subspecialties":"Neurology","expansion":"Secondary Prevention of Small Subcortical Strokes-Blood Pressure","briefResultsDescription":"No significant difference in all stroke types between two groups","published":"2013-05-29","pageName":"SPS3-BP","diseases":"Stroke","abbreviation":"SPS3-BP","title":"Blood-pressure targets in patients with recent lacunar stroke","pmid":"23726159"},{"timestamp":"2017-02-23T16:11:25Z","briefDesignDescription":"Gastric bypass vs. medical therapy for T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1200225","pageid":2266,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200225","trainingLevel":"Resident","citation":"Schauer PR, <i>et al</i>. \"Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes\". <i>The New England Journal of Medicine</i>. 2012. 366(17):1567-76.","subspecialties":"Endocrinology;Surgery","expansion":"Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently","briefResultsDescription":"Bypass plus medical therapy is superior to medical therapy alone","published":"2012-04-26","pageName":"STAMPEDE","diseases":"Diabetes Mellitus;Obesity","abbreviation":"STAMPEDE","title":"Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes","pmid":"22449319"},{"timestamp":"2013-06-20T19:29:27Z","briefDesignDescription":"Tamoxifen vs. raloxifene in breast cancer prevention","fulltexturl":"http://jama.jamanetwork.com/article.aspx?articleid","pageid":963,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/5028/JOC60074.pdf","trainingLevel":"Fellow","citation":"Vogel VG, <i>et al</i>. \"Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes\". <i>Journal of the American Medical Association</i>. 2006. 295(23):2727-2741.","subspecialties":"Oncology","expansion":"Study of Tamoxifen and Raloxifene (NSABP P-2)","briefResultsDescription":"Similar reduction in breast cancer risk but fewer adverse effects with raloxifene","published":"2006-06-21","pageName":"STAR","diseases":"Breast Cancer","abbreviation":"STAR","title":"Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes","pmid":"16754727"},{"timestamp":"2013-09-04T17:04:52Z","briefDesignDescription":"Tiered approach for depression","fulltexturl":"","pageid":1564,"pdfurl":"http://ajp.psychiatryonline.org/data/Journals/AJP/3782/06aj1905.PDF","trainingLevel":"Resident","citation":"Rush AJ <i>et al</i>. \"Acute and longer-term outcomes in depressed outpatient requiring one or several treatment steps: A STAR*D report\". <i>The American Journal of Psychiatry</i>. 2006. 163(11):1905-1917.","subspecialties":"Psychiatry","expansion":"Sequenced Treatment Alternatives to Relieve Depression","briefResultsDescription":"Most patients achieved remission in first two steps","published":"2006-11-01","pageName":"STAR-D","diseases":"Depression","abbreviation":"STAR-D","title":"Acute and longer-term outcomes in depressed outpatient requiring one or several treatment steps: A STAR*D report","pmid":"17074942"},{"timestamp":"2016-10-16T17:18:44Z","briefDesignDescription":"CABG in ischemic HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1100356","pageid":471,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1100356","trainingLevel":"Resident","citation":"Velazquez EJ, <i>et al</i>. \"Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction\". <i>The New England Journal of Medicine</i>. 2011. 354(17):1607-1616.","subspecialties":"Cardiology","expansion":"Surgical Treatment for Ischemic Heart Failure","briefResultsDescription":"No mortality benefit with CABG vs. OMT though improved CV outcomes","published":"2011-04-28","pageName":"STICH","diseases":"Heart Failure;Coronary Artery Disease","abbreviation":"STICH","title":"Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction","pmid":"21463150"},{"timestamp":"2015-03-13T07:01:08Z","briefDesignDescription":"BR vs. R-CHOP for indolent lymphomas","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(12)61763-2","pageid":1664,"pdfurl":"http://bit.ly/1owpykX","trainingLevel":"fellow","citation":"Rummel MJ, <i>et al</i>. \"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial\". <i>The Lancet</i>. 2013. 381(9873):1203-10.","subspecialties":"Oncology;Hematology","expansion":"Study Group Indolent Lymphomas","briefResultsDescription":"BR superior to R-CHOP in PFS, similar in OS, less toxic","published":"2013-04-03","pageName":"StiL","diseases":"Lymphoma","abbreviation":"StiL","title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","pmid":"23433739"},{"timestamp":"2016-03-31T14:40:19Z","briefDesignDescription":"Prednisolone vs. pentoxifylline in alcoholic hepatitis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1412278","pageid":2365,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1412278","trainingLevel":"Intern","citation":"Thursz MR, <i>et al</i>. \"Prednisolone or pentoxifylline for alcoholic hepatitis\". <i>The New England Journal of Medicine</i>. 2015. 372(17):1619-1628.","subspecialties":"Gastroenterology","expansion":"Steroids or Pentoxifylline for Alcoholic Hepatitis","briefResultsDescription":"No difference between groups","published":"2015-04-23","pageName":"STOPAH","diseases":"Alcoholic Hepatitis","abbreviation":"STOPAH","title":"Prednisolone or pentoxifylline for alcoholic hepatitis","pmid":"25901427"},{"timestamp":"2015-10-09T05:14:31Z","briefDesignDescription":"Palliative statin discontinuation","fulltexturl":"http://bit.ly/1LOZfB6","pageid":2432,"pdfurl":"","trainingLevel":"Resident","citation":"Kutner JS, <i>et al</i>. \"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial\". <i>JAMA Internal Medicine</i>. 2015. 175(5):691-700.","subspecialties":"Palliative Care;Cardiology","expansion":"","briefResultsDescription":"Discontinuing statin doesn't change 60 day all-cause mortality","published":"2015-05-01","pageName":"Stopping Statins at the End of Life","diseases":"Hyperlipidemia","abbreviation":"","title":"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial","pmid":"25798575"},{"timestamp":"2014-06-26T14:53:03Z","briefDesignDescription":"Cytoreductive nephrectomy in metastatic RCC","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa003013","pageid":1845,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa003013","trainingLevel":"Fellow","citation":"Flanigan RC, <i>et al</i>. \"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer\". <i>The New England Journal of Medicine</i>. 2001. 345(23):1655-9.","subspecialties":"Oncology;Surgery;Urology","expansion":"","briefResultsDescription":"Cytoreductive nephrectomy improves survival in mRCC","published":"2001-12-06","pageName":"SWOG 8949","diseases":"Renal Cell Carcinoma","abbreviation":"SWOG 8949","title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","pmid":"11759643"},{"timestamp":"2013-11-26T02:02:32Z","briefDesignDescription":"PCI vs. CABG in severe CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0804626","pageid":525,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0804626","trainingLevel":"Resident","citation":"Serruys PW, <i>et al</i>. \"Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 2009. 360(10):961-972.","subspecialties":"Cardiology;Surgery","expansion":"Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery","briefResultsDescription":"CABG reduces major CV events with 3VD or LM disease","published":"2009-03-05","pageName":"SYNTAX","diseases":"Coronary Artery Disease","abbreviation":"SYNTAX","title":"Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease","pmid":"19228612"},{"timestamp":"2016-04-25T13:46:30Z","briefDesignDescription":"Early vs. Delayed PCI for UA-NSTEMI","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM200106213442501","pageid":2656,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM200106213442501","trainingLevel":"Resident","citation":"Cannon CP, <i>et al</i>. \"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban\". <i>New England Journal of Medicine</i>. 2001. 344(25):1879-1887.","subspecialties":"Cardiology","expansion":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban","briefResultsDescription":"Early PCI improves outcomes in high-risk patients","published":"2001-06-21","pageName":"TACTICS-TIMI 18","diseases":"Coronary Artery Disease","abbreviation":"TACTICS-TIMI 18","title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban","pmid":"11419424"},{"timestamp":"2015-07-01T00:57:13Z","briefDesignDescription":"Tiotropium vs. others in asthma","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1008770","pageid":2267,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1008770","trainingLevel":"Fellow","citation":"Peters SP, <i>et al</i>. \"Tiotropium bromide step-up therapy for adults with uncontrolled asthma\". <i>The New England Journal of Medicine</i>. 2010. 363(18):1715-1726.","subspecialties":"Pulmonology","expansion":"Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid","briefResultsDescription":"Adding tiotropium improves peak expiratory flow better than doubling the ICS dose","published":"2010-10-28","pageName":"TALC","diseases":"Asthma","abbreviation":"TALC","title":"Tiotropium bromide step-up therapy for adults with uncontrolled asthma","pmid":"20979471"},{"timestamp":"2014-12-12T19:42:21Z","briefDesignDescription":"Atorvastatin in stable CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa050461","pageid":1762,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa050461","trainingLevel":"Student","citation":"LaRosa JC, <i>et al</i>. \"Intensive lipid lowering with atorvastatin in patients with stable coronary disease\". <i>The New England Journal of Medicine</i>. 2005. 352(14):1425-1435.","subspecialties":"Cardiology","expansion":"Treating to New Targets","briefResultsDescription":"Atorvastatin 80 mg better than 10 mg for major CV events in stable CAD","published":"2005-04-07","pageName":"TNT","diseases":"Coronary Artery Disease;Hyperlipidemia","abbreviation":"TNT","title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","pmid":"15755765"},{"timestamp":"2014-07-15T15:30:25Z","briefDesignDescription":"Spironolactone for HFpEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1313731","pageid":1797,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1313731","trainingLevel":"Resident","citation":"Pitt B, <i>et al</i>. \"Spironolactone for heart failure with preserved ejection fraction\". <i>The New England Journal of Medicine</i>. 2014. 370(15):1383-1392.","subspecialties":"Cardiology","expansion":"Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist","briefResultsDescription":"Spironolactone doesn't reduce CV mortality, aborted cardiac arrest or HF hospitalizations in HFpEF","published":"2014-04-20","pageName":"TOPCAT","diseases":"Heart Failure","abbreviation":"TOPCAT","title":"Spironolactone for heart failure with preserved ejection fraction","pmid":"24716680"},{"timestamp":"2015-05-29T16:40:40Z","briefDesignDescription":"Salmeterol/fluticasone in COPD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa063070","pageid":124,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa063070","trainingLevel":"Student","citation":"Calverley PM, <i>et al</i>. \"Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease\". <i>The New England Journal of Medicine</i>. 2007. 356(8):775-789.","subspecialties":"Pulmonology","expansion":"Towards a Revolution in COPD Health","briefResultsDescription":"Trend towards mortality benefit","published":"2007-02-22","pageName":"TORCH","diseases":"Chronic Obstructive Pulmonary Disease","abbreviation":"TORCH","title":"Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease","pmid":"17314337"},{"timestamp":"2015-03-09T17:49:43Z","briefDesignDescription":"Darbepoetin in CKD and T2DM","fulltexturl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907845","pageid":5,"pdfurl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0907845","trainingLevel":"Resident","citation":"Pfeffer MA, <i>et al</i>. \"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease\". <i>The New England Journal of Medicine</i>. 2009. 361(21):2019-32.","subspecialties":"Nephrology;Hematology;Endocrinology","expansion":"Trial to Reduce Cardiovascular Events With Aranesp Therapy","briefResultsDescription":"No mortality benefit when targeting higher hemoglobin with ESAs in patients with CKD and T2DM","published":"2009-11-19","pageName":"TREAT","diseases":"Chronic Kidney Disease;Anemia;Diabetes Mellitus","abbreviation":"TREAT","title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","pmid":"19880844"},{"timestamp":"2017-01-19T20:08:09Z","briefDesignDescription":"Transfusion thresholds in ICU","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199902113400601","pageid":104,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199902113400601","trainingLevel":"Intern","citation":"Hebert PC, <i>et al</i>. \"A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care\". <i>The New England Journal of Medicine</i>. 1999. 340(6):409-417.","subspecialties":"Critical Care;Hematology","expansion":"Transfusion Requirements in Critical Care","briefResultsDescription":"Restrictive hemoglobin goals improved mortality","published":"1999-02-11","pageName":"TRICC","diseases":"Anemia","abbreviation":"TRICC","title":"A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care","pmid":"9971864"},{"timestamp":"2017-01-19T20:02:31Z","briefDesignDescription":"Transfusion thresholds in sepsis","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1406617","pageid":2268,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1406617","trainingLevel":"Intern","citation":"Holst L, <i>et al</i>. \"Transfusion thresholds in Septic Shock\". <i>The New England Journal of Medicine</i>. 2014. 371(15):1381-1391.","subspecialties":"Critical Care","expansion":"Transfusion Requirements in Septic Shock","briefResultsDescription":"Similar mortality; Fewer transfusions with restrictive","published":"2014-10-09","pageName":"TRISS","diseases":"Sepsis;Shock;Anemia","abbreviation":"TRISS","title":"Transfusion thresholds in Septic Shock","pmid":"25270275"},{"timestamp":"2014-09-26T18:00:07Z","briefDesignDescription":"Prasugrel vs. clopidogrel in ACS","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0706482","pageid":1398,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0706482","trainingLevel":"Resident","citation":"Wiviott ST, <i>et al</i>. \"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2007. 357(20):2001-2015.","subspecialties":"Cardiology","expansion":"Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38","briefResultsDescription":"Prasugrel decreases CV mortality/morbidity, increases bleeding","published":"2007-11-15","pageName":"TRITON-TIMI 38","diseases":"Acute Coronary Syndrome","abbreviation":"TRITON-TIMI 38","title":"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes","pmid":"17982182"},{"timestamp":"2016-10-16T17:44:52Z","briefDesignDescription":"33 vs. 36°C body temperature after cardiac arrest","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1310519","pageid":1783,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310519","trainingLevel":"Resident","citation":"Nielsen N, <i>et al</i>. \"Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest\". <i>The New England Journal of Medicine</i>. 2013. 369(23):2197-2206.","subspecialties":"Cardiology;Neurology;Critical Care","expansion":"Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest","briefResultsDescription":"33°C cooling provides no survival benefit over 36°C","published":"2014-03-19","pageName":"TTM","diseases":"Cardiac Arrest","abbreviation":"TTM","title":"Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest","pmid":"24237006"},{"timestamp":"2017-02-21T19:52:57Z","briefDesignDescription":"Twice-daily RT in limited SCLC","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199901283400403","pageid":1773,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199901283400403","trainingLevel":"Resident","citation":"Turrisi AT, <i>et al</i>. \"Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide\". <i>The New England Journal of Medicine</i>. 1999. 340(4):265-271.","subspecialties":"Oncology;Pulmonology;Radiation Oncology","expansion":"","briefResultsDescription":"Twice-daily RT with better response, PFS, survival than once-daily RT for limited SCLC","published":"1999-01-28","pageName":"Twice-daily RT for SCLC","diseases":"Lung Cancer","abbreviation":"","title":"Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide","pmid":"9920950"},{"timestamp":"2015-07-20T22:59:42Z","briefDesignDescription":"Intensive glycemic therapy in T2DM","fulltexturl":"http://linkinghub.elsevier.com/retrieve/pii/S0140673698070196","pageid":253,"pdfurl":"","trainingLevel":"Intern","citation":"Turner R, <i>et al</i>. \"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes\". <i>The Lancet</i>. 1998. 352(9131):837-53.","subspecialties":"Endocrinology","expansion":"United Kingdom Prospective Diabetes Study","briefResultsDescription":"Reduction in microvascular complications","published":"1998-09-12","pageName":"UKPDS 33","diseases":"Diabetes Mellitus","abbreviation":"UKPDS","title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes","pmid":"9742976"},{"timestamp":"2014-05-11T21:55:20Z","briefDesignDescription":"Metformin in T2DM","fulltexturl":"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2898%2907037-8/fulltext","pageid":1747,"pdfurl":"http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673698070378.pdf","trainingLevel":"Intern","citation":"UKPDS Study Group. \"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.\". <i>The Lancet</i>. 1998. 352(9131):854-865.","subspecialties":"Endocrinology","expansion":"UK Prospective Diabetes Study 34","briefResultsDescription":"Metformin better than diet alone in T2DM","published":"1998-11-07","pageName":"UKPDS 34","diseases":"Diabetes Mellitus","abbreviation":"UKPDS 34","title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.","pmid":"9742977"},{"timestamp":"2012-10-29T23:28:48Z","briefDesignDescription":"Tiotropium in COPD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0805800","pageid":123,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805800","trainingLevel":"Resident","citation":"Tashkin DP, <i>et al</i>. \"A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease\". <i>The New England Journal of Medicine</i>. 2008. 395(15):1543-1554.","subspecialties":"Pulmonology","expansion":"Understanding Potential Long-Term Impacts on Function with Tiotropium","briefResultsDescription":"Decreased exacerbations and mortality","published":"2008-10-09","pageName":"UPLIFT","diseases":"Chronic Obstructive Pulmonary Disease","abbreviation":"UPLIFT","title":"A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease","pmid":"18836213"},{"timestamp":"2014-06-22T17:29:05Z","briefDesignDescription":"ISDN/hydralazine in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198606123142404","pageid":155,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198606123142404","trainingLevel":"student","citation":"Cohn JN, <i>et al</i>. \"Effect of vasodilator therapy on mortality in chronic congestive heart failure\". <i>The New England Journal of Medicine</i>. 1986. 314(24):1547-52.","subspecialties":"Cardiology","expansion":"Vasodilator Heart Failure Trial","briefResultsDescription":"Trend towards mortality benefit in ISDN/hydralazine","published":"1986-06-12","pageName":"V-HeFT","diseases":"Heart Failure","abbreviation":"V-HeFT","title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure","pmid":"3520315"},{"timestamp":"2014-09-24T22:23:54Z","briefDesignDescription":"Aspirin in unstable angina","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM198308183090703","pageid":261,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM198308183090703","trainingLevel":"Resident","citation":"Lewis HD, <i>et al</i>. \"Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina -- Results of a Veterans Administration Cooperative Study\". <i>The New England Journal of Medicine</i>. 1983. 309(7):396-403.","subspecialties":"Cardiology","expansion":null,"briefResultsDescription":"Aspirin decreases mortality","published":"1983-08-18","pageName":"VA Cooperative Study","diseases":"Acute Coronary Syndrome","abbreviation":null,"title":"Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina -- Results of a Veterans Administration Cooperative Study","pmid":"6135989"},{"timestamp":"2014-05-27T14:55:58Z","briefDesignDescription":"ACE+ARB in DM nephropathy","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1303154","pageid":1798,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1303154","trainingLevel":"Resident","citation":"Fried LF, <i>et al</i>. \"Combined angiotensin inhibition for the treatment of diabetic nephropathy\". <i>The New England Journal of Medicine</i>. 2013. 369(20):1892-1903.","subspecialties":"Nephrology;Endocrinology","expansion":"Veterans Affairs Nephropathy in Diabetes","briefResultsDescription":"ACE+ARB no more effective than monotherapy, increases complications","published":"2013-11-14","pageName":"VA-NEPHRON D","diseases":"Diabetes Mellitus;Diabetic Nephropathy","abbreviation":"VA NEPHRON-D","title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","pmid":"24206457"},{"timestamp":"2015-06-09T10:46:05Z","briefDesignDescription":"Intensive glycemic therapy in T2DM","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa0808431","pageid":254,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa0808431","trainingLevel":"Resident","citation":"Duckworth W, <i>et al</i>. \"Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2009. 360(2):129-39.","subspecialties":"Endocrinology","expansion":"Veterans Affairs Diabetes Trial","briefResultsDescription":"No effect on macrovascular or severe microvascular outcomes","published":"2009-01-08","pageName":"VADT","diseases":"Diabetes Mellitus","abbreviation":"VADT","title":"Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes","pmid":"19092145"},{"timestamp":"2014-08-24T17:55:57Z","briefDesignDescription":"Valsartan in HFrEF","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa010713","pageid":20,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa010713","trainingLevel":"Resident","citation":"Cohn JN, <i>et al</i>. \"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure\". <i>New England Journal of Medicine</i>. 2001. 345(23):1667-75.","subspecialties":"Cardiology","expansion":"Valsartan Heart Failure Trial","briefResultsDescription":"No mortality benefit of valsartan in NYHA II-IV HF","published":"2001-12-06","pageName":"Val-HeFT","diseases":"Heart Failure","abbreviation":"Val-HeFT","title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","pmid":"11759645"},{"timestamp":"2015-06-06T23:41:36Z","briefDesignDescription":"Sofosbuvir+ribavirin for HCV genotypes 2 or 3","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1316145","pageid":2261,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1316145","trainingLevel":"Student","citation":"Zeuzem S, <i>et al</i>. \"Sofosbuvir and ribavirin in HCV genotypes 2 and 3\". <i>The New England Journal of Medicine</i>. 2014. 370(21):1993-2001.","subspecialties":"Infectious Disease;Gastroenterology","expansion":"","briefResultsDescription":"Sofosbuvir+ribavirin effective without IFN","published":"2014-05-22","pageName":"VALENCE","diseases":"Hepatitis C","abbreviation":"VALENCE","title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","pmid":"24795201"},{"timestamp":"2015-07-05T22:55:54Z","briefDesignDescription":"Valsartan vs. captopril in MI with LV dysfunction","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa032292","pageid":462,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa032292","trainingLevel":"Resident","citation":"Pfeffer, MA <i>et al</i>. \"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both\". <i>The New England Journal of Medicine</i>. 2003. 349(20):1893-1903.","subspecialties":"Cardiology","expansion":"Valsartan in Acute Myocardial Infarction Trial","briefResultsDescription":"Valsartan as effective as captopril","published":"2003-11-13","pageName":"VALIANT","diseases":"Heart Failure;Acute Coronary Syndrome;Myocardial Infarction","abbreviation":"VALIANT","title":"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both","pmid":"12921816"},{"timestamp":"2014-07-28T20:00:24Z","briefDesignDescription":"Vancomycin vs. metronidazole in C. difficile","fulltexturl":"http://cid.oxfordjournals.org/content/45/3/302.long","pageid":6,"pdfurl":"http://cid.oxfordjournals.org/content/45/3/302.full.pdf","trainingLevel":"Intern","citation":"Zar FA, <i>et al</i>. \"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity\". <i>Clinical Infectious Diseases</i>. 2007. 45(3):302-7.","subspecialties":"Infectious Disease;Gastroenterology","expansion":null,"briefResultsDescription":"Vancomycin is superior to metronidazole in severe C. difficile-associated diarrhea","published":"2007-08-01","pageName":"Vancomycin vs. Metronidazole in C. difficile Diarrhea","diseases":"Clostridium difficile","abbreviation":null,"title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","pmid":"17599306"},{"timestamp":"2016-09-09T12:54:58Z","briefDesignDescription":"Ablation vs. antiarrhythmic drugs in VT","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1513614","pageid":2783,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1513614","trainingLevel":"Resident","citation":"Sapp JL, <i>et al</i>. \"Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs\". <i>The New England Journal of Medicine</i>. 2016. 375(2):111-121.","subspecialties":"Cardiology","expansion":"Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs","briefResultsDescription":"VT ablation superior to escalation of antiarrhythmic drugs","published":"2016-05-05","pageName":"VANISH","diseases":"Ventricular Tachycardia","abbreviation":"VANISH","title":"Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs","pmid":"27149033"},{"timestamp":"2017-01-19T19:51:35Z","briefDesignDescription":"Vasopressin in septic shock","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa067373","pageid":1910,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa067373","trainingLevel":"Resident","citation":"Russel JA, <i>et al</i>. \"Vasopressin versus norepinephrine infusion in patients with septic shock\". <i>The New England Journal of Medicine</i>. 2008. 358(9):877-887.","subspecialties":"Critical Care","expansion":"Vasopressin and Septic Shock Trial","briefResultsDescription":"Vasopressin doesn't reduce mortality in shock","published":"2008-02-28","pageName":"VASST","diseases":"Sepsis;Shock","abbreviation":"VASST","title":"Vasopressin versus norepinephrine infusion in patients with septic shock","pmid":"18305265"},{"timestamp":"2016-02-16T16:43:14Z","briefDesignDescription":"Aspirin after VTE treatment","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1114238","pageid":1244,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1114238","trainingLevel":"resident","citation":"Becattini C, <i>et al</i>. \"Aspirin for preventing the recurrence of venous thromboembolism\". <i>The New England Journal of Medicine</i>. 2012. 366(21):1959-1967.","subspecialties":"Hematology","expansion":"Warfarin and Aspirin","briefResultsDescription":"Aspirin reduces recurrent VTE","published":"2012-05-24","pageName":"WARFASA","diseases":"Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism","abbreviation":"WARFASA","title":"Aspirin for preventing the recurrence of venous thromboembolism","pmid":"22621626"},{"timestamp":"2016-09-27T11:08:01Z","briefDesignDescription":"Postmenopausal estrogen/progesterone","fulltexturl":null,"pageid":1507,"pdfurl":"http://jama.jamanetwork.com/data/Journals/JAMA/4840/JOC21036.pdf","trainingLevel":"Student","citation":"Rossouw JE, <i>et al</i>. \"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial\". <i>The Journal of the American Medical Association</i>. 2002. 288(3):321-333.","subspecialties":"Gynecology;Endocrinology","expansion":"Women's Health Initiative Estrogen and Progestin Trial","briefResultsDescription":"Postmenopausal estrogen/progesterone HRT increases rates of MI and breast cancer","published":"2002-07-17","pageName":"WHI","diseases":"Coronary Artery Disease;Menopause","abbreviation":"WHI E+P","title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial","pmid":"12117397"},{"timestamp":"2015-05-30T07:09:37Z","briefDesignDescription":"ICS withdrawal in COPD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJMoa1407154","pageid":2318,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1407154","trainingLevel":"Resident","citation":"Magnussen H, <i>et al</i>. \"Withdrawal of inhaled glucocorticoids and exacerbations of COPD\". <i>The New England Journal of Medicine</i>. 2014. 371(14):1285-1295.","subspecialties":"Pulmonology","expansion":"Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management","briefResultsDescription":"ICS withdrawal may reduce FEV1, no change in COPD flares","published":"2014-10-02","pageName":"WISDOM","diseases":"Chronic Obstructive Pulmonary Disease","abbreviation":"WISDOM","title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","pmid":"25196117"},{"timestamp":"2015-06-28T13:35:52Z","briefDesignDescription":"Clopidogrel ± ASA after PCI if on OAC","fulltexturl":"http://www.sciencedirect.com/science/article/pii/S0140673612621771","pageid":1792,"pdfurl":"","trainingLevel":"Resident","citation":"Dewilde WJM, <i>et al</i>. \"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial\". <i>The Lancet</i>. 2013. 381(9872):1107-1115.","subspecialties":"Cardiology;Hematology","expansion":"What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing","briefResultsDescription":"ASA increases bleeding when added to clopidogrel if chronic OAC","published":"2013-03-30","pageName":"WOEST","diseases":"Coronary Artery Disease","abbreviation":"WOEST","title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","pmid":"23415013"},{"timestamp":"2014-12-12T19:39:51Z","briefDesignDescription":"Pravastatin in CAD","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199511163332001","pageid":172,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199511163332001","trainingLevel":"Resident","citation":"Shepherd J, <i>et al</i>. \"Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia\". <i>The New England Journal of Medicine</i>. 1995. 333(20):1301-1308.","subspecialties":"Cardiology","expansion":"West of Scotland Coronary Prevention Study","briefResultsDescription":"Pravastatin reduces MIs and CV mortality","published":"1995-11-16","pageName":"WOSCOPS","diseases":"Hyperlipidemia;Coronary Artery Disease","abbreviation":"WOSCOPS","title":"Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia","pmid":"7566020"},{"timestamp":"2015-04-12T06:19:26Z","briefDesignDescription":"RSBI for predicting weaning","fulltexturl":"http://www.nejm.org/doi/full/10.1056/NEJM199105233242101","pageid":75,"pdfurl":"http://www.nejm.org/doi/pdf/10.1056/NEJM199105233242101","trainingLevel":"Resident","citation":"Yang KL, Tobin MJ. \"A Prospective Study of Indexes Predicting the Outcome of Trials of Weaning from Mechanical Ventilation\". <i>The New England Journal of Medicine</i>. 1991. 324(21):1445-1450.","subspecialties":"Pulmonology;Critical Care","expansion":"","briefResultsDescription":"RSBI predicts success and failure of weaning from mechanical ventilation","published":"1991-05-23","pageName":"Yang-Tobin Study","diseases":"Critical Illness","abbreviation":"","title":"A Prospective Study of Indexes Predicting the Outcome of Trials of Weaning from Mechanical Ventilation","pmid":"2023603"}]}}